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“Some people want it to happen,  
some wish it would happen,  
others make it happen.” 





“It is necessary to make a dream of life,  

















Research & Development and Innovation (R&D&I) are fundamental aspects for the growth and 
evolution of a company. Innovation is fast becoming a critical factor in the long-term growth 
development and survival of companies. The industrial doctorate manifested here, serves to bridge 
the gap between industry and academia, helps to industrialize the valuable knowledge that the 
academic research has generated, and puts the investigation into a practice in an industrial 
environment. 
In this industrial doctorate, the aim was to fulfill the Whole Genix innovative objectives, including: 
master Next Generation Sequencing (NGS) protocols; cover a bigger spectrum of diseases; develop 
new bioinformatic and telemedicine tools for analysis of different omics data; and consequently, 
progress towards personalized medicine. Four independent projects have been carried out to cover 
these objectives. 
1. Refining and improving an NGS gene panel for clinical diagnosis of hereditary hematologic 
diseases and focus on diseases with ferritin alterations. 
The goal of this project is to improve an already established NGS-gene panel for rare inherited blood 
diseases (commercialized by BLOODGENTICS SL, a company associated with Whole Genix, SL) in order 
to accelerate diagnostics. Four design, each more updated and with more genes, have been studied 
for the diagnosis of twelve groups of hereditary hematological diseases. The implementation of the 
NGS methodology in clinical practice for the diagnosis of hereditary hematological diseases allows the 
rapid and effective diagnosis of these cases and to improve the clinical classification of these diseases. 
Moreover, additional research in the FTL gene has been carried out due to its correlation with five 
hematological disorders. Two novel mutation in the FTL gene have been identified to be associated to 
two FTL-disorders thanks to the HHD gene panel: hyperferritinemia with cataracts syndrome 
(Esplugues mutation, c.-164_158del7) and L-ferritin deficiency with autosomal dominant inheritance 
(c.375+2T>A). Also, the second case of the mutation p.Met1Val in FTL gene associate with L-ferritin 
deficiency autosomal dominant is described. 
 
2. CoDysAn: a web tool for the diagnosis of Congenital Dyserythropoietic Anemia  
Congenital Dyserythropoietic Anemias (CDAs) are inherited hematological disorders characterized by 
chronic hyporegenerative anemia, morphological abnormalities of erythroblasts, and hemolytic 
component. Six subtypes of CDA has been defined genetically that present different morphological 
alterations of erythroblasts in the bone marrow. A proficient classification of CDA cases is crucial to 
provide efficient patient care and treatment. 
CoDysAn aims to provide a responsive webpage that brings awareness of congenital dyserythropoietic 
anemia (CDA) to doctors, patients and general public, and provides a step-by-step diagnostic tool. The 
diagnostic algorithm is based in hematological parameters of the patients, including: hemoglobin 
level, Mean Corpuscular Volume of erythrocytes, and reticulocytes and platelets count. The normal 
ranges are dependent of the gender and age. The diagnostic tool achieved a satisfactory specificity of 
89.5% and sensitivity of 78.5%. CoDysAn algorithm is connected to the NCBI Genetic Testing Registry 
(GTR) in a way to inform medical doctors about the existence of accredited diagnostic centers to 






3. BEA (BioMark Expression Analysis): a web tool to perform relative expression analysis from 
Fluidigm – BioMark raw data.  
The high-throughput technologies for transcriptome analysis are ubiquitously used in modern biology 
and medical research. Nowadays researchers are employing these methods to analyze multiple genes 
from multiple samples in parallel, significatively reducing the handling time and the cost. BioMark HD 
system is a nanofluidic high-throughput qPCR capable to run more than nine thousand reactions at 
the same time (96 samples x 96 assays). In these high-throughput settings, the relative quantification 
through the ∆∆CT method and the statistical analysis could be not affordable for non-bioinformatic 
users. 
BEA is a Shiny-based app to help wet-bench biologist with limited knowledge of programming and 
statistics to perform gene expression analysis from qPCR (quantitative Polymerase Chain Reaction) 
BioMark-Fluidigm data. BEA was designed to provide an easy step-by-step analysis workflow, with an 
appropriated statistical pipeline in a user-friendly interface. This enables users with low levels of 
programming and statistical knowledge to perform differential gene expression analysis for two or 
three groups of samples. The analysis includes relative quantification (∆∆CT method) and 
appropriated statistical testing to identify differentially expressed genes between tested groups. The 
BEA app is available from  http://bloodgenetics.com/otros/ web page.       
The bioinformatic tool has been tested using BioMark data from Myelodysplastic syndrome project, 
whose goal was to identify genes associated with mitochondrial iron overload (ring sideroblasts) in 
sideroblastic anemia. Twenty-three genes identified to be differentially expressed between patients 
with myelodysplastic syndrome with ring sideroblasts (MDS-RS), patients with myelodysplastic 
syndrome without ring sideroblasts (MDS-nonRS) and healthy controls.   
4. Pipeline for construction of gene expression signatures for prediction and prognosis using data 
from patients with muscle-invasive bladder cancer. 
The advance and expansion of high-throughput technology have brought the opportunity to discover 
specific genetic signatures that can help to diagnose and classify a pathogenic medical condition, or 
predict the prognosis or the pharmacological responses to a specified treatment. Nevertheless, most 
phenotypes are complex traits resulting from the influence of both genomic factor and external 
conditions (non-genomic factors). To understand these complex traits and be able to define a gene 
expression signature of these phenotypes it is essential to study the genomic information and the non-
genomic information jointly. However, the integration of these two types of data requires elaborated 
modeling and engenders some challenges that must be considered. 
In this project we have elaborated a statistical pipeline based on an integrative conditional modeling 
approach in which non-genomic variables are selected first and used subsequently to select and adjust 
the genetic model. The non-genomic variables are selected by Stepwise regression, and the genomic 
variables by LASSO penalized regression in a cross-validation process. The statistical modeling has 
been tested using data from a muscle-invasive bladder cancer project with the objective to identify a 
gene expression signature that can predict the prognosis and efficacy of platinum-based neoadjuvant 
chemotherapies. The integrative conditional modeling found three non-genomic variables (tumor 
morphology type, the presence of hydronephrosis and the taxonomic classification) and nine genes 
(RAD51, CXCL9, PARP, 53BP1, HERC2, ERCC2, CHEK1, Ku80 and RNF168) with the highest predictive 
ability (AUC=0.663). However, optimization analysis suggested that the non-genomic variables and 
the first three or four genes selected by LASSO (RAD51, CXCL9, PARP and 53BP1) may have enough 






La investigación y el desarrollo y la innovación (I+D+i) son unos de los aspectos más indispensables 
para el crecimiento y la evolución de una empresa. La innovación se está convirtiendo rápidamente 
en un factor crítico en el desarrollo y crecimiento a largo plazo y la supervivencia de las empresas. El 
doctorado industrial manifestado aquí sirve para abrir un puente entre la industria y la academia y 
ayuda a industrializar el valioso conocimiento que ha generado la investigación académica. 
En este doctorado industrial el objetivo era cumplir los propósitos innovadores de Whole Genix, que 
incluyen: dominar los protocolos de secuenciación masiva de próxima generación (en inglés next-
generation sequencing, NGS), cubrir un espectro más amplio de enfermedades, desarrollar nuevas 
herramientas bioinformáticas y de telemedicina para el análisis de diferentes datos ómicos; y 
consecuentemente, progresar hacia la medicina personalizada. Se han llevado a cabo cuatro proyectos 
independientes para cubrir estos objetivos. 
1. Refinar y mejorar un panel de genes NGS para el diagnóstico clínico de enfermedades 
hematológicas hereditarias e investigación sobre enfermedades con alteraciones de la 
ferritina. 
El objetivo de este proyecto es mejorar un panel de genes NGS para enfermedades sanguíneas 
hereditarias raras (comercializado por la empresa BLOODGENETICS SL asociada a la empresa Whole 
Genix SL) con el fin de acelerar el diagnóstico. Se han estudiado cuatro diseños, cada uno más 
actualizado y con más genes, para el diagnóstico de doce grupos de enfermedades hematológicas 
hereditarias. La implementación de la metodología de la secuenciación masiva en la práctica clínica 
para el diagnóstico de enfermedades hematológicas hereditarias permite el diagnóstico rápido y 
efectivo de estos casos y mejorar la clasificación clínica de estas enfermedades. 
Además, se han realizado investigaciones adicionales en el gen FTL debido a su correlación con cinco 
enfermedades hematológicas. Se han identificado dos nuevas mutaciones en el gen FTL asociadas a 
dos enfermedades distintas, gracias al panel de genes HHD: hiperferritinemia con síndrome de 
cataratas (mutación de Esplugues, c.-164_158del7) y deficiencia de L-ferritina con herencia 
autosómica dominante (c.375 + 2T> A). Además, se describe el segundo caso con mutación p. Met1Val 
en FTL asociado con deficiencia de L-ferritina autosómica dominante. 
2. CoDysAn: una herramienta web para el diagnóstico de anemia diseritropoyética congénita 
Las anemias diseritropoyéticas congénitas (CDA) son trastornos hematológicos hereditarios 
caracterizados por anemia hiporgenerativa crónica, anomalías morfológicas de los eritroblastos y 
componente hemolítico. Se han definido genéticamente seis subtipos de CDA que presentan 
diferentes alteraciones morfológicas de los eritroblastos en la médula ósea. Una clasificación 
competente de los casos de CDA es crucial para proporcionar atención y tratamiento eficientes al 
paciente. 
CoDysAn tiene como objetivo proporcionar una página web receptiva que concientice a médicos, 
pacientes y al público en general sobre la anemia diseritropoyética congénita (CDA) y proporcione una 
herramienta de diagnóstico de fácil uso. El algoritmo de diagnóstico está basado en parámetros 
hematológicos de los pacientes que incluye: nivel de hemoglobina, volumen corpuscular medio de 
eritrocitos y recuento de reticulocitos y plaquetas. Los rangos normales dependen del género y la 
edad. La herramienta de diagnóstico logró una satisfactoria especificidad del 89,5% y una sensibilidad 





informar a los médicos sobre la existencia de centros de diagnóstico acreditados para realizar una 
prueba genética completa, si es necesario. 
3. BEA (BioMark Expression Analysis): una herramienta web para realizar análisis de expresión 
relativa de datos provenientes del sistema BioMark-Fluidigm. 
Las tecnologías de alto rendimiento para el análisis de transcriptomas se utilizan de manera ubicua en 
la biología moderna y la investigación médica. Hoy en día, los investigadores están empleando estos 
métodos para analizar múltiples genes de múltiples muestras en paralelo, reduciendo 
significativamente el tiempo de manipulación y el coste. El sistema BioMark HD es un qPCR 
nanofluídico de alto rendimiento capaz de ejecutar más de nueve mil reacciones al mismo tiempo (96 
muestras x 96 ensayos). La cuantificación relativa a través del método ∆∆CT y el análisis estadístico no 
es fácilmente abordable para usuarios con bajos conocimientos de bioinformática. 
BEA es una aplicación basada en Shiny para ayudar al biólogo con conocimiento limitado de 
programación y estadística a realizar análisis de expresión génica a partir de datos de qPCR (reacción 
cuantitativa en cadena de la polimerasa) del sistema BioMark-Fluidigm. BEA fue diseñado para 
proporcionar un proceso de análisis de fácil uso estructurado en cómodos e intuitivos pasos, en una 
interfaz fácil de usar. Esto permite a los usuarios con bajos niveles de conocimientos de programación 
y estadística realizar análisis de expresión génica diferencial para dos o tres grupos de muestras. El 
análisis incluye cuantificación relativa (método ∆∆CT) y pruebas estadísticas apropiadas para 
identificar genes expresados diferencialmente entre los grupos probados. La aplicación BEA está 
disponible a través de la página web de BloodGenetics (http://bloodgenetics.com/otros/).  
La herramienta bioinformática se ha probado utilizando datos de BioMark del proyecto de síndrome 
mielodisplásico, cuyo objetivo era identificar genes asociados con la sobrecarga de hierro mitocondrial 
(sideroblastos en anillo) en la anemia sideroblástica. Veintitrés genes han sido identificados que se 
expresan diferencialmente entre pacientes con síndrome mielodisplásico con sideroblastos en anillo 
(MDS-RS), pacientes con síndrome mielodisplásico sin sideroblastos en anillo (MDS-nonRS) y controles 
sanos. 
4. Pipeline para la construcción de firmas de expresión génica para predicción y pronóstico 
utilizando datos de pacientes con cáncer de vejiga músculo-invasivo. 
El avance y la expansión de la tecnología de alto rendimiento ha brindado la oportunidad de descubrir 
firmas genéticas específicas, que pueden ayudar a diagnosticar y clasificar una condición médica 
patogénica, o predecir el pronóstico o las respuestas farmacológicas a un tratamiento específico. Sin 
embargo, la mayoría de los fenotipos son complejos, resultantes de la influencia tanto del factor 
genómico como de las condiciones externas (factores no genómicos). Para comprender estos rasgos 
complejos y poder definir una firma de expresión génica de estos fenotipos es esencial estudiar 
conjuntamente la información genómica y la información no genómica. Sin embargo, la integración 
de estos dos tipos de datos requiere un modelado elaborado y genera algunos desafíos que se deben 
tener en cuenta. 
En este proyecto hemos elaborado un pipeline estadístico basado en el modelado condicional 
integrativo, en el que las variables no genómicas se seleccionan primero y posteriormente se usan 
para seleccionar y ajustar el modelo genético. Las variables no genómicas se seleccionan por regresión 
Stepwise y las variables genómicas por regresión penalizada LASSO en un proceso de validación 
cruzada. El modelo estadístico se ha probado utilizando datos del proyecto de cáncer de vejiga 
músculo-invasivo, con el objetivo de identificar una firma de expresión génica que pueda predecir el 





condicional integrativo formuló que tres variables no genómicas (tipo de morfología tumoral, la 
presencia de hidronefrosis y la clasificación taxonómica) y nueve genes (RAD51, CXCL9, PARP, 53BP1, 
HERC2, ERCC2, CHEK1, Ku80 y RNF168) tenían la mayor capacidad predictiva (AUC = 0.663). Sin 
embargo, el análisis de optimización sugiere que las variables no genómicas y los primeros tres o 
cuatro genes seleccionados por LASSO (RAD51, CXCL9, PARP y 53BP1) pueden tener suficiente 
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iii. List of genes 
 
Gene name Gene description 
ABCB6  ATP binding cassette subfamily B member 6 (Langereis blood group) 
ABCB7  ATP binding cassette subfamily B member 7 
ABCG5  ATP binding cassette subfamily G member 5 
ABCG8  ATP binding cassette subfamily G member 8 
ACD  ACD 
ACO1  aconitase 1 
ACVR1  activin A receptor type 1 
ADA  adenosine deaminase 
AK1  adenylate kinase 1 
ALAS2  5'-aminolevulinate synthase 2 
ALDOA  aldolase 
ANK1  ankyrin 1 
ATP13A2 ATPase cation transporting 13A2 
ATP4A  ATPase H+/K+ transporting subunit alpha 
ATP7B  ATPase copper transporting beta 
ATPIF1  ATP synthase inhibitory factor subunit 1  
BMP6  bone morphogenetic protein 6 
BPGM  bisphosphoglycerate mutase 
BRCA1  BRCA1 
BRCA2  BRCA2 
BRIP1  BRCA1 interacting protein C-terminal helicase 1 
C15orf41 chromosome 15 open reading frame 41 
C19orf12 chromosome 19 open reading frame 12 
CDAN1  codanin 1 
CLPX  caseinolytic mitochondrial matrix peptidase chaperone subunit 
COASY  Coenzyme A synthase 
CP  ceruloplasmin 
CTC1  CST telomere replication complex component 1 
CYB5R3  cytochrome b5 reductase 3 
DCAF17 DDB1 and CUL4 associated factor 17 
DKC1  dyskerin pseudouridine synthase 1 
EGLN1  egl-9 family hypoxia inducible factor 1 
EPAS1  endothelial PAS domain protein 1 
EPB41  erythrocyte membrane protein band 4.1 
EPB42  erythrocyte membrane protein band 4.2 
EPOR  erythropoietin receptor 
ERCC4  ERCC excision repair 4 
EXOC6  exocyst complex component 6 
FA2H  fatty acid 2-hydroxylase 
FANCA  FA complementation group A 




FANCB  FA complementation group B 
FANCC  FA complementation group C 
FANCD2 FA complementation group D2 
FANCE  FA complementation group E 
FANCF  FA complementation group F 
FANCG  FA complementation group G 
FANCI  FA complementation group I 
FANCL  FA complementation group L 
FANCM  FA complementation group M 
FECH  ferrochelatase 
FTH1  ferritin heavy chain 1 
FTL  ferritin light chain 
G6PD  glucose-6-phosphate dehydrogenase 
GATA1  GATA binding protein 1 
GCLC  glutamate-cysteine ligase catalytic subunit 
GLRX5  glutaredoxin 5 
GNPAT  glyceronephosphate O-acyltransferase 
GPI  glucose-6-phosphate isomerase 
GPX1  glutathione peroxidase 1 
GSR  glutathione-disulfide reductase 
GSS  glutathione synthetase 
GYPC  glycophorin C (Gerbich blood group) 
HAMP  hepcidin antimicrobial peptide 
HEPH  hephaestin 
HFE  homeostatic iron regulator 
HFE2  also known as HJV (nomenclature is going to be officially change soon) 
HK1  hexokinase 1 
HSPA9  heat shock protein family A (Hsp70) member 9 
IREB2  iron responsive element binding protein 2 
JAK2  Janus kinase 2 
KCNN4  potassium calcium-activated channel subfamily N member 4 
KIF23  kinesin family member 23 
KLF1  Kruppel like factor 1 
LARS2  leucyl-tRNA synthetase 2 
MAD2L2 mitotic arrest deficient 2 like 2 
mtATP6 mitochondrially encoded ATP synthase 6 
NCOA4  nuclear receptor coactivator 4 
NDUFB11 NADH:ubiquinone oxidoreductase subunit B11 
NHP2  NHP2 ribonucleoprotein 
NOP10  NOP10 ribonucleoprotein 
NT5C3A 5'-nucleotidase 
PALB2  partner and localizer of BRCA2 
PANK2  pantothenate kinase 2 
PARN  poly(A)-specific ribonuclease 
PCBP1  poly(rC) binding protein 1 




PFKM  phosphofructokinase 
PGK1  phosphoglycerate kinase 1 
PIEZO1  piezo type mechanosensitive ion channel component 1 
PIM1  Pim-1 proto-oncogene 
PKLR  pyruvate kinase L/R 
PLA2G6 phospholipase A2 group VI 
PUS1  pseudouridine synthase 1 
RAD50  RAD50 double strand break repair protein 
RAD51C RAD51 paralog C 
RFWD3  ring finger and WD repeat domain 3 
RHAG  Rh associated glycoprotein 
RPL11  ribosomal protein L11 
RPL15  ribosomal protein L15 
RPL19  ribosomal protein L19 
RPL26  ribosomal protein L26 
RPL27  ribosomal protein L27 
RPL31  ribosomal protein L31 
RPL35A  ribosomal protein L35a 
RPL36  ribosomal protein L36 
RPL5  ribosomal protein L5 
RPL9  ribosomal protein L9 
RPS10  ribosomal protein S10 
RPS15  ribosomal protein S15 
RPS17  ribosomal protein S17 
RPS19  ribosomal protein S19 
RPS24  ribosomal protein S24 
RPS26  ribosomal protein S26 
RPS27  ribosomal protein S27 
RPS27A  ribosomal protein S27a 
RPS28  ribosomal protein S28 
RPS29  ribosomal protein S29 
RPS7  ribosomal protein S7 
RTEL1  regulator of telomere elongation helicase 1 
SEC23B  Sec23 homolog B 
SF3B1  splicing factor 3b subunit 1 
SH2B3  SH2B adaptor protein 3 
SLC11A2 solute carrier family 11 member 2 
SLC19A2 solute carrier family 19 member 2 
SLC25A37 solute carrier family 25 member 37 
SLC25A38 solute carrier family 25 member 38 
SLC25A39 solute carrier family 25 member 39 
SLC2A1  solute carrier family 2 member 1 
SLC40A1 solute carrier family 40 member 1 
SLC4A1  solute carrier family 4 member 1 (Diego blood group) 
SLX4  SLX4 structure-specific endonuclease subunit 




SPTA1  spectrin alpha 
SPTB  spectrin beta 
STEAP3  STEAP3 metalloreductase 
TERC  telomerase RNA component 
TERT  telomerase reverse transcriptase 
TF  transferrin 
TFR2  transferrin receptor 2 
TFRC  transferrin receptor 
TINF2  TERF1 interacting nuclear factor 2 
TMPRSS6 transmembrane serine protease 6 
TPI1  triosephosphate isomerase 1 
TRNT1  tRNA nucleotidyl transferase 1 
TSR2  TSR2 
UBE2T  ubiquitin conjugating enzyme E2 T 
UGT1A1 UDP glucuronosyltransferase family 1 member A1 
UROS  uroporphyrinogen III synthase 
USB1  U6 snRNA biogenesis phosphodiesterase 1 
VHL  von Hippel-Lindau tumor suppressor 
WDR45  WD repeat domain 45 
WRAP53 WD repeat containing antisense to TP53 
XK  X-linked Kx blood group 
XRCC2  X-ray repair cross complementing 2 








iv. List of Abbreviations 
 
Abbreviation Meaning 
∆∆Ct  Delta delta Ct method 
ACMG  American College of Medical Genetics  
AD  Autosomal dominant inheritance 
AIC  Akaike information criteria  
AML  Acute myelogenous leukemia  
AR  Autosomal recessive inheritance 
AUC   Area Under the Curve 
BEA  BioMark Expression Analysis 
BM  Bone marrow  
bp  Base pair 
CDA  Congenital dyserythropoietic anemia  
cDNA   Complementary DNA 
CE  Congenital Erythrocytosis  
CEP  Congenital Erythropoietic Porphyria  
CMV   Cisplatin, methotrexate vinblastine chemotherapy  
CNSHAs Congenital nonspherocytic hemolytic anemia  
CNVs  Copy number variants  
CoDysAn Congenital Dyseroproyetic Anemia project 
CSA  Congenital sideroblastic Anemia  
csv  Comma separated value (file format) 
Ct  Cycle threshold  
DBA  Diamond-Blackfan anemia  
DC  Dyskeratosis congenital  
DHS1  Dehydrated hereditary stomatocytosis type 1  
DHS2  Dehydrated hereditary stomatocytosis type 2  
DNA  Deoxyribonucleic acid 
ds-cDNA Double-stranded cDNA  
DSS  Disease-specific survival  
EFS  Event-free survival  
EMA  European Medicines Agency 
ENET   Elastic Net  
EPP  Erythropoietic Protoporphyria  
ExAC  Exome Aggregation Consortium 
FA  Fanconi anemia  
FDA  Food and Drug Administration 
fdr  False discovery rate  
FFPE  Formalin-Fixed Paraffin-Embedded 
FTM  Fundación Teresa Moretó (Teresa Moretó Fundation) 
GTR  NCBI’s Genetic Testing Registry  
HA  Hemolytic Anemia 




HB  Hemoglobin 
HGSV   The Human Genome Structural Variation Consortium 
HGTiP  Hospital Germans Trias i Pujol  
HH  Hereditary Hemochromatosis 
HHCS  Hereditary Hyperferritinemia Cataract Syndrome  
HHD  Hereditary Hematological Diseases 
IFC  Integrated fluidic circuits  
IRE  Iron-responsive element  
IRIDA  Iron-refractory Iron-Deficiency Anemia  
IRP  Iron regulatory protein 
LASSO   Least Absolute Shrinkage and Selection Operator 
MAF  Minor allele frequency 
MCV  Mean corpuscular volume  
MDS  Myelodysplastic syndrome 
MDS-nonRS Myelodysplastic syndrome without ring sideroblasts development  
MDS-RS  Myelodysplastic syndrome with ring sideroblasts development  
MDS-RS-MLD MDS with multilineage dysplasia and ring sideroblasts  
MDS-RS-SLD MDS with single linage dysplasia and ring sideroblasts  
MIBC  Muscle invasive bladder cancer  
MLASA  Mitochondrial myopathy with lactic acidosis and sideroblastic anemia  
MLPA  Multiplex ligation-dependent probe amplification 
MR  Magnetic resonance  
mtDNA  Mitochondrial DNA  
Mut  Mutation 
NA  Not available 
NAC  No Amplification Control 
NBIA  Neurodegeneration with brain Iron Accumulation  
NGS  Next Generation Sequencing  
NMD  Nonsense mediated decay  
nonRS  Myelodysplastic syndrome without ring sideroblasts development  
NTC  No Template Control 
OMIM  Online Mendelian Inheritance in Man 
OS  Overall survival  
PCR  Polymerase Chain Reaction 
PFS  Progression-free survival  
PMPS  Pearson marrow-pancreas syndrome  
qPCR  Quantitative Polymerase Chain Reaction 
R&D&I  Research and Development and Innovation 
REC  Research Ethics Committees  
RIN  RNA Integrity Number  
RLS  Restless leg syndrome 
RNA   Ribonucleic acid  
ROC   Ceiver Operating Characteristics)  
RS  Myelodysplastic syndrome with ring sideroblasts development  
RV  Regular Values 




SIF  Sample information file 
SIFD  Sideroblastic anemia, B cell immunodeficiency, fevers and developmental delay  
SMS  Single molecule sequencing  
SNVs  Single nucleotide variants  
TGS  Third Generation sequencing  
TNM   Malignant tumors classification 
TRMA  Thiamine-responsive megaloblastic anemia  
tRNA   Transfer RNA 
UTR  Untranslated region  
VUS   Variants of unknown clinical significance  
WES  Whole Exome Sequencing 
WG  Whole Genix  
WT  Wild-type  
XL  X-linked inheritance 
XLR  X-link recessive 
XLSA  X-linked sideroblastic anemia  



























Recent social, economic and cultural changes have brought the increase of the “knowledge-based 
economy.” Research & Development and Innovation (R&D&I) are fundamental aspects for the growth 
and evolution of a company. Innovation is fast becoming a critical factor in the long-term growth 
development and survival of companies. Therefore, in order to help solve the development and 
innovation challenges that the current environment demands, companies require employees with 
excellent training that respond to business needs. This situation remarks the need for close 
cooperation between education institutions and companies and the introduction of the industrial 
doctorate concept. 
An industrial doctorate is a process where a doctoral student develops a research project carried out 
at a company in collaboration with a university or research center. The research project is based on 
an in-depth investigation into a particular and relevant problem for the company, which is supervised 
by experts from universities or research institutions. Therefore, the doctoral thesis serves to bridge 
the gap between industry and academia.  
The benefits of the “hybrid” industrial doctoral degree respect traditional PhDs are: 
• The doctoral research is conducted in the workplace, so the investigation is put into practice 
in the industrial environment. 
• The company will be able to gain valuable academic knowledge that could be industrialized.  
 
Whole Genix 
This industrial Ph.D. program has been carried out in Whole Genix company. Whole Genix (WG) is a 
company dedicated to providing genetic analyses and to help hospitals and clinics in the diagnosis of 
different diseases. WG encourages to the improvement of people’s health and quality of life utilizing 
the latest biomedical techniques. 
WG offers specialized counseling in clinical genetics to doctors and hospitals regarding new forms of 
prevention, early diagnosis and the effective treatment of diseases, especially in the field of neoplastic 
processes. The company is a pioneer in translational medicine and precision medicine on neoplastic 
diseases. One of the revolutionary services is the analysis of genetic markers, resulting from the study 
of complete exomes (Whole Exome Sequencing, WES) from clinic Formalin-Fixed Paraffin-Embedded 
samples (FFPE), selecting those genetic targets that provide the oncologist with the necessary 
information to apply the most effective personalized medicine to a given patient. 
WG offers services not only related to neoplastic diseases but also in other disorders. These services 
include: 
• Development of custom next-generation sequencing panels: WG offers specialized counseling 
services to doctors and hospitals for the design, development, and production of specified 
genetic panels for sequencing. 
• Specialized analysis for the diagnosis or prevention of the disease: In order to set a specific 
diagnosis of the disease, WG performs an in-depth analysis of the data obtained from high-
throughput technology employing bioinformatics tools and protocols. 




• Interpretation of genomic sequencing data: We accomplish a selection and interpretation of 
clinically significant genetic data (genetic and structural variants, expression change), showing 
the genetic profile of patients in the framework of approved personalized therapies (FDA, 
EMA), or in the final phases of clinical trials. Finally, a concise clinical reported is delivered, 
supervised by experts in the field of clinical genomics and oncology. 
 
Which organizations are involved in this industrial Ph.D? 
This Industrial Ph.D. is carried out in Whole Genix company, in collaboration with two academic 
organizations: Josep Carreras Research Institute and the University of Vic - Central University of 
Catalonia. Part of the Ph.D. project has been performed with the participation of another company, 
BloodGenetics, which gave scientific guidance; and with the support of the non-profit entity Teresa 
Moreto Foundation (FTM), which provided laboratory facilities. 
 
Figure 0. 1. Institutions. Main company: Whole Genix; academic centers: Josep Carreras Research 
Institute and the University of Vic; other collaborators: BloodGenetics and Teresa Moreto Foundation 
Objectives of this industrial doctorate. 
Objectives 
The industrial research project for Whole Genix is formulated in four ideas:  
1. Acquire better know-how of Next Generation Sequencing (NGS) protocols. NGS technology 
is growing up faster, and WG needs to be updated to last technology and protocols.  
2. Cover different types of cancer and expand to other genetic diseases. WG is specialized in 
neoplastic diseases. 
3. Develop new bioinformatic and telemedicine tools for analysis of different omics data. 
Computational science is the base of this biotech company, and the development of new 




4. Progress towards personalized medicine. WG wants to endorse genetics and genomics in 
research and integrate this knowledge into clinical medicine to help accomplish the promise 
of personalized medicine. 
Projects  
 
In order to accomplish the WG objectives, four projects have been carried out: 
Refining and improving an NGS gene panel for clinical diagnosis of hereditary hematologic diseases 
and focus on diseases with ferritin alterations. 
The goal of this project is to improve an already established NGS-gene panel for rare inherited blood 
diseases in order to accelerate diagnostics. Moreover, additional research in the FTL gene has been 
carried out due to its correlation with five hematological disorders. (See page 7) 
CoDysAn: a web tool for the diagnosis of Congenital Dyserythropoietic Anemia  
CoDysAn aims to provide a responsive webpage that provides practical information about congenital 
dyserythropoietic anemia (CDA) awareness and a step-by-step diagnostic tool. (See page 59) 
BEA (BioMark Expression Analysis): a web tool to perform relative expression analysis from Fluidigm – 
BioMark raw data.  
By creating BEA program, the objective is to provide a web tool that helps scientists to analyze qPCR 
data generated from one high-throughput technology: Fluidigm – BioMark system. The analysis 
includes relative quantification (∆∆CT method) and appropriated statistical testing to identify 
differentially expressed genes between tested groups. (See page 77) 
Pipeline for the construction of gene expression signatures for prediction and prognosis using data 
from patients with muscle-invasive bladder cancer. 
In this project, the goal is to build the optimal statistical analysis, to find a clinical-molecular signature 
in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy, in order to 
predict the prognosis and efficacy of platinum-based chemotherapies. (See page 103) 
Heterogenicity of the projects 
The four projects described before cover the business needs of Whole Genix, for what the industrial 
doctorate was developed. (1) A better knowledge of NGS protocols will be acquired by developing the 
NGS panel for hereditary hematological diseases. (2) In order to cover other types of cancer and also 
expand the service to other diseases, we will study samples from bladder cancer, and from different 
hematological rare diseases. (3) CoDysAn and BEA tools will help to improve new skills in new 
bioinformatic tool development. (4) Overall, all projects help to acquire more knowledge of different 
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1.1.1. Hereditary Hematologic Diseases NGS Panel 
In order to achieve the first goal of the thesis, I contributed in the development of NGS targeted gene 
panel in Hereditary Hematologic Diseases (HDD). 
1.1.1.1. Hereditary hematological diseases 
One of the largest organs in the human body is blood, a liquid tissue containing several types of 
specialized cells needed for the correct performance of the human body. A wide variety of blood 
disorders can appear when one or more of these cell types are damaged. There is a broad spectrum 
of hematology diseases that are divided into oncological and non-oncological. Hereditary 
hematological diseases (HHD) are non-oncological disorders that are transmitted from parents to 
offspring (De Falco et al. 2014; 2013; Caroline Kannengiesser et al. 2011; Sara Luscieti et al. 2013). 
These diseases are also called benign or non-malignant hematological diseases and cover a broad 
spectrum of disorders (Table 1.1 and Supplementary Material Table S1). 
Table 1. 1 Hereditary hematological disorders 
Studied hereditary hematological disorders (HHD) groups 
1 Hereditary hemochromatosis 
2 Congenital sideroblastic anemia 




Microcytic and hypochromic anemia with iron 
overload 
Iron refractory Iron Deficiency Anemia 
Wilson disease 
  
4 Congenital dyserythropoietic anemia    
5 Congenital Erythrocytosis / Familial Polycythemia 
   




7 Congenital Erythropoietic Protoporphyria and 
Congenital Erythropoietic Porphyria 
   





9 Neurodegeneration with Brain Iron Accumulation  
Disorders 
  
10 Hyper- and Hypoferritinemia   
 
1.1.1.2. Hereditary Hemochromatosis  
Hereditary hemochromatosis (HH) is a group of genetic disorder characterized by excessive 
accumulation of iron in vital organs, due to the disruption of the iron regulation in the body. HH has 
an estimated prevalence of up to 1 in 100 individuals in northern European populations 
(Merryweather-Clarke et al. 2000). Iron overload in HH is associated with a variety of genetic 
conditions. Of these, HFE hemochromatosis (Hemochromatosis Type 1) is by far the most frequent 





due to a homozygous missense mutation in HFE gene: C282Y (rs1800562). HFE protein is responsible 
for regulating hepcidin, the primary iron regulatory hormone. When iron is high in the system, 
hepcidin is secreted by the hepatocytes, decreasing intestinal iron absorption in the enterocytes and 
decreasing iron release by macrophages. Hepcidin maintains iron levels in a physiologic interval. When 
the C282Y variant is present, the expression of hepcidin is not stimulated in response to excess iron, 
resulting in an inappropriate iron loading in the body (Crownover et al. 2013). 
Persons with HH usually are clinically asymptomatic, especially in the early stages. Women have less 
severe disease manifestation due to the menstruation (24-fold less risk of iron-overload respect men) 
(Allen et al. 2009). When symptoms are presents, the most common are weakness, lethargy, erectile 
dysfunction and arthralgias (McDonnell et al. 1999). 
Beyond the HFE C282Y mutation, other rare forms of genetic iron overload have been identified, 
presenting pathogenic mutations in other genes. Up to now, five hereditary hemochromatoses have 
been described discerning on the molecular biology aspects (Table 1.2 and Figure 1.1).  
Hereditary hemochromatosis Type 1 (OMIM #235200) is the classical HFE gene mutation already 
described.  
Hereditary hemochromatosis Type 2 or juvenile hemochromatosis is caused by homozygous or 
compound heterozygous mutation on HFE2 gene (type 2A; HFE2A; OMIM #602390) (Papanikolaou et 
al. 2004) or homozygous mutation in the HAMP gene (type 2B; HFE2B; OMIM #613313)(Roetto et al. 
2003). Manifestation appears before 30 years of age.  
Hereditary hemochromatosis Type 3 (HFE3; OMIM #604720) is caused by homozygous or compound 
heterozygous mutation in the transferrin receptor-2 gene (TFR2)(Camaschella, Roetto, et al. 2000). 
Hereditary hemochromatosis Type 4 (HFE4; OMIM #606069) is an autosomal-dominant condition 
caused by heterozygous mutation in the SLC40A1 (ferroportin) gene (Njajou et al. 2001).  
Hereditary hemochromatosis Type 5 (HFE5; OMIM #615517) is caused by heterozygous mutation in 
the FTH1 gene – Autosomal-dominant inheritance. Only one Japanese family have been reported (J. 
Kato et al. 2001). 
Table 1. 2 Hereditary hemochromatosis sub-types 
Type OMIM Inheritance Genes 
Hereditary hemochromatosis Type 1 235200 AR HFE 
Hereditary hemochromatosis Type 2A 602390 AR HFE2 
Hereditary hemochromatosis Type 2B 613313 AR HAMP 
Hereditary hemochromatosis Type 3 604250 AR TFR2 
Hereditary hemochromatosis Type 4 606069 AD SLC40A1 
Hereditary hemochromatosis Type 5 615517 AD FTH1 
HFE, Hereditary hemochromatosis; AR, autosomal recessive, AD, autosomal dominant; OMIM, Online Mendelian 
Inheritance in Man 




Figure 1.1 Proteins involved in the regulation of hepcidin and the development of Hereditary Hemochromatosis (HH). HFE 
is decoupled from the transferrin receptor 1 (TFR1) when there are high levels of transferrin saturated with iron (TF-2Fe3+) 
and interact with the transferrin receptor 2 (TFR2) to activate the transcription of the HAMP gene that encodes to hepcidin. 
The TFR2-HFE complex also interacts with hemojuvelin (HJV or HFE2), the co-receptor of BMP6 (bone morphogenic protein6), 
to activate the hepcidin transcript. The hepcidin is produced and secreted by the hepatocytes, and interacts with the iron-
regulated transported ferroportin-1 (FPN1) inhibiting its primary function: to prevent iron to be released into the circulation 
and decrease iron-plasma concentration. In hemochromatosis 1,2 and 3 the signaling pathway of hepcidin production is 
affected since that its expression is reduced, which leads to an over-absorption of intestinal iron, and an iron overload in the 
organism. Figure adapted from chapter 30 book Eritropatología author Dr. Mayka Sanchez (Sanchez and Altés 2017). 
1.1.1.3. Congenital sideroblastic Anemia and acquired sideroblastic Anemia 
Sideroblastic anemias are anemic disorders characterized by the presence of ring sideroblasts in the 
bone marrow aspirate smear. Ring sideroblasts are pathologic iron deposits in erythroblast 
mitochondria (Patnaik and Tefferi 2017). These disorders are typically divided into two groups, 
congenital sideroblastic anemia (CSA), and acquired sideroblastic anemia (non-hereditary), which 
include the well-defined subtype Myelodysplastic syndrome (MDS) with ring sideroblasts: MDS with 
single lineage dysplasia and ring sideroblasts (MDS-RS-SLD), and MDS with multilineage dysplasia and 
ring sideroblasts (MDS-RS-MLD). CSA can be classified into four types depending on the affected 
molecular pathway: heme biosynthesis, iron-sulfur (Fe-S) cluster biosynthesis, mitochondrial protein 
synthesis, and t-RNA biosynthesis (Table 1.3 and Figure 1.2) (Bottomley and Fleming 2014; Ducamp 
and Fleming 2019). 
CSA caused by defects in heme biosynthesis 
Heme is the principal element of hemoglobin, composed by a porphyrin ring with an atom of iron. One 
heme molecule binds one molecule of oxygen. Several enzymes are involved in the heme biosynthesis. 
Impairment of any of these enzymes could cause anomaly heme synthesis and affect iron 
homeostasis, leading to iron overload in mitochondrial erythroblast and the clinical manifestation of 
sideroblastic anemia (Bottomley 2006; Fontenay et al. 2006). Hitherto, three genes encoding enzymes 
that participate in the heme biosynthesis have been identified to cause this type of sideroblastic 
anemia: ALAS2, SLC25A38, and SLC19A2. 
X-linked sideroblastic anemia due to ALAS2 mutation 
X-linked sideroblastic anemia (XLSA; OMIM #300751) is the most prevalent form of CSA (around 40% 
of cases (Bergmann et al. 2009), and it is caused by mutations in ALAS2 gene (Harigae and Furuyama 





of the disease is much higher in men than in women. To date, more than eighty different mutations 
in ALAS2 have been reported, including missense, nonsense and frameshift mutation distributed from 
exon 5 to exon 11 and in regulatory regions (Ducamp and Fleming 2019; Long et al. 2018). Mutation 
in this gene leads to ALAS2 enzyme deficiency, disturbing the heme synthesis which results in iron 
overload in mitochondrial erythrocyte precursor and anemia.  
SLC25A38 deficiency 
The second most prevalent nonsyndromic CSA is caused by a mutation in the SLC25A38 gene (OMIM 
#205950), located on chromosome 3p22.1 This gene encodes an erythroid-specific protein of the inner 
mitochondrial membrane, and is involved in the importation of glycine into mitochondria, which is 
essential for the ALA synthesis and the generation of heme. Defects of the mitochondrial SLC25A38 
transporter causes severe hypochromic microcytic anemia with the accumulation of iron in the 
mitochondria of erythroblasts, and the formation of ring sideroblasts. This disease is inherited in 
autosomal recessive manner.  
Thiamine-responsive megaloblastic anemia due to SLC19A2 mutation 
Thiamine-responsive megaloblastic anemia (TRMA) is a form of syndromic anemia (OMIM #249270), 
presenting other symptoms including diabetes and sensory deafness (Ricketts et al. 2006; Beshlawi et 
al. 2014).  
More than 30 mutations in SLC19A2 gene have been identified to cause this condition in autosomal-
recessive inheritance. SLC19A2 gene is located on chromosome 1q23.3 and encodes high-affinity 
thiamin transporter, which is responsive to the thiamine supplementation. The complete mechanism 
of pathogenesis of mutations in SLC19A2 is still unclear, but seems to lead to thiamin deficiency, and 
affect the generation of succinyl-CoA and consequently, a defective synthesis of heme (Labay et al. 
1999; Setoodeh et al. 2013). 
CSA caused by defects in iron-sulfur cluster biosynthesis 
Iron-sulfur (Fe-S) clusters are inorganic cofactor synthesized in the mitochondria by comprising iron 
and sulfur. These clusters are transported out of the organelle to regulate ALAS2 transcription and 
keep the maintenance of iron homeostasis. To date, three genes are involved in the development of 
sideroblastic anemia due to a defect in iron-sulfur cluster biosynthesis: ABCB7, GLRX5 and HSPA9. 
X-linked SA with ataxia due to defects in ABCB7 
Sideroblastic microcyst anemia with X-linked ataxia (XLSA/A) is a syndromic form XLSA associated with 
spinocerebellar ataxia. XLSA/A is caused by mutations in ABCB7 gene (Allikmets et al. 1999) (OMIM 
#301310), which is located on chromosome Xp13 and encodes a mitochondrial transporter of FE-S 
cluster. The ABCB7 protein is situated in the inner membrane of mitochondria and is fundamental for 
hematopoiesis. The deficiency of the Fe-S cluster leads to the activation of the IRP1 protein that 
inhibits the synthesis of the ALAS2 protein, the first enzyme in the construction of the heme group, 
and finally leading to anemia. ABCB7 gene is expressed not only in bone marrow but also in the 
cerebellum so that iron overload can happen in the mitochondria of the nervous system (Napier 2005). 
Glutaredoxin 5 deficiency 
GLRX5 gene is localized on chromosome 14q32.13 and encodes glutaredoxin 5, a mitochondrial 
protein, with an essential role in the formation of iron-sulfur clusters (Fe-S cluster). The deficiency of 
this enzyme engenders a mild microcytic hypochromic anemia with iron overload in the liver, an 
extension of spleen and liver and type 2 diabetes (OMIM #616860). Only two mutations have been 
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reported with recessive inheritance transmission: and homozygous splicing mutation (Camaschella et 
al. 2007) and two compound heterozygous mutations (G. Liu et al. 2014).  
HSPA9 deficiency 
Heat shock protein family A member 9 (HSPA9) is a protein constituent of the Fe-S cluster assembly 
complex, involved in its biogenesis. This protein is encoded by HSPA9 gene, located on chromosome 
5q31.2. Mutation in HSPA9 has been described to generate a severe loss of function allele and 
resulting in the development of CSA (OMIM #182170) in recessive or pseudo-dominant inheritance 
manner (Schmitz-Abe et al. 2015). 
HSCB deficiency 
Recently, one patient has been reported to have two mutations in the HSBC gene, a frameshift variant 
and a nucleotide substitution in the promoter area of the gene, that is predicted to alter a conserved 
ETS transcription factor binding site (Crispin et al. 2017). HSCB cooperate with HSPA9 to stimulate 
ATPase activity and promote the transfer of Fe-S cluster to target proteins 
CSA caused by mitochondrial protein synthesis defects and mitochondrial respiratory protein 
mutations 
The mammalian mitochondrial respiratory chain compromises of several subunits encoded by 
mitochondrial DNA (mtDNA) and NDUFB11. Dysfunction in the respiratory chain results in a deficiency 
of cytochrome c, iron reduction inability and impaired heme biosynthesis. As a result, iron is 
accumulated in the mitochondria and sideroblastic anemia appears. Several genes associated with 
mitochondrial respiratory chain pathway have been found to be causative of this condition. We have 
separated these genes in: CSA caused by mitochondrial protein synthesis defects and CSA caused by 
mitochondrial protein synthesis defects mitochondrial respiratory protein mutations 
CSA caused by mitochondrial protein synthesis defects 
Pearson marrow-pancreas syndrome (PMPS) 
PMPS is a rare syndrome presented in early childhood associated with lactic acidosis, ataxia, hepatic 
failure and endocrine pancreas dysfunction (OMIM #557000). Nearly half of the patients reported 
have been detected to carry a 4977-bp deletion in the mitochondrial DNA (mtDNA), affecting essential 
mitochondrial tRNAs for the translation of proteins (Pearson et al. 1979; Rotig et al. 1989).  
Mitochondrial myopathy with lactic acidosis and sideroblastic anemia (MLASA) 
Mitochondrial myopathy with lactic acidosis and sideroblastic anemia (MLASA) belongs to the 
heterogeneous family of metabolic myopathies. MLASA is an autosomal recessive disorder caused by 
defects in PUS1 and YARS2 genes, denominated MLASA1 and MLASA2 respectively. 
The MLASA1 subtype is due to mutations in the gene PUS1, which is located at 12q24.33 and encodes 
for nuclear pseudo-uridine synthase 1 (OMIM #600462). MLASA2 form is due to mutations in the 
YARS2 gene (Riley et al. 2013) that codes for the mitochondrial enzyme tyrosyl-tRNA synthetase 
(OMIM #613561). Mutation in PUS1 and YARS2 compromise the translation of respiratory complexes, 
particularly complex I and IV, leading to mitochondrial respiratory chain dysfunction.  
Sideroblastic anemia, B cell immunodeficiency, fevers and developmental delay (SIFD) 
SIFD is a severe form of congenital sideroblastic anemia characterized by severe microcytic anemia, B-





caused by mutations in the TRNT1 gene, which encodes the CCA addition enzyme, an essential enzyme 
that catalyzes the inclusion of CCAs at the 3 ‘end of the tRNA precursors (Wiseman et al. 2013; 
Chakraborty et al. 2014). This reaction is crucial for the tRNAs maturation, so a mutation in TRNT1 
leads to decreased mitochondrial protein synthesis, resulting in mitochondrial respiratory chain 
dysfunction in erythroid cells. The disease occurs in childhood with recurrent fever episodes, 
gastrointestinal disorders, developmental delay, convulsions, ataxia and sensorineural deafness.  
LARS2 deficiency 
LARS2 encodes mitochondrial leucyl-tRNA synthase, which can attach leucine to its cognate tRNA. To 
date, two mutations have been reported in homozygous and in heterozygous compound form (Riley 
et al. 2015). Patients exhibit syndromic sideroblastic anemia, including hydrops, lactic acidosis, and 
“Perrault syndrome” (premature ovarian failure and hearing loss). 
CSA caused by mitochondrial respiratory protein mutations 
MT-ATP6 sideroblastic anemia (MT-ATP6-SA) 
A single nucleotide variation in mtDNA-encoded ATP6 gene (MT-ATP6) has been reported to cause 
MLASA-like phenotype (OMIM #500011). This mutation causes respiratory chain complex V defect and 
is inherited in a maternal or sporadic pattern (Burrage et al. 2014; Berhe et al. 2018).  
CSA due to defects in NDUFB11 
One deletion, no other than c.276_278del, in NDUFB11 gene has been identified to cause sideroblastic 
anemia and variable symptoms, including lactic acidosis (Lichtenstein et al. 2016). NDUFB11 is an X-
linked gene, which encodes noncatalytic subunit mitochondrial respiratory complex I protein B11. The 
underlying molecular pathogenesis of mutation in NDUFB11 remains unclear. 
Other cases: 
CSA due to mutation in STEAP3 
A new form of hypochromic and transfusion-dependent anemia associated with a nonsense mutation 
of the STEAP3/TSAP6 gene (AHMIO2 OMIM #609671) has been described (Grandchamp et al. 2011)). 
The clinical presentation of the patients was in some respects similar to that of non-syndromic 
sideroblastic anemia (CSA) with the presence of sideroblasts and iron overload. However, in this 
family, protoporphyrin levels are increased, while they are normal or even low in cases of non-
syndromic CSA. This gene codes for prostate transmembrane epithelial antigen (steap3), a 
ferrireductase involved in the reduction of iron in the endosomes of erythroblasts. The heme or the 
Fe-S biosynthesis may be compromised due to defects in STEAP3, although the molecular mechanism 









Figure 1.2. Scheme of the pathways and genes involved in CSA in erythroid cells. The pathways implicated in the CSA 
pathogenesis are diagrammed: Heme biosynthesis pathway genes are in red (ALAS2, SLC25A38, SLC19A2); Iron-sulfur cluster 
biosynthesis are in green (GLRX5, HSPA9, HSCB, ABCB7); Genes implicated in the synthesis of mitochondrial proteins (PUS1, 
YARS2, TRNT1, LARS2) and respiratory chain proteins (MT-ATP6, NDUFB11) are in blue. The gene STEAP3 (in purple) is 
classified as other mechanism since its function occurs outside the mitochondria. ALA, delta-aminolevulinate synthase; CoA, 
succinyl-coenzyme A; PPgen, protoporphyringen; PPIX, protoporphyrin IX; IRP1, Iron regulatory protein 1; IRE, Iron regulatory 
protein; Fe/S, iron-sulfur; Tf, transferrin; TFR1, transferrin receptor 1. This figure is original and was designed by Beatriz 
Cadenas and adapted from different literature sources (Ducamp and Fleming 2019; Long et al. 2018). 
Acquired sideroblastic anemia, myelodysplastic syndrome with ring sideroblasts 
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders of hematopoietic 
stem cells characterized by peripheral blood cytopenias and the increased risk to progress to acute 
myelogenous leukemia (AML). MDS with single lineage dysplasia and ring sideroblasts (MDS-RS-SLD) 
and MDS with multilineage dysplasia and ring sideroblasts (MDS-RS-MLD) care two phenotypically 
well-defined subtypes of MDS that are characterized by ring sideroblasts (Arber et al. 2016). 
Iron overload is common in patients with MDS and has a negative influence on survival in these 
patients (worse overall survival and worse leukemia-free survival). Recently, somatic mutations in the 
SF3B1 gene, which is involved in RNA splicing machinery, have been reported to be particularly 





Table 1. 3 Genetic classifications of Sideroblastic anemias 
Pathway Disorder 
 
Gene Inheritance CSA class 
Heme 
biosynthesis 
X-linked sideroblastic anemia  XLSA ALAS2  X-linked Non-syndromic 
SLC25A38 deficiency SA SLC25A38 AR Non-syndromic 
Thiamine-responsive megaloblastic 
anemia  




X-linked SA with ataxia  XLSA/A  ABCB7  X-linked Syndromic 
Glutaredoxin 5 deficiency SA GLRX5 AR Non-syndromic 
HSPA9 deficiency SA HSPA9 AR/D? Non-syndromic 





Pearson marrow-pancreas syndrome PMPS mtDNA SP/M Syndromic 
MLASA1  MLASA PUS1 AR Syndromic 
MLASA2 MLASA YARS2  AR Syndromic 
Sideroblastic anemia, B cell 
immunodeficiency, fevers and 
developmental  
SIFD TRNT1  AR Syndromic 






MLASA-like  MLASA MT-ATP6 SP/M Syndromic 
CSA due to defects in NDUFB11 XLSA NDUFB11  X-linked Syndromic 
Other cause CSA due to defects in STEAP3 SA STEAP3 AD Syndromic 
Acquired SA MDS-RS-SLD 
 
 SF3B1 SOM N/A 




AD, autosomal dominant; AR, autosomal recessive; SP, sporadic; M, maternal; SOM, somatic; CSA, congenital sideroblastic 
anemia; SA, sideroblastic anemia, MLSASA, mitochondrial myopathy with lactic acidosis and sideroblastic anemia; N/A, Not 
applicable. MDS-RS-SLD, MDS with single lineage dysplasia and ring sideroblasts; MDS-RS-MLD, MDS with multilineage 
dysplasia and ring sideroblasts; MDS, Myelodysplastic syndrome 
1.1.1.4. Iron and Copper Related Anemias 
Defects in genes involved in the metabolism of iron (globin genes, heme synthesis, maintenance of 
iron, or the acquisition of iron by erythroid precursors) genes can lead to hypochromic and microcytic 
anemias (Table 1.4). 
Atransferrinemia  
Atransferrinemia (OMIM #209300) is a rare autosomal recessive disorder, characterized by microcytic 
anemia and by iron loading, caused by mutations in the gene that codes for Transferrin (TF), a plasma 
protein that transports iron in the blood. Values of TF are usually half the standard values (204-360 
mg/dl) in carriers and extremely low in affected patients (lack of TF is incompatible with life). The 
decrease in TF levels leads to a reduction in the transfer of iron to the bone marrow, resulting in 
reduced development of erythroid precursors, and the accumulation of iron in peripheral tissues. 
Affected patients show severe microcytic hypochromic anemia in childhood, grow retardation and 
frequent infections. Mainly, iron overload occurs in the liver, joints, heart, pancreas, thyroid, kidney 
and bone, leading to symptoms such as liver problems, heart malfunction, arthropathy and 
hypothyroidism (Athiyarath et al. 2013).  




Aceruloplasminemia (OMIM #604290) is an autosomal recessive disorder due to mutations in the gene 
encoding ceruloplasmin (CP), which is involved in the release of iron from macrophages and other cells 
to the blood. Clinical manifestation of the disease includes reduced levels or absence of serum 
ceruloplasmin, low levels of serum iron, high serum ferritin, mild to moderate microcytic anemia, iron 
overload in the tissues, diabetes mellitus, and late-onset neurological symptoms (Kono 2013). 
Microcytic and hypochromic anemia with iron overload 
Mutations in the SLC11A2 gene generate a deficiency of the divalent metal transporter 1 (DMT1), a 
major transporter involved in the absorption of duodenal iron and for the transfer of iron from the 
endosomes to the cytosol. Abnormal DMT1 may disturb the development of erythroid cells and leads 
into microcytic and hypochromic anemia with progressive iron overload (AHMIO1; OMIM # 206100). 
This disease is inherited in an autosomal recessive manner (Iolascon et al. 2006).  
Grandchamp et al. identified a nonsense mutation of the STEAP3/TSAP6 gene in three siblings with a 
new form of hypochromic anemia and iron overload (AHMIO2 OMIM #609671) (Grandchamp et al. 
2011).  The clinical presentation of the patients was chronic hypochromic anemia with the presence 
of sideroblasts and iron overload, similar to that of non-syndromic sideroblastic anemia (CSA), but 
with increased level of protoporphyrin. STEAP3 gene codes for prostate transmembrane epithelial 
antigen (steap3) that is involved in regulation of cell cycle, apoptosis, and in the secretion of non-
classical proteins, including exosomes. In iron metabolism, the STEAP3/TSAP6 gene codes for a 
ferrireductase involved in the acquisition of iron by red blood cells.  
 
Table 1. 4 Genetic classification of Iron and Copper deficiency Anemia 
Disease OMIM Gene/s Inheritance 
Atransferrinemia 209300 TF AR 
Aceruloplasminemia 604290 CP AR 
AHMIO1 206100 SLC11A2 AR 
AHMIO2 609671 STEAP3 AR 
Iron-refractory Iron-Deficiency Anemia (IRIDA) 206200 TMPRSS6 AR 
Wilson disease 277900 ATP7B AR 
IRIDA-like (new form)  TMPRSS6 + ACVR1 Digenic 
AHMIO1, microcytic and hypochromic anemia with iron overload type 1; AHMIO2, microcytic and hypochromic anemia 
with iron overload type 2; AR, autosomal recessive; AD, autosomal dominant 
 
Iron-refractory Iron-Deficiency Anemia (IRIDA) 
Protein matriptase-2, is a serine protease with an important function in the absorption of iron which 
encoded by TMPRSS6 gene. Mutations in this gene produce a reduction in the activity of matriptase-
2 in hepatocytes, increase the hepcidin activity inhibiting iron absorption and leads to moderate 
hypochromic microcytic anemia from birth. This disorder is named Iron-refractory Iron- Deficiency 
Anemia (IRIDA; #206200) and is inherited in autosomal recessive pattern (De Falco et al. 2013; 2014). 
Pagani et al, reported in 2017 a new form of IRIDA due to combined heterozygous mutations in 







Wilson disease (OMIM #277900) is an autosomal recessive disorder caused by mutations in the ATP7B 
gene and is characterized by severe accumulation of intracellular hepatic copper with subsequent 
hepatic and neurologic abnormalities (Thomas et al. 1995). 
 
1.1.1.5. Congenital dyserythropoietic anemia (CDA) 
Congenital dyserythropoietic anemia (CDA) is a heterogeneous group of inherited conditions 
characterized by abnormal production of red blood cells, due to erythropoietic maturation arrest 
phenomenon, that could lead to anemia of variable severity. Five different forms of CDA have been 
defined: type I, II, III, IV and XLTDA (Table 1.5). The shared symptoms include variable severity anemia, 
jaundice, hepatomegaly, splenomegaly, and progressive iron overload. Bone marrow examination 
reveals polychromatic erythroblasts with abnormal shape and size (Iolascon, Esposito, and Russo 
2012; Iolascon et al. 2013; Russo et al. 2014). 
Type I CDA may be caused by mutations in the CDAN1 gene (Dgany O et al., Am J Hum Genet, 2002 
Dec; 71 (6): 1467-74) (OMIM #224120), which codes for a protein involved in maintaining the integrity 
of the nuclear envelope.  Type I CDA is characterized by mild to severe anemia generally diagnosed in 
childhood or adolescence. Iron overload can lead to arrhythmia, congestive heart failure, diabetes, 
and chronic liver disease (cirrhosis). Variants in gene C15ORF41 has also been associated with being 
causative of CDA I (Babbs et al. 2013). 
Type II CDA is due to mutations in the SEC23B gene (Schwarz et al. 2009) (OMIM #224100), and is 
characterized by the presence of binucleated erythroblasts (diplo erythroblasts) with a double 
membrane derived from endoplasmic reticulum residues that are visualized by electron microscopy.  
CDA Type III (OMIM #105600) is a rare form of dyserythropoietic anemia characterized by moderate 
to mild and non-progressive hemolytic iron deficiency, dyserythropoiesis, large multinucleated 
erythroblasts in bone marrow, and macrocytosis in the peripheral blood. The clinical presentation is 
variable. Recently, the KIF23 gene has been described as the gene that causes the autosomal dominant 
form of CDA III. This gene codes for the mitotic kinesin-like protein 1 (MKLP1), which is a crucial protein 
for cytokinesis (Liljeholm et al. 2013).  
CDA IV (ORPHA293825, OMIM #613673) is caused by mutations in the KLF1 gene that encodes an 
erythroid transcription factor that plays a crucial role in the development of the erythroid lineage, 
including the expression of globin and other erythropoiesis genes. CDA IV is characterized by 
inefficient erythropoiesis and hemolysis that leads to severe anemia at birth with the requirement of 
multiple repeated transfusions. Patients showed increased levels of fetal hemoglobin, and vast multi-
nucleated erythroblasts with morphologic abnormalities.  
XLTDA, X-linked thrombocytopenia and dyserythropoietic anemia, (OMIM #300367) is a rare 
hematological disorder characterized by moderate to severe thrombocytopenia and abnormal 
platelet morphology and activity due to damage in the maturation of platelets. XLTDA is caused by 
mutations in the erythroid transcription factor GATA1, which play an essential role in the development 
of megakaryocytes and erythroid precursors. The disease affects mainly males as females are usually 
asymptomatic or have only mild symptoms (X-linked inheritance pattern). It is presented in infancy as 
a bleeding disorder with further manifestations of thrombocytopenia including epistaxis, petechiae, 
ecchymoses, or splenomegaly. 
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Other rare syndromes have been found to be associated with mutations in GATA1: X-linked 
thrombocytopenia (XLT), X-linked thrombocytopenia with beta-thalassemia (XLTT; OMIM #314050) 
and X-linked anemia with or without neutropenia and/or platelet abnormalities (XLANP, OMIM 
#300835) (Nichols et al. 2000; Hollanda et al. 2006). 
 
Table 1. 5 Classification of CDAs 
Subtype OMIM Gene Inheritance Cellular or hematological abnormalities 
CDA I 224120 CDAN1, 
C15ORF41 
AR Abnormal chromatin structure, chromatin 
bridge 
CDA II 224100 SEC23B AR Bi- or multi-nuclearity of mature erythroblasts 
CDA III 105600 KIF23 AD Giant multi-nucleated erythroblasts 
CDA IV 613673 KLF1 AD Multi-nucleated erythroblasts 
XLDA 300367 GATA1 X-linked CDA I or CDA II-like with thrombocytopenia 
AD, autosomal dominant; AR, autosomal recessive; CDA, Congenital dyserythropoietic anemia 
 
1.1.1.6. Congenital Erythrocytosis / Familial Polycythemia 
Congenital erythrocytosis or familial polycythemia is a hereditary hematological disorder, 
characterized by a high absolute mass of red blood cells caused by uncontrolled production of red 
blood cells. Clinical symptoms, if developed, include headache, dizziness, epistaxis, and exertional 
dyspnea. Although the hematologic disorder is present from birth, clinical symptoms can be detected 
at any time during childhood or adulthood. Hematologic manifestations include the presence of 
erythrocytosis without platelets or leukocytes incrementation and progression to leukemia. Low levels 
of serum EPO is found in type 1 familial erythrocytosis, while type 2 familial erythrocytosis shows 
normal or high EPO. Familial polycythemia is triggered by mutations in different genes (Table 1.6). 
Type 1 familial erythrocytosis or primary familial polycythemia (OMIM #133100) is due to mutations 
in the EPO receptor gene (EPOR), located on chromosome 19p13.3-p13.2 (Juvonen et al. 1991; 
Chapelle et al. 1993). EPOR mutations lead to hypersensitivity to EPO and cause the receptor to be 
permanently activated to stimulate red blood cells production. Few cases have been described 
following an autosomal dominant inheritance (Kralovics et al. 1997). The diagnosis is based on the 
presence of isolated erythrocytosis without splenomegaly, low levels of serum EPO, the normal affinity 
of hemoglobin for oxygen, and erythroid progenitors in the bone marrow exhibiting hypersensitivity 
to EPO. 
Polycythemia Vera is the most common form of primary polycythemia and is due to a somatic 
mutation in JACK2 and SH2B3 genes (Prchal 2005; Tefferi and Barbui 2017; Bento et al. 2014) [refs]. 
These genes need to be evaluated to exclude polycythemia Vera in the differential diagnosis of 
congenital erythrocytosis. 
Type 2 familial erythrocytosis (also known as Von Hippel-Lindau syndrome or Chuvash polycythemia; 
OMIM #263400) is an autosomal recessive disorder due to mutations in the VHL gene (3p25), 
characterized by an increased volume of erythrocytes, high serum EPO levels, and normal oxygen 
affinity (Ang et al. 2002). This type of familial erythrocytosis has aspects of both primary and secondary 
erythrocytosis: increased circulating levels of EPO, consistent with a secondary; and erythroid 





Type 3 familial erythrocytosis (OMIM #609820) is a disorder caused by heterozygous mutations in the 
EGLN1 gene (an autosomal dominant inheritance), located on chromosome 1q42. Phenotypic 
manifestations are similar than ECYT1 but showing average levels of EPO in blood (Ladroue et al. 
2008).  
Type 4 familial erythrocytosis (OMIM #611783) is an autosomal dominant disorder caused by 
mutations in the EPAS1 gene, that encodes the protein HIF2A (Percy et al. 2008). It is characterized by 
increased serum red blood cell mass and elevated serum hemoglobin and erythropoietin (EPO).  
Type 5 familial erythrocytosis (OMIM #617907) has been reported to be caused by heterozygous 
mutation in EPO gene. Deletion of single nucleotide in exon 2 of EPO gene produces a frameshift 
mutation that disturbs the translation of the EPO mRNA transcript (Zmajkovic et al. 2018).  
Type 6 familial erythrocytosis (OMIM #617980) and type 7 familial erythrocytosis (OMIM #617981) 
are autosomal dominant forms of erythrocytosis due to mutations in beta (HBB) and alpha globin 
genes (HBA1 or HBA2) (Charache, Weatherall, and Clegg 1966; González Fernández et al. 2009). 
Type 8 familial erythrocytosis is (OMIM #222800) caused by compound heterozygous mutation in the 
BPGM gene (Lemarchandel et al. 1992).  
Table 1. 6 Familial Erythrocytosis Subtypes 
Familial Erythrocytosis Type OMIM Gene/s Inheritance 
ECYT1 133100 EPOR AD 
  JAK2; SH2B3 SOM 
ECYT2 263400 VHL AR 
ECYT3 609820 EGLN1 AD 
ECYT4 611783 EPAS1 AD 
ECYT5 617907 EPO AD 
ECYT6 617980 HBB AD 
ECYT7 617981 HBA1; HBA2 AD 
ECYT8 222800 BPGM AR 
AD, autosomal dominant; AR, autosomal recessive 
 
1.1.1.7. Hereditary hemolytic anemia including membranopathies and enzymopathies 
Hemolytic anemia (HA) is a heterogeneous disorder represented by premature destruction of red 
blood cells, and is manifested in hereditary and acquired forms. Among hereditary hemolytic anemia, 
the most common causes are due to defects in the membrane of erythrocytes (membranopathies) 
and in the glycolytic pathways enzymes (enzymopathies). HA is commonly presented with severe 
expression in infancy, although milder forms are also shown in adulthood. Clinical manifestations 
include anemia, pallor, jaundice and in some cases splenomegaly. Other laboratory presentations are 
anemia of variable degree, mild-to-moderate chronic hemolysis and increased reticulocytes (Haley 
2017; Gallagher 2015). 
Membranopathies are a subgroup of hereditary hemolytic anemias, characterized by defects in red 
blood cells membrane due to abnormal cytoskeletal proteins. Peripheral blood smear analysis shows 
atypical erythrocyte shape. Mutations in genes encoding proteins that are implicated in the red cell 
membrane skeleton generate this type of hemolytic anemias (Table 1.7). The two most common types 
of membranopathy are hereditary spherocytosis (spherocytes) and hereditary elliptocytosis (elliptical-
shaped erythrocyte) (Bolton-Maggs et al. 2012). 
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Table 1. 7 Membranopathies subtypes 
 
OMIM GENE Inheritance 
Hereditary spherocytosis 
   
Type 1 182900 ANK1 AD 
Type 2 616649 SPTB AD 
Type 3 270970 SPAT1 AR 
Type 4 612653 SLC4A1 AD 
Type 5 612690 EPB42 AR 
Hereditary elliptocytosis 
   
Type 1 611804 EPB41 AR, AD 
Type 2 130600 SPAT1 AD 
Type 3 617948 SPTB AD 
Type 4 166900 SLC4A1 AD 
AD, autosomal dominant; AR, autosomal recessive 
 
The primary metabolic functions of erythrocytes include sustaining membrane proteins, conserving 
iron hemoglobin in the redox state and modulating the oxygen affinity of hemoglobin. These capacities 
are dependent upon the production of ATP, NADH, NADPH, and 2,3 diphosphoglycerate (Koralkova, 
van Solinge, and van Wijk 2014). Enzymopathies are the result of deficiencies in the glycolytic pathway 
enzymes, and they are also denominated as congenital nonspherocytic hemolytic anemia (CNSHAs), 
as these conditions do not present deficiencies in morphology in RBC. The two more common 
enzymatic defects are glucose 6-phosphate dehydrogenase (G6PD) deficiency and pyruvate kinase 
(PK) deficiency. Less frequent defects in other enzymes have been reported (Table 1.8). 
Glucose 6-phosphate dehydrogenase (G6PD) deficiency is a common disorder (more than 400 million 
people affected worldwide) caused by mutations in G6DP gene. This gene is located on the X 
chromosome (X-linked disorder), so males are more likely to be affected. Defects in this enzyme, 
reduce the production of NADPH, leading to the oxidation of hemoglobin sulfhydryl groups, 
hemoglobin precipitation and damages of the RBC membrane, and finally, to hemolysis (Beutler 2008).  
Pyruvate Kinase deficiency is the second most popular enzymopathy. Defects of PK results in the 
depletion of ATP and 2,3-DPG, but the molecular mechanism of hemolysis is not entirely understood 














Table 1. 8 Enzymopathy subtypes 
Enzymopathies OMIM Gene/s Inheritance 
Pyruvate kinase deficiency 266200 PKLR AR 
Hemolytic anemia, G6PD deficient 300908 G6PD XLD 
Hemolytic anemia due to hexokinase deficiency 235700 HK1 AR 
Hemolytic anemia, nonspherocytic, due to glucose phosphate 
isomerase deficiency 
613470 GPI AR 
Diphosphoglycerate mutase deficiency of erythrocyte, DPGM 
Deficiency (Erythrocytosis, familial, 8) 
222800 BPGM AR 
Hemolytic anemia due to glutathione reductase deficiency  GSR AR 
Hemolytic anemia due to glutathione synthetase deficiency 231900 GSS AR 
Hemolytic anemia due to glutathione peroxidase deficiency 614164 GPX1 AR 
Hemolytic anemia due to gamma-glutamylcysteine synthetase 
deficiency 
230450 GCLC AR 
Anemia, hemolytic, due to UMPH1 deficiency 266120 NT5C3A AR 
Hemolytic anemia due to adenylate kinase deficiency 612631 AK1 AR 
Phosphoglycerate kinase 1 deficiency 300653 PGK1 XLR 
Hemolytic anemia due to triosephosphate isomerase deficiency 615512 TPI1 AR 
Glycogen storage disease VII 232800 PFKM AR 
Glycogen storage disease XII 611881 ALDOA AR 
Hemolytic anemia due to elevated adenosine deaminase 102700 ADA AD 
Methemoglobinemia, type I and type II 613213 CYB5R3 AR 
AD, autosomal dominant; AR, autosomal recessive; XLR, X-link recessive 
 
1.1.1.8. Congenital Erythropoietic Protoporphyria and Congenital Erythropoietic 
Porphyria  
Erythropoietic porphyrias are metabolic disorders caused by defects in heme synthesis occurring in 
red blood cells, resulting in the aggregation of porphyrins and porphyrin precursors in erythrocytes. 
Beside increased levels of porphyrins in the urine, feces and blood, clinical manifestations include 
photosensitivity to visible light.  
Erythropoietic Protoporphyria (EPP) is an autosomal-recessive trait caused by mutation in FECH gene, 
which encodes the enzyme ferrochelatase (Kieke et al. 2019). EPP is clinically distinguished by 
photosensitivity to visible light initiated in early childhood, and biochemically by high levels of 
protoporphyrin in red blood cells. Two more genes have been identified to cause EPP: ALAS2 gene (X-
link inheritance)(Brancaleoni et al. 2016; Whatley et al. 2008) and CLPX (autosomal dominant) (Yien 
et al. 2017) (Table 1.9).  
Congenital Erythropoietic Porphyria (CEP) or Gunther disease is caused by a deficiency of the enzyme 
in the heme biosynthesis pathway (URO-S protein) that leads to a massive accumulation of isomeric 
porphyrins I (uro and coproporphyrins) in the bone marrow. The enzymatic deficiency appears due to 
mutations of the UROS gene, which encodes URO-S, in an autosomal recessive inheritance (Xu, Astrin, 
and Desnick 1996). 
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Table 1. 9 Congenital Erythropoietic Porphyria subtypes 
Type Acronym OMIM Gene Inheritance 
EPP EPP1 177000 FECH AR 
XLEPP 300752 ALAS2 X-Linked 
EEP2 618015 CLPX AD 
CEP CEO 263700 UROS AR 
AD, autosomal dominant; AR, autosomal recessive; XLR, X-link recessive 
 
1.1.1.9. Bone marrow failure 
The inherited bone marrow failure (BMF) syndromes are a heterogeneous group of disorders 
characterized by bone marrow failure usually in association with one or more somatic abnormalities. 
These diseases are often presented in infancy but may not do so until adulthood in some cases, and 
can be caused by defects in DNA repair-FA/BRCA pathway; telomere maintenance- dyskeratosis 
congenita-related genes; and ribosome biogenesis-Diamond-Blackfan anemia (DBA) genes.  
Fanconi anemia (FA) is a rare congenital heterogeneous disorder characterized by congenital 
progressive bone marrow failure, malformations, hematological problems and predisposition to 
malignancies in children. To date, 22 genes involved with the cross-linked DNA repairment, have been 
reported to be associated with FA (Table 1.10). Among these, FANCA is the most frequent (60-65%) 
(Solomon et al. 2015) The disorder is autosomal-recessive inherited in most of de cases, except for 
those rare cases with a mutation in FANCB (X-linked) and FANCR (autosomal dominant) (Knies et al. 
2017; Bagby 2018). 
Diamond-Blackfan anemia (DBA), or congenital hypoplastic anemia, is a rare congenital red blood cell 
aplasia that belongs to bone marrow failure disorders (Ulirsch et al. 2018; Da Costa et al. 2018). DBA 
is usually manifested in the first year of life with normochromic macrocytic anemia, reticulocytopenia, 
and a scarcity of erythroid precursors in the bone marrow. Patients show growth restriction, and about 
30-50% have physical anomalies (craniofacial, upper limb, and heart malformations).  DBA is 
considered a ribosomopathy, as this disorder is almost exclusively driven by haploinsufficient 
mutations in a ribosomal protein (RP) genes (Table 1.11).  
Dyskeratosis congenita (DC) is a rare multisystem disease characterized by defective telomere 
maintenance. Clinical aspects are heterogeneous and include BMF, cancer predisposition, and 
pulmonary and hepatic fibrosis (Kelmenson and Hanley 2017; Dokal 2011; Fernández García and 
Teruya-Feldstein 2014). In addition, patients can present abnormal skin pigmentation, leukoplakia, 
and nail dystrophy, although it is not always observed. 
DC is a genetically heterogeneous disorder, presented in three modes of inheritance: autosomal 
recessive, autosomal dominant and X-linked, and is caused by mutations in genes involved in the 
telomere maintenance. DKC1 was the first gene identified to be associated with DC, and it is the most 
frequent presentation of the (30%) (Heiss et al. 1998; Kelmenson and Hanley 2017). DKC1 encodes for 
the nuclear dyskerin protein and is X-linked inherited. In total, 12 genes have been reported to cause 








Table 1. 10 Genetic classification of Fanconi Anemia 
FA type Gene OMIM Inheritance 
FANCA FANCA 227650 AR 
FANCB FANCB 300514 XL 
FANCC FANCC 227645 AR 
FANCD1 BRCA2 605724 AR 
FANCD2 FANCD2 227646 AR 
FANCE FANCE 600901 AR 
FANCF FANCF 603467 AR 
FANCG XRCC9 614082 AR 
FANCI FANCI 609053 AR 
FANCJ BRIP1 609054 AR 
FANCL FANCL 608111 AR 
FANCM FANCM NA AR 
FANCN PALB2 610832 AR 
FANCO RAD51C 613390 AR 
FANCP SLX4 613951 AR 
FANCQ ERCC4 615272 AR 
FANCR RAD51 617244 AD 
FANCS BRCA1 617883 AR 
FANCT UBE2T 616435 AR 
FANCU XRCC2 617247 AR 
FANCV MAD2L2 617243 AR 
FANCW RFWD3 617784 AR 












CHAPTER I: Hereditary Hematologic Diseases NGS Panel 
25 
 
Table 1. 11 Genetic classification of DBA 
Subtype Gene OMIM Inheritance 
DBA1 RPS19 105650 AD 
DBA2 8p23.3-p22 606129 
 
DBA3 RPS24 610629 AD 
DBA4 RPS17 612527 AD 
DBA5 RPL35A 612528 AD 
DBA6 RPL5 612561 AD 
DBA7 RPL11 612562 AD 
DBA8 RPS7 612563 AD 
DBA9 RPS10 613308 AD 
DBA10 RPS26 613309 AD 
DBA11 RPL26 614900 AD 
DBA12 RPL15 615550 AD 
DBA13 RPS29 615909 AD 
DBA14 TSR2 300946 XLR 
DBA15 RPS28 606164 AD 
DBA16 RPL27 617408 AD 
DBA17 RPS27 617409 AD 
DBA18 RPL18 618310 AD 
DBA19 RPL35 618312 AD 
DBA20 RPS15A 618313 AD 
AD, autosomal dominant; AR, autosomal recessive; XLR, X-link recessive 
 
Table 1. 12 Genetic classification of Dyskeratosis congenita 
Subtype OMIM Gene Inheritance 
Dyskeratosis congenita, X-linked  305000 DKC1 XLR 
Dyskeratosis congenita, autosomal dominant 1 127550 TERC AD 
Dyskeratosis congenita, autosomal dominant 2 613989 TERT AD, AR 
Dyskeratosis congenita, autosomal recessive 4 613989 TERT AD, AR 
Dyskeratosis congenita, autosomal dominant 4 615190 PARN AD, AR 
Dyskeratosis congenita, autosomal recessive 5 615190 PARN AD, AR 
Dyskeratosis congenita, autosomal recessive 6 616353 PARN AR 
Dyskeratosis congenita, autosomal recessive 2 613987 NHP2 AR 
Dyskeratosis congenita, autosomal dominant 3 613990 TINF2 AD 
Dyskeratosis congenita, autosomal dominant 6 616553 ACD AD, AR 
Dyskeratosis congenita, autosomal recessive 7 616553 ACD AD, AR 
Dyskeratosis congenita, autosomal recessive 1 224230 NOP10 AR 
Dyskeratosis congenita, autosomal recessive 3 613988 WRAP53 AR 
Dyskeratosis congenita, autosomal dominant 4 615190 RTEL1 AD, AR 
Dyskeratosis congenita, autosomal recessive 5 615190 RTEL1 AD, AR 






1.1.1.10. Neurodegeneration with Brain Iron Accumulation Disorders  
Neurodegeneration with brain Iron Accumulation (NBIA) is a clinically and genetically heterogeneous 
group of neurodegenerative disorders. This disease is characterized by the accumulation of iron in the 
basal glia regions (globus pallidus and subsantia nigra), although other regions like the cortex and the 
cerebellum can be affected. The hallmarked clinical manifestations of this disorder are extrapyramidal 
symptoms, including progressive dystonia, spasticity, parkinsonism, and neuropsychiatric anomalies. 
To date, 15 genes have been reported as causative for this neurodegenerative disorder, of which only 
two are associated with iron metabolism: CP and FTL (Figure 1.3). This rare monogenetic disease is 
typically inherited in AR trait, although it has also been presented in AD and X-linked pattern (Table 




Figure 1. 3 Scheme of the genes associated to the pathogenesis of NBIA. The iron-proteins (CP and FTL) are represented 
in light blue; the proteins (PANK2 and COASY) involved in CoA synthesis are in pink; in yellow are the proteins linked to 
lipid metabolism (PLA2G6, FA2H,SCP2, CRAT, C19orf12); in orange are the proteins (WDR45, ATP13A2) implicated in 
autophagy; in grey are the proteins (RESP1 and AP4M1) related to vesicle trafficking; and the proteins in green (DCAF17 
and GTPBP2) in green still have unknown functions. Picture reproduced with permission from Levi et al. 2019. 
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Table 1. 13 Genetic classification of NBIA 
Gene Disease Inheritance OMIM NBIA Type 
PANK2 Pantothenate Kinase-associated 
neurodegeneration (PKAN) 
AR 234200 NBIA1 
PLA2G6 PLA2G6-associated neurodegeneration (PLAN) AR 256600 NBIA2 
FTL Neuroferritinopathy (NF) AD 606159 NBIA3 
C19orf12 Mitochondrial membrane protein-associated 
neurodegeneration (MPAN) 
AR 614298 NBIA4 
WDR45 B-propeller-associated neurodegeneration 
(BPAN) 
XL 300894 NBIA5 
COASY COASY protein-associated neurodegeneration 
(CoPAN) 
AR 615643 NBIA6 
REPS1 Neurodegeneration with brain iron 
accumulation 7 
AR 617916 NBIA7 
CRAT Neurodegeneration with brain iron 
accumulation 8 
AR 617917 NBIA8 
CP Aceruloplasminemia AR 604290 
 








ATP13A2 Kufor-Rakeb disease (KRS) AR 606693 
 
AP4M1 AP4 deficiency AR 
  
DCAF17 Woodhouse-Sakati syndrome (WSS) AR 241080 
 
GTPBP2 Jaberi-Elahi syndrome AR 617988 
 
AD, autosomal dominant; AR, autosomal recessive; XL, X-linked 
 
1.1.1.11. Hyper and hypoferritinemia 
Five diseases have been identified as directly resulting from mutations in the FTL gene: hereditary 
hyperferritinemia with cataract syndrome (HHCS), neuroferritinopathy (NBIA3), benign 
hyperferritinemia (or hyperferritinemia without iron overload), autosomal dominant L-Ferritin 
deficiency and autosomal recessive L-ferritin deficiency (Cadenas et al. 2019).  
Hereditary Hyperferritinemia Cataract Syndrome (HHCS) (OMIM #600886) is associated with excess 
production of ferritin and its accumulation in the lens of the eye, resulting in the development of 
cataracts (Mumford et al. 2000). More than 40 mutations in the iron-responsive element (IRE) at the 
5’ untranslated region (UTR) of the FTL gene have been reported as causative of this disorder (Sara 
Luscieti et al. 2013; Cadenas et al. 2019). Defects in the FTL-IRE results in the disability to linkage with 
iron regulatory proteins (IRPs) and the disturbance of the IRP-IRE post-transcriptional regulatory 
system (Beaumont et al. 1995; Girelli et al. 1995; Muckenthaler et al. 2017).  
Benign hyperferritinemia, also known as genetic hyperferritinemia without iron overload (OMIM 
#600886), is another disorder associated with mutations in the FTL gene. To date, only three mutations 
have been reported (Caroline Kannengiesser et al. 2009). This disorder is characterized by high 






L-ferritin deficiency or hypoferritinemia (OMIM#615604) is a rare disorder that presents different 
manifestation whether the inheritance is autosomal dominant or recessive. Autosomal recessive 
inheritance of this disorder is associated with more severe symptoms, including undetectable levels 
of serum ferritin, seizures and restless leg syndrome (Cozzi et al. 2013). However, patients with 
autosomal dominant pattern of L-ferritin deficiency, the sole sign is low level of ferritin in blood, but 
no other manifestations (Cremonesi et al. 2004). The ATP4A gene have been also associated with low 
levels of ferritin in serum in pediatric patients with type 1 diabetes (Chobot et al. 2018). 
 
1.1.2. NGS and genetic diagnosis 
Inherited blood diseases affect millions of people, and cause substantial morbidity and mortality, in 
addition to an immense burden on those affected (Engert et al. 2016). In recent decades, the diagnosis 
and treatment of congenital blood disorders have received enormous progress. In the past, physical 
examination, the patient´s medical history, and laboratory testing from blood and bone marrow have 
been used by clinicians to diagnose hematologic diseases. However, the diagnosis of rare inherited 
hematological diseases using these methods is complicated in most of the patients and may involve a 
significant delay in the diagnosis and high healthcare costs. An accurate diagnosis is crucial for optimal 
clinical management. 
Since the identification of rare congenital anemia syndromes is laborious, genetic diagnosis is 
achieving an essential role in patient care. Early on, Sanger sequencing was the chosen clinical testing 
method for disorders for which a single causative gene was wholly responsible (when there is a clear 
phenotypic indication of a classic Mendelian disorder) (Williams et al. 2015). However, since that most 
of congenital anemias can have several genes implicated, and may present similar clinical and 
laboratory presentation, Sanger sequencing is getting unproductive and outdated. The ability to 
sequence multiple genes and multiplexing several patients allows NGS to be ideally suited for 
addressing the limitations of traditional Sanger sequencing.  
The introduction of next-generation sequencing (NGS) in genomic laboratories was established about 
10 years ago. This revolutionary high-throughput technology provides massive parallel sequencing 
data, and has the ability to sequence multiple genes and multiplexing several patients. After 
improvements in management, robustness and accuracy, this revolutionary technology is becoming 
widely used for genetic diagnosis as an alternative to the single causative gene-Sanger sequencing 
approach (Di Resta et al. 2018; Vrijenhoek et al. 2015; Rehm 2013). 
Since there is a good knowledge of the genes involved in hereditary hematological diseases, the 
development of a targeted NGS panel is considered an excellent tool for the genetic diagnosis of these 
diseases.  The aim of this project is to refine and improve an already established NGS targeted gene 
panel for rare inherited blood diseases (HHD panel) in order to accelerate diagnosis.  
 
1.1.3. HHD Panels  
During the progress of this project and in the time covered by this doctorate, four versions of the HHD 
panel have been developed: v13, v14, v15 and v16 (Table 1.14). The version v13 of the panel 
comprised 58 genes for 8 groups of hematological diseases. The target region size was 382,058 bases 
with a total coverage of 98.99 % (15,729 amplicons). The read length was predefined to 250 bases.  
This panel v13 was validated with 26 patients suffering from different congenital hematological 
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disease. Subsequently, this panel was updated increasing the number of genes to 74 for the same 
hematological diseases (version 14, v14). The target region size was 374,978 bases with a total 
coverage of 99.67 % (18,454 amplicons). The version v15 has been designed covering 153 genes for 
12 groups of hematological diseases, with 31,193 amplicons covering 99,63 % of the total target region 
size (618,664 bases). Finally, the version v16 has been designed covering 203 genes for 12 groups of 
hematological diseases, with 44,656 amplicons covering 99.16 % of the total target region size 
(898,561 bases).  
The following project will be focused in the design and implementation of version 15 of the panel, 
where I was more involved. However, the other versions (v13, v14 and v16) will be also mentioned in 
some substantial points, such as the validation of the HHD panel. Finally, a comparison of the four 
designs used will be made to verify the improvement in the diagnosis of HHD with the refining and 






























Total number of genes 58 74 153 203 
Design Haloplex Haloplex Haloplex HS Haloplex HS 
Read Length 250 150 150 150 
Target Region Size 382,058 374,978 618,664 918,841 
Total Amplicon 15,729 18,454 31,193 44,656 
Total Coverage (%) 98.99 99.67 99.50 99.16 
Tier 1 1 2 2 
    
  DISEASES N genes N genes N genes N genes 


















2 Congenital sideroblastic anemias and acquired sideroblastic anemia 14 14 14 16 
3 Iron related Anemias (Aceruloplasminemia, Atransferrinemia, IRIDA, DMT1- deficiency 
anemia, Hypochromic microcytic Anemia with Iron overload 2) 
5 5 8 9 
4 Congenital dyserythropoietic anemia 6 6 6 9 
5 Congenital Erythrocytosis/Familiar Polycythemia 5 5 7 11 
6 Hereditary hemolytic anemias due to RBC enzymopathies or glycogen storage disease 17 17 17 17 
7 Hereditary hemolytic anemias Membranopathies and Gilbert syndrome 5 13 16 16 
8 Erythropoietic Protoporphyria and Congenital Erythropoietic Porphyria 2 3 4 6 
9 Fanconi Anemia 0 0 21 22 
10 Diamond- Blackfan-Anemia, DBA1 0 0 23 30 
11 Dyskeratosis congenita 0 0 12 15 
12 NBIA, Neurodegeneration with brain iron accumulation 0 0 10 32 
- Candidates genes - 9 12 14 
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1.2. MATERIAL AND METHODS 
 
1.2.1. Design of the new panel (version 15) 
An extensive search in several databases, including USCS Genome Browser, 1000 Genomes, dbSNP, 
HGMD, OMIM, and ORPHANET, has been done to obtain the most updated list of genes that are known 
to be mutated in anemia syndromes till the date of the design of the gene panel. Our custom-made 
targeted NGS panel (version 15) covers 153 genes known to be mutated in anemia syndromes, as 
detailed in Table 1.15. The panel includes 12 candidate genes, that are known to be related with HHD, 
although they have not been reported as a disease causative gene yet. Genes associated with 
hemoglobinopathies (HBB, HBA1, HBA2) were not included in the panel, due to the high homology 
and the consequent difficulty to design efficient probes that discriminate the sequencing between 
these genes. The target regions for sequencing include the exons, intron-exon boundaries (50pb), and 
5’UTRs. The 3’UTR was entirely covered for 44 genes, while for the rest of the genes (n = 109) only 
75pb was sequenced. 
The panel was designed using SureDesign software (Agilent Technologies, Santa Clara, CA, USA) and 
optimized for HaloPlex for high-sensitivity sequencing technology (HaloPlexHS), Illumina Platform and 
a read length of 150bp. The custom design was constructed under the hg19 human reference genome 
(Homo sapiens, UCSC hg19, GRCh37, February 2009). The custom panel includes a total of 31,193 
amplicons with a target coverage of 99.63% of the total target region size (618.664 kbp). Some regions 
of interest with difficulties to design regular probes, were designed as Formalin-fixed paraffin-
embedded (FFPE) to enrich the target sequencing and increase the target length coverage. 
1.2.2. Validation of the NGS panel and diagnosis of new cases 
All subjects gave their informed diagnostic and research consent for inclusion before they participated 
in the genetic analysis. The research was conducted in conformity with the Declaration of Helsinki, 
and the Ethics Committee approved the protocol on 10th July 2015. 
1.2.2.1. Validation of the NGS panel 
Twenty-six patients with inherited hematological diseases were used to carry out internal validation 
of the HHD panel version 13. All patients were previously genetically diagnosed by Sanger 
methodology. Samples were distributed as following: six for hereditary hemochromatosis (10010); 
four patients with CSA (10020); five samples from Iron and Cooper related diseases (10030); four from 
CDA (10040); 1 from CE (10050) and 6 from HA (10070). 
1.2.2.2. Diagnosis of patients with HHD using panel v15 
Moreover, the study included 42 patients, referred to the molecular laboratory of BloodGenetics 
(Esplugues de Llobregat, Spain) for genetic diagnosis due to the manifestation of any of the congenital 
hematologic diseases described before. The clinical data provided by the referring medical doctors 
included: the presumed diagnosis, current age, age at presentation, ethnicity, description of the 
peripheral blood and bone marrow morphology, other symptoms and the administered treatment 
(including blood transfusion, medical treatment and splenectomy). 
 
 




Table 1. 15 Genes included in version 15 of the NGS target panel for the diagnosis of HHD. 
Panel ID Group DISEASES 
N 
genes 






HFE HFE2 HAMP TFR2 ATP4A 
SLC40A1 BMP6 FTL FTH1 GNPAT 
10020 2 
Congenital sideroblastic 
anemias and acquired 
sideroblastic anemia 
14 
ALAS2 SLC25A38 GLRX5 ABCB7 STEAP3 
TRNT1 PUS1 YARS2 SLC19A2 SF3B1 
HSPA9 LARS2 NDUFB11 MT-ATP6  
10030 3 
Iron and Copper related 
Anemias 
8 
TF CP TMPRSS6 SLC11A2 STEAP3 





CDAN1 C15ORF41 SEC23B KIF23 KLF1 
GATA1     
10050 5 Congenital Erythrocytosis 7 
EPOR VHL EGLN1 EPAS1 BPGM 
SH2B3 JAK2    
10061 6.1 
Hereditary hemolytic 
anemias due to RBC 
enzymopathies or glycogen 
storage disease 
17 
PKLR G6PD HK1 GPI BPGM 
GSR GSS GPX1 GCLC NT5C3A 
AK1 PGK1 TPI1 PFKM ALDOA 





ANK1 SPTB SPTA1 SLC4A1 EPB42 
UGT1A1 EPB41 GYPC PIEZO1 KCNN4 
SLC2A1 ABCB6 RHAG  
 







PKLR G6PD HK1 GPI BPGM 
GSR GSS GPX1 GCLC NT5C3A 
AK1 PGK1 TPI1 PFKM ALDOA 
ADA CYB5R3 ANK1 SPTB SPTA1 
SLC4A1 EPB42 UGT1A1 EPB41 GYPC 
PIEZO1 KCNN4 SLC2A1 ABCB6 RHAG 






4 FECH ALAS2 UROS CLPX  
10090 9 Fanconi Anemia 21 
FANCA XRCC2 FANCI RAD51C FANCM 
FANCB FANCE BRIP1 SLX4 MAD2L2 
FANCC FANCF FANCL ERCC4 FANCD2 
BRCA2 FANCG PALB2 UBE2T RFWD3 





RPS19 RPL11 RPL15 RPS28 RPS27A 
RPS24 RPS7 RPS29 RPL27 RPL36 
RPS17 RPS10 TSR2 RPL31 RPL9 
RPL35A RPS26 GATA1 RPS27 RPS15 
RPL5 RPL26 RPL19   
10110 11 Dyskeratosis congenita 12 
TERC NHP2 NOP10 RTEL1 USB1 
TERT TINF2 WRAP53 DKC1 CTC1 
PARN ACD    
10120 12 
NBIA, Neurodegeneration 
with brain iron accumulation 
10 
PANK2 FTL WDR45 FA2H CP 
PLA2G6 C19orf12 COASY ATP13A2 DCAF17 
  Candidate genes 12 
ACO1 ATPIF1 EXOC6 HEPH IREB2 
Pim1 SLC25A37 SLC25A39 TFRC NCOA4 
PCBP1 BMP2    
  TOTAL 153 unique genes* (141 without candidate genes) 
 
*Note: some genes are implicated in different subpanels. The total number of unique genes is displayed at the end of the 
table. 
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1.2.2.3. DNA extraction 
Genomic DNA was extracted from peripheral blood using the Maxwell® Blood DNA Purification 
(Promega), FlexiGene DNA kit (Qiagen, Hilden, Germany) or QIAamp DNA Blood Mini Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. 
DNA samples were quantified by using the QuantiFluor® dsDNA System (Promega), and fluorescence 
was detected using Quantus™ Fluorometer (Promega). Nanodrop concentration was also calculated 
and DNA quality was accepted if the A260/280 ratio and A260/230 ratio were between 1.7 and 1.9 
Integrity evaluation of DNA extracts was performed by electrophoresis in 0.8 % agarose gels. 50 ng of 
the DNA sample was loaded on the gels individually. Electrophoresis was run for 60 min at 80 V in Tris-
Borate-EDTA (TBE) buffer. Gels were stained with 2.5 μl MIDORIGREEN Advance (NIPPON Genetics 
Europe, Dueren, Germany) and captured under UV light (NuGenius, Sygene, Cambridge, United 
Kingdom). 
1.2.2.4. Library preparation and Sequencing 
The capture of genomic regions was conducted starting from 225 ng of gDNA using a custom design 
HaloPlex HS Target Enrichment kit (Agilent Technologies, Santa Clara, CA) Tier 2 (501-2599 bp; up to 
200k probes) according to the manufacturer’s instructions. The quality of the library was determined 
using the Agilent 2100 Bioanalyzer and high sensitivity DNA chips (Agilent Technologies Inc., Palo Alto, 
CA, USA). Libraries were sequenced using MiniSeq Mid Output Kit (300 cycles) (Illumina, San Diego, 
CA) on an Illumina MiniSeq sequencer (Illumina, San Diego, CA), generating paired-end reads of 150bp 
length. Samples were aligned using the GRCh37/hg19 reference human genome and data analysis was 
performed employing our algorithms. Conventional Sanger sequencing was performed to confirm the 
mutations detected by our NGS panel. 
1.2.2.5. Results, Interpretation, and Reporting 
Sequencing reads were aligned against the reference genome GRCh37/hg19 and variants were called 
and annotated using the SureCall software (v.3.5.1.46; Agilent Technologies). Variant filtering was 
established using our own variant database. Filtering cut-off values were as follows: variant call quality 
threshold >100; minor allele frequency (MAF) < 3%; deep read > 50; variant allele frequency of > 25%; 
primary effect: missense, stop gained, stop lost, initiator codon, frameshift, in frame-insertion, in-
frame deletion and splicing. Filtered variants were visualized in genomic context IGV Viewer tool 
integrated in SurCall software. 
BloodGenetics Laboratory classifies sequencing variants following the guidelines of the American 
College of Medical Genetics (ACMG) Laboratory Practice Committee Working Group (Richards et al. 
2015; Ogino et al. 2007). The clinical significance of each variant was estimated by the presence of the 
variant in known databases (ClinVar, HGMD, dbSNP), but also in our own database based on deep 
search on publications about HHD. The degree of evolutionary conservation of the encoded amino 
acid, and the MAF was also considered to determine pathogenicity. In silico analysis was also done to 
predict the pathogenicity of a variant according to its potential to modify the protein function. These 
bioinformatics tools include: SIFT (https://sift.bii.a-star.edu.sg/), PROVEAN 
(http://provean.jcvi.org/index.php), and Polyphen2 (http://genetics.bwh.harvard.edu/pph2/). 
Variant of Unknown significance (VUS) were reported if found in genes relevant to the primary 
indication for testing (Richards et al. 2015; Ogino et al. 2007). Progeny Laboratory Information 
Management System (LIMS, Progeny, USA) was used to annotate and organize patients’ samples and 
to include all the obtained results. 




1.2.2.6. Variant validation with Sanger 
Variants identified by the HHD panel reported as pathogenic or likely pathogenic were validated by 
Sanger. The region of DNA containing the variant (~300pb) was amplified using 50-100 ng of genomic 
DNA. The resulting amplification products were verified on a 2% agarose gel, dyed with MIDORIGREEN. 
PCR products were purified by mixing 5ul of PCR product with 1 μl of FastAP Thermosensitive Alkaline 
Phosphatase and 0.5 μl Exonuclease I (Thermo Fisher) and incubating the mixture 15 minutes at 37ºC 
and 15 minutes at 95 ºC. The purified PCR products were sequenced using a Sanger sequencing service 
provided by GATC Biotech (Konstanz). Sequencing results were analyzed using Mutation Surveyor 
software (SoftGenetics LLC, PA, USA). 
All primers were designed using Primer 3 software (http://bioinfo.ut.ee/primer3-0.4.0/), acquired in 
25nmole, desalted and dry from Invitrogen (Thermo Fisher Scientific) and diluted in MilliQ water to a 
100μM working solution. 
 
1.2.3. External validation (EMQN-EQA) 
HHD NGS Panel was externally validated by participating in the external quality assessment (EQA) 
scheme for germline NGS analysis provided by the European Molecular Genetics Quality Network 
(EMQN). The “DNA Sequening – NGS (vGermline)” scheme is designed specifically for labs doing NGS 
based germline testing. One germline DNA sample was provided by the organization to test the NGS 
strategy.  
1.2.4. RNA Fold Predictions for 5’UTR FTL variant 
The RNA folds were analyzed with the Sfold web server (http://sfold.wadsworth.org/) (Ding, Chan, 
and Lawrence 2004) to predict IRE structure of wild-type (WT) as well as mutated FTL-IRE. 
Supplementary Material Table S2 shows the reference DNA sequences use to make the predictions. 
Ion-responsive elements were also predicted with SIREs web server tool (Campillos et al. 2010). 
 






1.3.1. The final design (genes and diseases) 
The HHD Panel compromise a total of 153 genes, including exons, exon/intron boundaries, 5’UTR 
regions and 3’UTR regions (except some genes that have been shorted). The total target region size is 
618.664 kbp, being covered the 99.63% for 31193 amplicons. The design covers the exons of all 
isoforms of the genes. As an illustrative example, Figure 1.4 shows the covered regions and the 
amplicons that cover all the exon from three isoforms of ALAS2 gene and the five isoforms of ALDOA 
gene. 
Not all genes described in the introduction were included in the panel v15. Genes involved in the 
development of Familial Erythrocytosis due to defects in globin proteins, were finally not included in 
the panel. Because of the high homology of the genes, that alpha-globin and beta-globin proteins 
(HBB, HBA1 and HBA2 genes), the SureCall software is not able to design probes for these genes. The 
Figure 1.5 presents in red the missing regions for sequencing of HBB and HBA2, which exon sequences 
are almost completely missed. 
Some genes known to be causative genes of HHD were not included in our NGS panel since the 
publication of these genes was posterior to the date of design of the panel. Those genes are included 
in the version 16 of the panel. Other genes have been identified to be associated with HHD, but they 
remain confidential until they are published in a scientific paper. 
Our version 15 of the NGS panel for HHD cover 75.36% (153 out of 203 genes) of the genes that are 
known to be associated with HDD to present day and are part of the NGS panel version 16 (Table 1.16). 
Apart from the genes described in the introduction, new genes have been identified to be causative 
of HHD, but their confidentiality must be maintained until publication.  
The less covered subpanel of the panel 15 compared with the version 16 is NBIA with 31.25 % (10 out 
of 32 genes) of coverage (Table 1.16). DBA and FA are the two-following diseases with less gene 
coverage (88.46% and 95.45% respectively). Four subpanels were uncovered with less than 80% 
compared with version 16: the congenital erythrocytosis with a 63.63% of coverage; CDAs with 
66.67%; erythropoietic protoporphyria with 63.63% and DBA with 76.67%. The rest of disease were 
highly covered (more than 80%), and only the hemolytic anemias due to enzymopathies or 









Example of genes completely covered by Haloplex probes 
  A – ALAS2 gene 
  
   
   B- ALDOA gene 
 
Figure 1.4. Example of two genes (ALAS2 and ALDOA) entirely covered by Haloplex probes. In green are the “Target Regions”, regions of interest to be sequenced; the “Covered” 
regions, the region covered by the panel; and the “Agilent Haloplex – Amplicons”. In these two genes, the Haloplex probes cover all the exons and intron boundaries of the genes.  
 





Example of genes not covered by Haloplex probes 
  A – HBA2 gene 
 
 
  B – HBB gene 
 
 
Figure 1.5. Example of genes (HBA2 and HBB) not covered by Haloplex probes. In green are the “Target Regions”, regions of interest to be sequenced; the “Covered” regions, the region 
covered by the panel; and the “Agilent Haloplex – Amplicons”. In red are the “Missed” regions, the target regions of interest that will not be covered by the panel. In these two genes, a 
large part of the region of interest is not covered by the amplicons designed by Agilent Haloplex.  





Table 1. 16 Coverage of the HHD panel 15 respect the total of known causative genes for the time being. 
Panel Group DISEASES 









Hereditary hemochromatosis and Hyperferritinemia / 
hypoferritinemia 
10 11 90,90% 
10020 2 
Congenital sideroblastic anemias and acquired 
sideroblastic anemia 
14 16 87,50% 
10030 3 Iron and Copper related Anemias  8 9 88,89% 
10040 4 Congenital dyserythropoietic anemia 6 9 66,67% 
10050 5 Congenital Erythrocytosis/Familiar Polycythemia 7 11 63,63% 
10061 6.1 
Hereditary hemolytic anemias due to RBC enzymopathies 
or glycogen storage disease 
17 17 100,00% 
10062 6.2 
Hereditary hemolytic anemias membranopathies and 
Gilbert syndrome 
16 16 100,00% 
10070 6.1+6.2 
Hereditary hemolytic anemias including 
membranopathies and enzymopathies 
33 33 100,00% 
10080 8 
Erythropoietic Protoporphyria and Congenital 
Erythropoietic Porphyria 
4 6 66,69% 
10090 9 Fanconi Anemia 21 22 95,45% 
10100 10 Diamond- Blackfan-Anemia, DBA1 23 30 76,67% 
10110 11 Dyskeratosis congenita 12 15 80,00% 
10120 12 Neurodegeneration with brain iron accumulation (NBIA) 10 32 31,25% 
  Candidates genes 12 14 85,71% 
  
Total number of unique genes (no candidate genes 
included) 
153 203 75,36% 
 
1.3.2. Patients analyzed for validation (Internal validation) 
The NGS panel version 13 was validated by including 26 cases with known mutation by Sanger 
methodology (Table 1.17). In 25 out of 26 cases analyzed (96.15%), the previously described variant 
was detected (Table 1.18). In one case, the mutation detected by sanger (NM_000551.3 
c.[376G>A]:[376G>A]; NP:000542.1 p.(Asp126Asn);(Asp126Asn) ) was not validated by the panel, 
since the variant was located in a GC-rich region (~60%), and is not covered by the Haloplex panel (see 
Figure 1.6). This data was reported as a selected poster at the EHA congress 2018 Stockholm (see 
Appendix-2.1. Congress presentations).




Table 1. 17 Samples used for validation through NGS panel version 15 including additional findings 











TFR2 NM_003227.3 NP_003218.2 Mut 1: c.[916C>T];[=]; p.(Gln306Ter);(=) Yes  
























SLC25A38 NM_017875.2 NP_060345.2 Mut 1:c.[1552T>C];[=]; p.(Leu 51Pro);(=) Yes  












SF3B1 NM_012433.1 NP_036565.2 NO MUTACION (negative control) Yes  
10030 P-00004 Aceruloplasminemia 
CP NM_000096.3 NP_000087.1 Mut 1: c.[1783_1787delGATAA];[=]; p.(Asp595Tyrfs*2);(=) Yes  
CP NM_000096.3 NP_000087.1 Mut 2: c.[2520-2523_delAACA];[=]; p.(T841Rfs*52);(=) Yes  
10030 P-00014 Atransferrinemia TF NM_001063.3 NP_001054.1 Mut 1: c.[665_668delCCTT];[=] ; p.(Ala222Valfs*32);(=) Yes  
10030 P-00015 Atransferrinemia 
TF NM_001063.3 NP_001054.1 Mut 1: c.[665_668delCCTT];[=] ; p.(Ala222Valfs*32);(=) Yes  
TF NM_001063.3 NP_001054.1 Nothing else found by Sanger  
Var 1: c.[*53A>G];[=] ; 
p.(?);(=). In 3'UTR 
10030 P-00010 Anemia with iron-overload 
SLC11A2 NM_000617.2 NP_000608.1: Mut 1: c.635G>T; [=]; p.Gly212Val; [=] Yes 
Mut 3: c.[1336C>T]; [=]; 
p.(Gln446Ter);(=) 
SLC11A2 NM_001174125.1 NP_001167596.1 Mut 2: c.49+3A>T Splicing defect Yes  
10030 P-00002 IRIDA 
TMPRSS6 NM_153609.2 NP_705837.1 Mut 1: c.[76_80delGGTGA];[=]; p.(Gly26Trpfs*14);(=) Yes  






(continuation Table 1.17) 





















SEC23B NM_006363.4 NP_006354.2 Mut 1: c.[1254T>G];[=]; p.(Ile418Met);(=) Yes  








VHL NM_000551.3 NP_000542.1 Mut 1: c.[376G> A];[376G>A]; p.(Asp126Asn);(Asp126Asn) No 
Region not covered by 
the HHD panel 
10070 P-00011 
Hemolytic anemia due to GPI 
deficiency 
GPI NM_000175.3 NP_000166.2 Mut 1: c.[341A>T]; [=]; p.(Asp114Val);(=) Yes  
GPI NM_000175.3 NP_000166.2 Mut 2: c.663T>G; p.(Asn221Lys);(=) Yes  
10070 P-00024 
Hemolytic anemia due to GPI 
deficiency 
GPI NM_000175.3 NP_000166.2 Mut 1: c.[145G>C];[=]; p.(Gly49Arg);(=) Yes  
GPI NM_000175.3 NP_000166.2 Mut 2: c.[921C>A];[=]; NP_000166.2: p.(Phe307Leu);(=) Yes  
10070 P-00025 Hemolytic anemia  BPGM NM_001724.4 NP_001715.1 Mut 1: c.[269G>A];[=]; p.(Arg90His);(=)Yes Yes  
10070 P-00026 Hemolytic anemia NT5C3A NM_016489.12 NP_001002009.1 




Hereditary hemolytic anemia 
=-NADH diaphorase 
deficiency 
CYB5R3 NM_000398.6 NP_000389.1 Mut 1: c.[637G> A];[637G>A]; p.(Glu213Lys);(Glu213Lys) Yes  
10070 P-00081 
Hereditary eliptocytosis with 
Hereditary spherocitosys 
SPTA1 NM_003126.2 NP_003117.2 Mut 1: c.[460_462dupTTG];[=]; p.(Leu155dup);(=) Yes  
SLC4A1 NM_000342.3 NP_000333.1 Nothing else found by Sanger  
Var 1: c.[1530C>G];[=] ; 
p.(Ser510Arg);(=) 
EPB42 NM_000119.2 NP_000110.2 Nothing else found by Sanger  











Table 1. 18 Validation results 




Identified gene mutations 
Sanger Panel 
HH + HHCS 10010 6 6 (100%) 7 7 FTL; HFE; TFR2; HFE2; SLC40A1 
CSA 10020 4 4 (100%) 4 4 ALAS2; SLC25A38; SF3B1 
Fe/Cu metabolism 10030 5 5 (100%) 8 10 CP; TF; SLC11A2; TMPRSS6 
CDA 10040 4 4 (100%) 5 5 CDAN1; C15ORF41; SEC23B 
Erythrocytosis 10050 1 0 (0%) 1 0 VHL 
HA 10070 6 6 (100%) 8 10 
GPI; BPGM; NT5C3A; CYB5R3; SPTA1; 
SLC4A1; EPB42 
Total cohort  26 25 (96.15%) 32 37 (115%)  
F, Female; M, Male; VUS, Variants of Unknown significance 
 
 
Figure 1.6. Region of VHL gene (exon 2) not covered by the HHD panel. The mutation NM_000551.3: c.[376G> A]; p.(Asp126Asn)  is situated in a missed region of the 























Figure 1.7. Proportion of patients analyzed in the HHD Panel (version 15) by group of disease (subpanel). The 
percentage of patients analyzed for each subpanel respect the total number of patients analyzed in the HHD panel 
version 15 is represented in the pie chart. The different subpanels are represented in different colors. The largest 
group belongs to subpanel 10010 (in blue) with 54.8% of the patients analyzed for HH or hypo/hyperferritinemia. CSA 
(subpanel 10020 in orange) and anemias due to Fe/Cu metabolism (subpanel 10030 in grey) are the following most 
popular groups of disease (11.9%). 
1.3.3. External Validation (EQMN – EQA) 
The HHD NGS panel version 15 was satisfactorily validated by participating in the 2018 European 
Molecular Genetic Quality Network (EMQN) external quality scheme of DNA sequencing – NGS 
(vGermline). The certificate is attached in Appendix – Other documents page 216 of this dissertation.   
1.3.4. Diagnosis 
A total of 42 patients were analyzed using the HHD Panel, including 13 females and 29 males. Patients 
were referred from various medical centers mainly from Spain but also from other countries. The 
mean age was 46.97 years with a range of 1-82 years. 
The initial diagnosis before genetic testing was hereditary hemochromatosis in 18 patients, 
hyperferritinemia with cataract syndrome in five patients (therefore, 23 patients from subpanel 
10010), congenital sideroblastic anemia in five patients (10020), iron-related anemias in five patients 
(10030), congenital erythrocytosis in two patients (10050), one patient for hemolytic anemia (10062), 
one case for Hemolytic anemia (10070), one case for Fanconi Anemia (10090) and two cases with NBIA 
(10120). More than 50% of the cases were patients with hereditary hemochromatosis or 
hyperferritinemia (subpanel 10010) (see Figure 1.7).   
   
 












Overall, 27 out of the 42 patients (64.3%) who underwent HHD panel sequencing, were found a 
significant variant, but only 18 (42.9%) cases were solved by obtaining a pathogenic or likely 
pathogenic variant agree with the mode of inheritance of the disease that can explain the cause of the 
disorder (category A, see Figure 1.8). In 3 patients (7.1%), only one pathogenic variant was found in 
heterozygous state, but the disease is autosomal recessive, so the genetic diagnosis is not resolved 
(category B). In 14.3% of the cases (6 patients), we found variants of unknown significance (category 
C). VUS variants are rare variants (present in less than 3% of the population), but the evidence that 
we have is insufficient to classify them as pathogenic or likely pathogenic variants. However, they 









A- Resolved (Pathogenic variant according wih inheritance)
B- Pathogenic variant not resolved due to inheritance
C- Variant of Unknown Significance (VUS)
D- Negative
could be implicated in the disease as mutations in those genes cause the disease that is present in the 
patient (there is a correlation with the clinical presentation of the disease and a genetic defect in the 
gene where we detect the VUS). These variants need to be further investigated with functional 
analysis. The 35.7% remaining were negative results: no variant was found in the analyzed genes, or 









Figure 1.8. Genetic results of the patients analyzed by the HHD panel (v15). The results were categorized in four 
groups: A, patients with pathogenic or likely pathogenic variants that fit with the mode of inheritance of the disease; 
B, patients with pathogenic variants that do not agree with the mode of inheritance; C, Variants of Unknown 
significance (VUS); and D, Negative results (no variants found, or benign or likely benign variant detected). 
Six runs were performed to evaluate the 42 diagnostic samples and seven samples were analyzed per 
run on average (min=5, max=11), using the Mid Output Kit and MiniSeq Instrument both from Illumina. 
The average output size is 4.29 Gb, and the mean Qscore (>=30) was 89. The HHD panel v15 acquires 
high read depth of the regions of interest, with an average depth coverage of 388x, and a mean read 
length of 115 pb. On average, the total number of reads detected per run is 20,498,214 (2,729,438 
per sample) with a cluster density of 368 K/mm2 (the first run was overclustered with 1037 K/mm2, 
and the rest of runs ranged from 147-358). The total number of variants found per sample was 562 on 
average, including all the genes from all the subpanels. Between 3 and 6% of the total variants had 
low depth coverage (<50). 
The subpanel 10010 (HH and hypo/hyperferritinemia) was the group with more genes identified (see 
Table 1.19), probably because it was the most demanded with the highest number of samples 
analyzed. Thirteen out of the 23 patients from this subpanel (56.52%) had a pathogenic variant, likely 
pathogenic variant or a VUS. The rest of subpanels were more dispersed, with mutation detection 
ranging from 0 to 100% due to the low number of samples. The total variant detection is 57.14%, 
highly influenced by the subpanel 10010.  
42.9% of the patients obtained a genetic result with a pathogenic or likely pathogenic variant that can 
explain the disease phenotype. Some patients, mostly from Hereditary hemochromatosis, have no 
mutations or only a VUS was identified. However, negative results are also very relevant. First, 
negative results are used to discard the presence of a genetic disease in an individual (disease could 
be acquired and without a genetic component). Second, in negative result cases other genes of the 
panel, including candidate genes, can be tested to try to identify new genes implicated in human 
diseases. If no variants are found with the panel, whole exome sequencing is performed for some 
cases (research studies), including the mother and the father if it is possible (trio analysis), to try to 






Table 1. 19 Summary of the genetic diagnosis by HHD Panel (version 15) 






Categories Patients with 
genetic result 
(A + B + C) 
Identified gene  
F M A B C D mutations 
10010-HH and hypo/hyperferritinemia 23 7 16 10-82 56.27 9 1 3 10 13 (56.52%) FTL; HFE; TFR2; HAMP; BMP6 
10020-CSA 5 1 4 25-38 31.5 3 0 1 1 4 (80%) ALAS2; SF3B1 
10030-Fe/Cu metabolism 5 2 3 1-78 32.4 2 0 1 2 3 (60%) SLC11A2; TMPRSS6 
10040-CDA 2 1 1 31-38 34.5 0 2 0 0 2 (100%) SEC23B 
10050-Erythrocytosis 2 0 2 1-30 15.5 1 0 0 1 1 (50%) EPAS1 
10062- Membranopathies 1 0 1 47 47 1 0 0 0 1 (100%) SPTA1 
10070-Hemolytic anemia 1 1 0 72 72 0 0 0 1 0 (0%)  
10090-FA 1 0 1 37 37 1 0 0 0 1 (100%) FANCA 
10120-NBIA 2 1 1 7-59 33 1 0 1 0 2 (100%) CP; DCAF17 
Total cohort 42 13 29 1-82 46.97 18 3 6 15 27 (64,28%)   
 
F, Female; M, Male; A, Patients with genetic diagnosis resolved (pathogenic or likely pathogenic variant according with inheritance); B, Pathogenic variant 
not resoled due to inheritance; C, Variant of Unknown Significance (VUS); D, Negative result (no variant found or benign or likely benign variant detected




1.3.5. L-Ferritin: One Gene, Five Diseases.  
We have focused part of the research on studying patients with variants in FTL gene, in order to have 
an overview and update of the different diseases that mutations in this gene cause. The results here 
exposed were published in the journal Pharmaceuticals (see Appendix-3. Publications, page 193 for a 
copy of the manuscript). 
Pharmaceuticals (Basel). 2019 Jan 23;12(1). pii: E17. doi: 10.3390/ph12010017. 
“L-Ferritin: One Gene, Five Diseases; from Hereditary Hyperferritinemia to Hypoferritinemia-Report 
of New Cases.” 
Cadenas B, Fita-Torró J, Bermúdez-Cortés M, Hernandez-Rodriguez I, Fuster JL, Llinares ME, Galera 
AM, Romero JL, Pérez-Montero S, Tornador C, Sanchez M. 
 
Three probands were studied due to the suspicion of mutation in FTL gene (hyperferritinemia or 
hypoferritineamia). We completely sequenced the entire coding region, intron-exon boundaries and 
5’ and 3’ regulatory regions for the FTL gene either by Sanger sequencing or by next generation 
sequencing (NGS).  
Family 1 - a case with autosomal dominant L-ferritin deficiency 
Proband II.1 from family 1 shown in Figure 1.9 A is a Spanish female aged four who was referred to 
the Pediatric Oncohematology Unit of the Virgen de la Arrixaca University Hospital due to refractory 
hypoferritinemia, with serum ferritin levels of 4-9 ng/mL (Table 1.20). The proband was not responsive 
to the oral administration of iron capsules but exhibited no further symptoms. A physical examination 
determined her weight and size were normal for her age. When she was six years old, the proposita 
began to experience severe migraines. CT and MRI scans of the brain uncovered a small subcortical 
area of gliosis located in the right frontal lobe; everything else was normal. This discovery was 
incidental since pediatric neurologists had initially diagnosed the proband with a primary headache 
and suggested flunarizine as treatment. 
 
 
Figure 1.9. Pedigree of the three analyzed families affected from dominant L-ferritin deficiency and HHCS. Squares indicate 
males and circles females. Filled symbols indicate affected members and asterisks indicate subjects with genetic studies done 





Mutation testing unveiled an A>T substitution in intron 3 of the FTL gene, specifically at position 375 
+ 2 (NM_000146.3:c.[375 + 2T > A][=], HGSV nomenclature). Proband I.1, the father of proposita II.1, 
also exhibited this mutation in a heterozygous state. As predicted by Human Splicing Finder, the 
variant disrupts mRNA splicing by modifying the wild type splicing donor site. This mutation has not 
been mentioned in literature or in public databases (e.g. NCBI, ENSEMBL, HGMD, and 1000Genomes). 
Nevertheless, the SNP database has identified another variant at the same position (c.375 + 2T > C) 
known as rs1371561306. According to the TOPMed database, the allele frequency of this other 
mutation is very low (MAF = 0.000008), but its precise clinical implications remain a mystery. 
 
Table 1. 20 Genetic and clinical features of the probands. 
Case Family 1 Family 2 Family 3 Reference Values 
Patient II.1 II.1 II.1 - 
Gender F F M - 
Age at diagnosis 
(years) 
4 2 67 - 
Hb (g/dL) 12.2-13.3 13.1-13.7 14.0 
13.5-17.5 (M); 
12.1-15.1 (F) 
MCV (fL) 78-84 80 90.2 80-95 
Ferritin (ng/mL) 4-9 2-7 3037 
12-300 (M);  
12-200 (F) 
Transferrin sat (%) 12.9 17.2-26.2 22.0-41.0 25-50 
Iron (µL/dL) n/a 61.95 46 49-226 
Mutation 
c.375+2T>A p.Met1Val c.-164_158del7 - 
Novel 
Previously reported 
(Cremonesi et al. 
2004) 
Novel - 
Disease L-ferritin deficiency L-ferritin deficiency HHCS - 
Inheritance AD AD AD - 
The following abbreviations were used: HB, hemoglobin; MCV, mean corpuscular volume; TF sat, transferrin saturation; F, 
female; M, male; n/a, not available. The mutation nomenclature used follows the HGVS guidelines. 
 
Family 2 - a case with autosomal dominant L-ferritin deficiency 
Proband II.1 from family 2 (Figure 1.9 B and Table 1.20) was referred to the Pediatric Oncohematology 
Unit of the Virgen de la Arrixaca University Hospital for an in-depth analysis of her asymptomatic mild 
neutropenia and eosinophilia. A small ventricular septal defect had been previously detected in the 
patient’s heart. A subsequent medical checkup failed to find hematological anomalies, but rather 
marked hypoferritinemia without anemia. The proband’s condition did not improve with oral iron 
supplementation. She experienced mild asthenia and sporadic mild headaches, which a pediatric 
neurologist attributed to tension headaches after examination. The serum ferritin levels and 
transferrin saturation percentages of the proposita’s mother were low (<6 ng/mL and 9.6% 
respectively), but her transferrin levels were normal. 




Sequencing analysis of this proband (Figure 1.9 B, II.1) showed an A>G substitution at position 1 in the 
heterozygous state. This caused methionine, the start codon, to be replaced with valine. The SNP 
database identified this variant—rs139732572—in 2004, with a very low allele frequency (MAF = 
0.000008 according to the ExAC database). The ClinVar database has classified this mutation (Variation 
ID 96689) as pathogenic because it is linked to L-ferritin deficiency in dominant inheritance mode.  
Here, we report the second case of a patient with hypoferritinemia and this same mutation in the FTL 
gene (NM_000146.3:c[1A>G];[=], NP_000137.2:p(Met1Val);(=), HGSV nomenclature). 
Family 3 - a case with HHCS 
The proband I.1 in family 3 (Figure 1.9 C and Table 1.20) is a 65-year-old man with a history of 
alcoholism and dyslipidemia, showing high levels of serum ferritin (>3000 ng/ml) motive for what he 
was referred to the Hematology Service at the University Hospital Germans Trias i Pujol (HGTiP). He 
previously had cataract surgery, when aged 45, and had three therapeutic phlebotomies which had to 
be stopped due to anemia advancement. Magnetic resonance (MR) imaging showed normal deposits 
of iron in the liver, with his levels being at 30μmol/g. There is reasonable evidence in the family’s 
history to support the presence of HHCS. The proband’s son and uncle had hyperferritinemia and his 
mother had cataracts. The proband’s son (II.1) is a 39-year-old male with history of stage 1 
orchiectomized and disease-free seminoma, but no surgically associated cataracts. He was contacted 
by the same Hematology Service (HGTiP) under suspicion of HHCS because of hyperferritinemia 
(>2000 ng/ml) and cataracts. The hematological evaluation was normal, with normal amounts of 
hepatic iron (20 μmol/g), but higher ferritin levels. 
The genetic studies performed on family 3 showed the presence a heterozygous deletion c.[-164_-
158del7] located in the 5’ FTL-IRE in the proband (I.1) and his son (II.1), both affected with hereditary 
hyperferritinemia with cataracts syndrome (Figure 1.9). Genetic analyses were not available for the 
mother and the uncle of the proband. This variant consists of a deletion of seven nucleotides 
(CAACAGT), excising part of the hexanucleotide loop and upper stem of the FTL-IRE (Figure 1.10). 
Following the traditional nomenclature for FTL-IRE mutations, we refer to these mutations as 
Esplugues +36_42del7 mutation (HGVS nomenclature as NM_000146.3:c.[-164_158del7];[=]). This 
deletion is predicted to impair the IRE structure. RNA secondary structure modelling of WT and 
mutated FTL 5′ IRE sequences was performed using the Sfold web server (Ding, Chan, and Lawrence 
2004), which predicted that -164_-158del7 mutation, located at the hexanucleotide loop, is likely to 
disturb the WT IRE conformation (Figure 1.11). In addition, the SIREs web server prediction (Campillos 
et al. 2010) indicate loss of the IRE structure, as the mutated query returned no results. This mutation 
has not been previously described in the literature, but other similar IRE deletions have been 
previously demonstrated to be pathogenic for HHCS (Cadenas et al. 2019; Sara Luscieti et al. 2013). 
The location and severity of this mutation, together with the clinical manifestations of HHCS present 
in the affected individuals of this family, indicates that this variant is most probably the genetic cause 







Figure 1.10. Schematic localization of literature reported and new FTL mutations. Mutations described in this work are 
in bold and new mutations are boxed. The domains of the five alpha helices (A to E) are represented in the protein 
(NP_000137.2). Mutations are classified as nonsense, frameshift, missense or splicing. We report here FTL protein 
changes using the three-letter amino acid code. 





Figure 1.11. WT and mutated FTL-IRE fold prediction. Predicted secondary structure of WT and mutated FTL-IRE using 
Sfold web server (Ding, Chan, and Lawrence 2004). Deletion in hexanucleotide loop (c.-164_158del7) is expected to 
disturb completely the IRE structure. Nucleotides are numbered from the transcription starting site. Free energy (ΔG) is 
detailed. 
Update on L-ferritin mutations and diseases 
Table 1.21 summarizes the five phenotypic diseases that are triggered by L-ferritin gene mutations. A 
thorough review of literature yielded 63 different known variants for these five diseases, which 
includes the two novel mutations identified the present work (Figure 1.10 and Supplementary 
Material: Table S2). 
Most of FTL gene mutations described above are linked to hereditary hyperferritinemia with cataracts 
syndrome (HHCS), including 36 point mutations, nine deletions, and two insertion-deletions. All HHCS-
associated mutations occur at the 5’UTR location of the FTL gene (chr19:49468566-49468764), which 
disrupts the primary sequence and structure of FTL-IRE (Figure 1.10). HHCS is classified as an 
autosomal dominant disorder, and all reported variants are in heterozygous state except for three 
cases (Sara Luscieti et al. 2013; Alvarez-Coca-Gonzalez J et al. 2010; Van de Sompele et al. 2017) where 
homozygous mutations have been described. HHCS patients exhibit congenial bilateral nuclear 
cataracts and high serum ferritin levels but manifest no additional signs or symptoms. 
Neuroferritinopathy is the only NBIA disorder with an autosomal dominant inheritance. It is caused by 
mutation in the FTL gene. Up to now, nine insertions from one to 16 nucleotides located in the exon 
4 of FTL gene have been reported to cause this neurodegenerative disorder (Figure 1.10). These 
insertions alter the reading frame of the C-terminal region, generating a longer protein with additional 





described to cause neuroferritinopathy; amino acid 96 is predicted to be situated at the same tertiary 
structure region as the pathogenic insertions (Maciel et al. 2005). Mutations in the C-terminal region 
of FTL disrupt α-helix D or E, which seems to be essential for the stability of the peptide (Kubota et al. 
2009; Baraibar et al. 2010). Clinical and biochemical manifestations of this disease include low serum 
ferritin levels, iron accumulation in the basal ganglia and progressive and severe neurological 
dysfunctions with subtle cognitive deficits in some cases. 
Three heterozygous mutations in FTL exon 1 have been associated with hyperferritinemia without iron 
overload where cataracts were absent; this condition has also been named benign hyperferritinemia. 
The Thr30Ile mutation (rs397514540, ExAC MAF=0.000008) has been identified in French and British 
families (Caroline Kannengiesser et al. 2009; Bhuva et al. 2018). Two further pathogenic mutations - 
p.(Ala27- Val) and p.(Gln26Ile) - have been reported in two additional patients (Thurlow et al. 2012). 
Mutations in exon 1 of FTL are associated with higher than normal serum ferritin glycosylation. These 
three variants alter the A α-helix near the N terminus of L-ferritin; it has been hypothesized that the 
aberrant peptide extends the length of the hydrophobic cluster of amino acids at the N terminus, 
increasing the secretion of L-ferritin (Caroline Kannengiesser et al. 2009). However, the reason for the 
development of hyperferritinemia and hyperglycosylation associated with these mutant ferritin forms 
is still not fully elucidated (Bhuva et al. 2018). 
We have described here a novel intronic splicing mutation in the FTL gene 
(NM_000146.3:c.[375+2T>A];[=]) associated also with autosomal dominant L-ferritin deficiency. 
Including this novel splicing mutation, two heterozygous mutations have been described to cause L-
ferritin deficiency with autosomal dominant transmission. Cremonesi and collaborators identified in 
2004 a heterozygous A>G substitution in the first nucleotide of FTL, which change the ATG start codon 
(methionine) into a valine (Cremonesi et al. 2004). This mutation is predicted to encode a non-
functional and unstable protein. Despite the low serum levels of L-ferritin, the proband presenting this 
mutation does not show either serious neurological problems (other than headaches) indicating that 
the molecular mechanism of L-ferritin deficiency with autosomal dominant inheritance is 
haploinsufficiency. 
Finally, only one Italian case has been reported to cause L-ferritin deficiency with autosomal recessive 
inheritance; a homozygous substitution at nucleotide 310 G to T that produces a premature stop 
codon (E104X) (Cozzi et al. 2013). This amino acid change is predicted to be located in the middle of 
the α-helix C domain, a critical region for the stability of the protein. In silico analysis predicted that a 
stop codon at this position produces a truncated protein unable to fold into a functional peptide and, 
therefore, leads to the generation an L-ferritin subunit with a complete loss of function. This 
homozygous mutation is associated with a more aggressive phenotype, which is characterized by 
undetectable ferritin levels, idiopathic generalized seizures and atypical restless leg syndrome. 
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MECHANISM LOST of IRP REGULATION (Do not proceed) DOMINANT NEGATIVE EFFECT HAPLOINSUFICIENCY TOTAL LOSS OF FTL 
MUTATION/S Many in the 5’ IRE Missense in exon 1 Frameshift in exon 4 p.(M1V; =) p.(E104X; E104X) 
TYPE 5’ UTR 
Affects the A α-helix near the 
N-terminus 
Predicted to cause loss of the C-
terminal secondary structure 
Start loss Nonsense 
HAEMATOLOGICAL 
FEATURES 
High serum ferritin  
Normal serum iron  
Normal transferrin saturation  
 Normal red cell counts  
Normal hematologic 
parameters 





Low serum ferritin 
Low serum ferritin 
Low transferrin saturation 
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Congenital bilateral nuclear 
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1.4.1. Discussion regarding HHD panel  
The recent advances in genetic have enabled to simultaneous sequence many genes for many samples 
at the same time. Here, we developed a 154-gene targeted NGS panel in order to evaluate the genetic 
basis of hereditary hematological diseases in 42 patients. If we only consider genetically pathological 
or likely pathological mutations, we found that 42.9% of the patients were genetically diagnosed, 
finding a genetic cause that can explain the clinical features that they present (category A). If we 
include Variants of unknown significance (VUS) the rate of diagnosis is 57.2%. These results are in 
agreement with others where they report a genetic diagnostic rate of 44-60% (Shefer Averbuch et al. 
2018; Muramatsu et al. 2017). 
 
1.4.1.1. Limitations 
Although targeted NGS is a widely used method to detect clinically significant genetic changes, this 
technology still has some limitations that can hinder the analysis. These limitations include the 
interpretation of VUS and negative results, the areas of the DNA that are uncovered by NGS 
technology such as deep intronic region or promoter regions, the limitation in databases and in 
medical knowledge to classify variants, and the limitation in the detection of structural variants and 
copy number variants.  
Interpretation of VUSs 
Six out of the 42 patients (14.3%) were variants of unknown clinical significance (VUS). These variants 
represent a challenge to interpret, and the American College of Medical Genetics (ACMG) developed 
a guideline to help to pathogenically classify them (Green et al. 2013). 
In order to categorize the pathogenicity of this type of variants, it is important to consider the allele 
frequency in the population (from 1000 Genomes, ExAc or other databases), the amino acid 
conservation, and the effect on the protein (Richards et al. 2015). In order to better understand a VUS, 
a functional analysis help to observe the effect of the mutation in the protein; however, functional 
studies are very tedious and are not available in many VUSs. Also, a segregation analysis of trio 
families, or large families if it is possible, can help to determine if the mutation is present in other 
member of the family and confirm the mode of inheritance, or if the variant is a de novo variant. When 
in vitro analysis is not possible, a variety of in silico tools (SIFT, PolyPhen-2, PROVEAN, Human Splicing 
Finder…) are widely used to interpret missense, indels and splicing variations, and predict the effect 
of the variant in the protein. However, these tools have some intrinsic limitation and caveats that can 
lead to potential false-positive and false-negative interpretations (Di Resta et al. 2018).  
In the HHD panel v15 the exons of each transcript, 50bp of the intron boundaries and the 3 'and 5' 
regions of specific genes are sequenced. The clinical report does not contain information on 
uncovered areas of genes such as deep intronic regions or any currently uncharacterized alternative 
exon, so we may be missing variants in these regions. Nevertheless, the fact that deep intronic regions 
are not analyzed, decrease the number of variants that are difficult to interpret, as bioinformatics 






Fifteen patients (38.5%) were classified in the D category (negative result), since no mutation was 
found in subpanel genes, or benign or likely benign variant was detected. However, negative results 
are also meaningful. Some negative cases belong to patients that are sent to our laboratory to discard 
a particular congenital disease, and this is a valuable information for the medical doctor. In other 
cases, patients with negative results present a clear family history of a particular disease or a clear 
phenotype of a particular genetic disease; however, no significant variant was found; therefore in 
those cases, an exhaustive investigation is performed. First, candidate genes included in the HHD 
panel are screened to check the existence of mutations in new genes. These candidates’ genes have 
been selected from the literature (i.e. they might be involved in mouse in iron-related anemias but 
have never been involved in human diseases) or from pathway analysis, that indicate that they might 
be associated with the diseases. If still noting relevant is found, WES analysis is performed for selected 
samples, including the parents and other members of family if it possible (trio approach). The WES 
application may allow the identification of new genes responsible of HHD. However, one limitation of 
WES is that 10% of the sequenced bases do not have the recommended depth coverage for clinical 
diagnosis (>50x), and other method may be necessary to confirm the presence of a potential causative 
variant (Di Resta et al. 2018).   
Database and Knowledge 
The interpretation of the results is limited by the information currently available in databases, medical 
literature, and clinical experience. Every year, new genes are identified to be associated with HHD. 
The difference between the versions of the HHD panel that have been designed in the study evidence 
this point: as more recent is the design of the panel, more genes are incorporated. Databases are not 
always updated with the information supplied by novel publications, and this may result in two issues: 
variants described in publications but not found in databases; and variants with conflict of 
interpretation between databases and publications (e.g. variant reported as likely benign in databases 
and a novel publication that demonstrates the pathogenicity). Furthermore, the knowledge about 
digenic or multigenic influence in HHD is limited. A better interpretation will be possible in the future 
as data and knowledge about human genetics and specific diseases increase. 
Difficult-to-sequence areas 
Also, there are areas of some genes that are not covered by the panel such as homologous regions 
(Figure 1.5) and GC-rich regions (Figure 1.6). Homologous regions are areas of the genome with high 
sequence similarity that may differ between them by only few base pairs. The alpha and beta globin 
sequences have a high gene sequence similarity (HBA2 and HBB have almost 97% of similarity) 
(Moradkhani et al. 2009; Fan et al. 2019), so design probes to sequence these genes efficiently is a 
challenge for the NGS technology. The Agilent SureDesign was not able to design reliable amplicons 
for these genes, a difficulty that may be solved by the use of longer reads. Moreover, since the 
Haloplex library is dependent on restriction enzyme, several Single Nucleotide Variants (SNVs) may be 
missed generating potential false negatives, possibly because their location in the proximity of 
restriction-enzyme digestion sites (Samorodnitsky, Datta, et al. 2015; Samorodnitsky, Jewell, et al. 
2015). 
Besides, amplification technologies such as PCR, are sensitive to high content of G and C nucleotides, 
so GC-rich regions are typically uncovered by NGS technology based in amplification (such as Illumina). 
In figure 1.6 we can see an area of the VHL gene (  2̴0 nucleotide) that is not covered by the Haloplex 
design probably due to high GC-content (around 60%). Unfortunately, one patient with mutation in 




this region was not able to be genetically diagnosed using NGS targeted panel. It is essential to know 
the conflicting regions in the NGS panel in order to cover them with alternative methods (i.e. Sanger 
sequencing). 
Moreover, few regions (ideally <10%) may be poorly depth covered with less than 50 reads, the 
minimum depth coverage for genetic diagnosis. To get this target area covered, missing targets could 
be re-sequenced through Sanger sequencing. These limitations must be considered, and the use of 
other techniques such as Sanger sequencing can be applied to complete the genetic diagnosis of the 
uncovered regions, although this could be labor-intensive and time-consuming. 
Even though NGS has some limitations, advantages are also present (sequencing of multiple genes at 
once and multiplexing patients) what makes of this technology a superior one compare with the still 
gold standard sequencing method (Sanger Sequencing). 
Structural Variant and Copy Number Variant 
NGS platforms based in short length reads, such as Illumina, are reasonable efficient to detect SNVs 
and small insertions or deletions (indels). However, structural variants (large deletions, insertions, 
duplication, translocations and inversions) and copy number variants (CNVs) are not detected with 
ease, especially with NGS enrichment systems, and require a particular bioinformatics analysis. Since 
HHD are primarily caused by SNVs and indels, structural variants and CNVs have been not examined 
in our patients. Therfore, we cannot discard that some cases present a CNV or large reorganizations 
as causative of their disease. Alternative techniques such as MLPA should be used to discard this 
possibility. 
Some of the technical limitations described here, including the detection of CNV and structural 
variants, and the coverage of areas “difficult to sequence”, may be solved with the development of 
Third Generation sequencing (TGS) instruments, based in long sequencing reads or single-molecule 
sequencing (SMS). The TGS instruments that are available until now are the PacBio SMRT (single 
molecule real time) and Oxford Nanopore (Oxford, United Kingdom). Illumina has developed the True-
seq Synthetic Long-Read system, but some authors do not accept its inclusion in the TGS methodology 
since the length of the reads (   ̴10 kb) are no as longer as the PacBio and Oxford Nanopore (>80 Kb) 
[Van Dij,2018]. The use of TGS instruments, that are exempt of amplification steps, may allow 
overcoming the limitations of the SNV and structural variants detection, and to cover areas that are 
difficult to sequence by amplification methods (GC-rich areas, homologous genes and repetitive areas) 
(Di Resta et al. 2018; Yohe and Thyagarajan 2017; van Dijk et al. 2018). Also, TGS help to estimate the 
haplotype pashing, and reconstruction of the parental homologs (van Dijk et al. 2018). Said so, 
nowadays these new technologies are still in development and have not been validated and 
standardized for clinical diagnosis. 
Clinical reports and patient care 
Finally, the genetic results found in the patients are communicated to the clinician in an 
understandable clinical report to facilitate the medical care of the patients, including the genetic 
testing results and also clinical recommendations written by hematologic medicine experts for 
management and treatment of the patient (see Appendix- 4.Other documents- page 217 for an 







1.4.2. Discussion regarding FTL gene and diseases  
 L-ferritin disease is a clear case of Mendelian disease-related genes that are associated with multiple 
diseases, including Hereditary Hyperferritinemia Cataract Syndrome (HHCS), isolated 
hyperferritinemia (benign hyperferritinemia), hypoferritinemia associated with other symptoms 
(neurological symptoms as in neuroferritinopathy, or muscular symptoms in autosomal recessive L-
ferritin deficiency) or isolated hypoferritinemia (Autosomal dominant L-ferritin deficiency). For 
improving the diagnosis of these different diseases, we have created a clinical diagnostic algorithm of 
diseases caused by mutations in FTL gene (Figure 1.12). 
The underlying mechanisms for these disease patterns are not fully elucidated for all these diseases. 
In HHCS, it is known that the pathological molecular mechanism is linked to the disruption of the IRP-
IRE post-transcriptional regulatory system, with the de-repression of L-ferritin mRNA and the 
subsequent overproduction of L-ferritin protein that precipitates and deposits in the lens of the eyes, 
producing cataracts. In HHCS, authors have argued that an association exists between the clinical 
severity of the disease and the location of the mutation in FTL-IRE (Sara Luscieti et al. 2013; Faniello 
et al. 2009; Allerson, Cazzola, and Rouault 1999). Higher serum ferritin levels are mostly associated 
with mutations in the apical loop or the C-bulge area, compared with mutations in the upper or lower 
stems. These findings are consistent with our cases in family 3, i.e. a father and son with a seven-
nucleotide deletion in the IRE of the FTL gene (5’-CAACAGU3’). The deletion partially affects the 
hexanucleotide loop of the IRE, and patients show considerably high serum ferritin levels (2071-3037 
ng/ml) and develop early bilateral cataracts (Table 1.20). 
Mutations in exon 4 of FTL gene that alter the C-terminal sequence and the length of the protein have 
been reported to cause neuroferritinopathy. These mutations affect the D- or E α-helix (see Figure 
1.10), leading to significant disruption of the tertiary and quaternary structure of the FTL protein and 
producing unstable and leaky ferritin. Studies have shown that mutant ferritin maintains the normal 
spherical shell structure and size (Baraibar et al. 2008). However, mutant FTL C-termini, rich in amino 
acids with iron-binding properties, may be extended and unravel out of the shell. These mutant 
structures could initiate aggregation, forming ferritin inclusion bodies/precipitates (Baraibar et al. 
2008; R. Vidal et al. 2004). Previous in vitro functional analysis and in vivo mouse models have revealed 
that these molecular-level defects have two main consequences: (1) the loss of normal protein 
function, reducing iron incorporation; (2) and the acquisition of toxic function through radical 
production, ferritin aggregation and reactive oxygen species (ROS) generation (Muhoberac and Vidal 
2013; Garringer et al. 2016; Ruben Vidal et al. 2008; Muhoberac, Baraibar, and Vidal 2011). It has been 
demonstrated that mutations in the C terminus have a dominant-negative effect, which explains the 
dominant transmission of the disorder (S. Luscieti et al. 2010).  
In benign hyperferritinemia, missense variations in exon 1 of FTL increase the hydrophobicity of the 
ferritin N-terminal site. The A-α-helix of the protein is altered and hyperglycosylated, although the 
precise molecular mechanism is not clear yet.  
L-ferritin deficiency is characterized by haploinsufficiency of the FTL protein in autosomal dominant L-
ferritin deficiency, or complete loss of function in autosomal recessive L-ferritin deficiency. Mutations 
associated with this condition are predicted to affect protein expression. The inactivation of one allele 
of the FTL gene, which occurs in the two described heterozygous cases of autosomal dominant L-
ferritin deficiency, produces a significant reduction of L-ferritin protein in serum. The phenotype of 
this dominant condition is normal apart from low levels of serum ferritin and low transferrin 
saturation. However, the homozygous mutation Glu104Ter causes a total loss of function of L-ferritin 
and leads to ferritin missing the FTL chain. Previous mutational studies have suggested that the 




presence of H homopolymer ferritin in fibroblasts is associated with reduced cellular iron availability 
and increased ROS production, which triggers cellular damage. These findings were also found in 
neurons derived from patient fibroblasts and correlate with the neurological phenotype of this more 
severe condition (Cozzi et al. 2013).  
In this study, we have identified two new cases of autosomal dominant L-ferritin deficiency, one due 
to a new mutation in intron 3 of the FTL gene that most probably affects splicing. The T>G substitution 
in nucleotide 375+2 (genomic coordinates g.49469665 in Assembly GRCh37.p13) modifies a highly 
conserved dinucleotide GT donor site, a key sequence recognized by the spliceosome during splicing. 
Mutations in splice site junctions are likely to lead to exon skipping or total or partial intron retention 
in the mRNA transcript in most cases (Ruben Vidal et al. 2008). Our in silico analysis using Human 
Splicing Finder suggests that our variant would activate a new alternative donor site onwards (375+5G 
and +6T), leading to the insertion of four additional nucleotides in the mRNA sequence between exon 
3 and 4 and altering the reading frame of the transcript (Muhoberac, Baraibar, and Vidal 2011). 
Therefore, this change would lead to a premature stop codon formation and the putative generation 
of a truncated FTL protein of 128 amino acids, if the aberrant mRNA is not detected and degraded by 
the nonsense mediated decay (NMD) system. According to our bioinformatics prediction, the 
c.375+2T>A mutation will not generate a dominant-negative version of FTL protein, but a truncated 
FTL protein completely missing the E- α-helix domain and partially lacking the D- α-helix domain. 
Supported by the clinical manifestations found in this family (low serum ferritin levels, low transferrin 
saturation and lack of serious neurological or movement abnormalities), the molecular mechanism, in 
this case, is most probably due to the loss of function of FTL and it will be not expected that the disease 
derives in neuroferritinopathy. However, we cannot totally and completely exclude the later 
development in life of brain iron overload and neuroferritinopathy in these patients by a yet unknown 
and novel mechanism.  
Patients with hereditary hyperferritinemia could be misdiagnosed as patients suffering from 
hereditary haemochromatosis, liver dysfunction or inflammation. Some patients have received 
unnecessary invasive diagnostic techniques, such as liver biopsy, and are inappropriately treated with 
venesections and phlebotomies that can cause severe iron-deficiency anemia. On the other hand, 
clinical manifestations of neuroferritinopathy including tremor, parkinsonism, psychiatric problems 
and abnormal involuntary movements, the presence of ferritin-iron precipitation in glia cells and 
neurons (R. Vidal et al. 2004), are often misdiagnosed and treated as Huntington’s or Parkinson’s 
disease. Potential treatment targets for neuroferritinopathy may include an optimized iron chelator 
to induce the re-solubilization of iron aggregations, in combination with radical scavengers to prevent 
oxidative ferritin damage (Baraibar et al. 2012). Patients with benign hyperferritinemia could be 
misdiagnosed as patients with HHCS due to the presence of high ferritin levels and the possible late-
onset appearance of cataracts. Apart from the surgical removal of cataracts in HHCS, HHCS and L-
ferritin deficiency have no specific therapy. 
These facts emphasize the importance of a correct and early genetic diagnosis for the subsequent 
implementation of proper treatment, avoiding detrimental or inappropriate treatments. Following 
clinical algorithms, such as the one included in this publication (Figure 1.12) and also HIGHFERRITIN 
Web Server (http://highferritin.imppc.org/) (Altes, Perez-Lucena, and Bruguera 2014) will surely help 







Figure 1.12. Algorithm for diagnosis of diseases caused by defects in FTL gene.  
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The aim of CoDysAn web page is to provide a freely accessible web site where the general public, 
patients and medical doctors can better understand and learn more about Congenital 
Dyserythropoietic Anemia. The results of this work have been recently published in Frontiers 
Physiology (Tornador et al. 2019). See Appendix-3.Publication, page 209 for a copy of the manuscript. 
Frontiers in Physiology - Red Blood Cell Physiology section; doi: 10.3389/fphys.2019.01063 
CoDysAn: A telemedicine tool to improve awareness and diagnosis for patients with Congenital 
Dyserythropoietic Anemia 
C. Tornador, E. Sánchez-Prados, B. Cadenas, R. Russo, V. Venturi, I Andolfo, I. Hernández-Rodriguez, A 
Iolascon, M. Sánchez* 
 
2.1.1. Congenital Dyserythropoietic Anemias: subtypes and associated 
genes 
Congenital Dyserythropoietic Anemias (CDAs) are inherited hematological disorders characterized by 
chronic hyporegenerative anemia, morphological abnormalities of erythroblasts, and hemolytic 
component (Iolascon et al. 2012). CDA is a subtype of inherited bone marrow failure syndromes 
(IBMFS), hallmarked by ineffective erythropoiesis during differentiation and proliferation stages, and 
consequently a faulty production of red blood cells. Patients with CDA present congenital and chronic 
anemia of variable degree with relative reticulocytosis, jaundice, and frequently splenomegaly and/or 
hepatomegaly (Iolascon, Esposito, and Russo 2012; Iolascon et al. 2013). 
Five classical types of CDAs (I-II-III-IV and XLTDA) have been defined based on the morphological 
alteration of erythroblasts in the bone marrow. Despite the fact that the morphological classification 
is still widely used, a most recent genetic reclassification has been introduced in clinical practice. So 
far, six subtypes of CDA exist depending on the causative gene (Table 2.1 and Figure 2.1).  
CDA I 
Patients with CDA type 1 present macrocytic anemia with mean cell volume of variable range (100-
120 fL) and variable values of Hb, although the disorder can be normocytic in infancy. Inadequately 
decreased reticulocytes count is typically observed in these patients. All the cases develop 
splenomegaly, although 4-20% patients can manifest other phenotypic anomalies: pigeon chest, short 
stature, neurologic deficiency or malformation in hands or feets like syndactyly, polydactyly, or 
absence of nails.  
Bone marrow (BM) exploration in optical microscopy shows hypercellularity and hyperplasia of 
erythroid precursors. The ratio of erythropoietic to granullo-poietic cells (E:G ratio) is four to eight 
times more elevated (3-8/1) than the normal range (0.2-1/1) (Heimpel, Matuschek, et al. 2010). A 
typical feature of CDA type I is the presence of internuclear chromatin bridges in erythroblasts.  
Electron microscopy shows spongy heterochromatin, also called “swiss cheese” appearance, due to 
the widening of nuclear pores and presence of invaginations of the nuclear membrane (Heimpel, 
Matuschek, et al. 2010; Heimpel et al. 2006).  
The inheritance of CDA type I is autosomal recessive and is generated due to mutations in CDAN1 (CDA 
type Ia; OMIN #224120) (Dgany et al. 2002) and C15ORF41 (CDA type Ib; OMIM #615631) (Babbs et 
al. 2013). More than 40 pathogenic variants have been identified in CDAN1 (chr15q15.2) so far. This 





increased during S phase of the cell cycle, due to transcriptomic regulation by E2F1 (Figure 2.1). The 
function of codain-1 is not totally elucidated, although different studies suggest that this protein is 
implicated in the organization of the heterochromatin during DNA replication and the nucleosome 
assembly and disassembly (Noy-Lotan et al. 2009; Ask et al. 2012).  
C15ORF41 (chr15q14) gene was the second gene identified as causative of type I CDA (CDA Ib;). Two 
missense pathogenic variants were identified by Babbs et al. on three unrelated families: L178Q and 
Y94C (Babbs et al. 2013). This gene encodes metal dependent restriction endonuclease, and although 
the function is still unknown, it has been hypothesized in different studies to have an essential role in 
the chromosome segregation between metaphase and anaphase directly involved with the Holliday 
junction solvates (Figure 2.1) (Gambale et al. 2016), and in the DNA replication and chromatin 
assembly due to the interaction with Asf1b protein (Babbs et al. 2013).   
CDA II 
CDA type II (OMIM #224100) is the most common form of CDA, presented with moderate normocytic 
anemia (HB: 8.5-9.5 g/dL) with inadequate low reticulocyte count (ineffective erythropoiesis), 
accompanied with jaundice, splenomegaly, and cholelithiasis due to hemolytic component (Iolascon, 
Esposito, and Russo 2012; Iolascon et al. 2013). The mean age of diagnosis is around 22 years old, as 
a consequence of the moderate symptoms or the misdiagnosis with other diseases as hereditary 
spherocytosis.  
BM biopsy shows hypercellularity and erythroid hyperplasia, resulting in raised E:G ratio. More than 
10% of erythroblasts are binucleated, and rarely multinucleated. The nucleus of erythroblasts is typical 
of equal size with condensed chromatin (pyknosis). Electronic microscopy examination exhibits the 
appearance of double plasma membrane in mature erythroblasts, caused by the excess of 
endoplasmic reticulum cisternae (Heimpel, Kellermann, et al. 2010; Alloisio et al. 1996).  
CDA type II is inherited in an autosomal-recessive manner and is caused by mutations in SEC23B gene 
(chr 20p11.23). More than 80 different mutations have been described so far (Russo et al. 2014). This 
gene encodes for coat complex II component (COP II), which participate in protein vesicle trafficking 
through endoplasmic reticulum (Schwarz et al. 2009). The mechanism of pathogenesis is still not 
totally understood, but SEC23B could play an important role in the assembly and deconstruction of 
the midbody during cytokinesis (Figure 2.1), and defects in SEC23B could lead impairment of cell 
division (Skop et al. 2004). 
CDA III 
Type III (OMIM #105600) CDA is a rare dyserythropoietic anemia characterized by giant erythrocytes 
or giant multinucleated (up to ten nuclei) erythroblasts. Patients show vague to moderate anemia, 
and the number of reticulocytes is normal or low. Hemoglobinuria with hemosiderinuria is presented 
due to the presence of hemolytic component. Peripheral blood smear exhibit macrocytes, some 
gigantocytes and poikilocytes. At optical and electron microscopy, BM shows hyperplasia of erythroid 
precursors and giant multinucleated erythroblasts (Sandström and Wahlin 2000; Björkstén et al. 
1978).  
Familiar CDA III is an autosomal dominant condition caused by a mutation in KIF23 gene (chr 15q21) 
which encodes a mitotic kinesin protein, MKLP1, involved in the formation of the central spindle and 
the midbody during telophase, that is essential for the cell division (Figure 2.1) (Liljeholm et al. 2013).  
CDA IV 




Only four cases of CDA type IV (OMIM #613673) have been described to date. Patients with CDA IV 
suffer from severe normocytic anemia (HB range between 5 and 9.5 g/dL), with normal or slightly 
increased reticulocyte count and splenomegaly. Other physical manifestations include short stature, 
hydrops fetalis, thalassemic face and female genitalia in an XY Karyotype patient (Jaffray et al. 2013; 
Ravindranath et al. 2011)  
The morphological evaluation of peripheral blood smears of patients with CDA IV reveals the presence 
of anisopoikilocytosis and polychromasia in erythroblasts and erythrocytes. The examination of bone 
marrow aspirate at optical microscopy shows tri- and multinucleated erythroblasts, erythroid 
hyperplasia, and karyorrhexis (Jaffray et al. 2013). At electron microscopy, we can find invagination of 
the nuclear membrane and intranuclear precipitates. 
The four described patients with CDA IV evidence the same heterozygous missense mutation (E325K) 
in KLF1 gene (chr 19p13.2), which encodes the Erythroid-Krüppel-like factor (EKLF), essential for the 
activation of erythroid-specific genes (Figure 2.1). Erythrocytes of these patients have reduced 
expression of CD44 and AQP1. The disorder is inherited in an autosomal dominant manner 
(Wickramasinghe, Illum, and Wimberley 1991; Arnaud et al. 2010; Jaffray et al. 2013; Ravindranath et 
al. 2011). 
XTLDA 
X-linked thrombocytopenia with or without dyserythropoietic anemia (OMIM #300367) is a variant of 
CDA, marked by anemia with a paucity of platelets (thrombocytopenia) and erythrocytes with 
abnormal size and shape. Bone marrow aspiration exhibits dyserythropoiesis and dysplastic 
megakaryocytes. Electron microscopy of patient's bone marrow showed abnormal megakaryocytes 
with clusters of smoothy endoplasmic reticulum and paucity of alpha-granules (Nichols et al. 2000; 
Mehaffey et al. 2001).  
This variant of CDA is originated by a mutation in GATA1 (chr Xp11.23), which encodes for the zinc 
finger DNA binding protein GATA1. This protein is involved in the regulation of hematopoiesis and the 
development and maintenance of megakaryocytes and erythrocytes cells (Figure 2.1). This disorder 
has x-linked inheritance (K. Freson et al. 2001; Kathleen Freson et al. 2002).  
Different treatments have been established depending on the CDA subtype. Allogenic bone marrow 
transplantation has been successfully employed in a few severe cases of CDA I and CDA II. Patients 
with CDA III may require a blood transfusion only during times of extreme anemia such as pregnancy 
or surgery. Treatment focuses on hemoglobin normalization with the administration of interferon 
(IFN) alpha is used with success in CDA I patients with CDAN1 mutations; however, patients bearing a 
mutation in a different gene i.e. C15ORF41 were unresponsive to this same treatment. Severe cases 
of fetal anemia associated with CDAI, CDAII and XLTDA may require intrauterine transfusions. Blood 
iron levels should be closely monitored in CDA I, CDA II and other CDA patients undergoing regular 
transfusions. In these cases, morbidity may be severe due to iron overload complications that can be 
fatal if left untreated (Gambale et al. 2016; Palmer et al. 2018). Therefore, it is imperative to monitor 
iron overload and induce iron depletion by iron chelation when needed.  
2.1.2. Aim of CoDysAn 
Although the morphological diagnosis is still in use in clinical practice, the identification of the mutated 
genes involved in the majority of CDA subgroups will improve the diagnostic possibilities and allow a 
better classification of CDA patients. In many cases of CDA, a final diagnosis is not achieved due to 





there are cases that fulfill the general definition of CDA, but do not conform to any of the classical CDA 
classification. Therefore, it is very plausible that new forms of CDA exist, which may be possible to 
identify if a proper genetic diagnosis is performed in each case with suspected CDA.  
We have developed a new telemedicine tool named as CoDysAn (Congenital Dyserythropoietic 
Anemia) for improving the management and the diagnosis of patients with this condition. The aim of 
CoDysAn web page is to provide a freely accessible web site where general public, patients and 
medical doctors can better understand and learn more about this disease. Moreover, CoDysAn web 
page includes a diagnosis algorithm tool, to ease the classification and diagnosis of CDA types. 
 
Figure 2. 1 Pathogenic mechanism of CDA. CDA is caused by ineffective erythropoiesis during differentiation and 
proliferation stages, and consequently a faulty production of red blood cells. Mutation in CDAN1 cause CDA Ia, and may 
affect the organization of heterochromatin during DNA replication and the nucleosome assembly. CDA Ib is caused by 
mutation in C15ORF41, and seems to influence the chromosome segregation between metaphase and anaphase due to its 
homology to the Holliday junction resolvases. The protein encoded by SEC23B is a component of the midbody, and a defect 
in this protein impairs the cell division during cytokinesis. (CDAII). The cell division is also disable due to mutation in KIF23, 
that is also involved in the formation of the midbody and the central spindle during telophase (CDAIII).  The gene KLF1 is 
essential for the activation of erythroid-specific genes (CDA IV). Finally, XTLDA is produced by a mutation in GATA1, that is 
involved in the regulation of hematopoiesis and the development of erythrocytes cells. This figure is original and was 
designed by Beatriz Cadenas and adapted from different literature sources (Gambale et al. 2016).  
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Table 2. 1 Classification of CDAs 
CDA 
subtype 
Phenotype OMIM Gene Locus Inheritance 
 
Phenotype 
Bone Marrow Examination 
OM EM 
CDA Ia Congenital 
dyserythropoietic 
anemia type 1a 
224120 CDAN1 15q15.2 AR Macrocytic anemia; 
Malformations in fingers and 
toes. 
Incompletely divided cells; 
binucleated erythroblasts 






heterochromatin CDA Ib Congenital 
dyserythropoietic 
anemia type 1b 
615631 C15orf41 15q14 AR 
CDA II Congenital 
dyserythropoietic 
anemia type 2 
224100 SEC23B 20p11.23 AR Normocytic anemia; jaundice, 
splenomegaly, and 
cholelithiasis 
>10% of erythroblasts are 





CDA III Congenital 
dyserythropoietic 
anemia type 3 
105600 KIF23 15q21 AD Normocytic anemia; 
reticulocytes count is normal 
or low 
Giant multinucleated (up to 12 nuclei) erythroblasts; 
CDA IV Congenital 
dyserythropoietic 
anemia type 4 
613673 KLF1 19p13.2 AD Severe normocytic anemia; 
normal or slightly increased 
reticulocyte count; 
splenomegaly; short stature, 
hydrops fetalis, thalassemic 
face and female genitalia in an 
XY Karyotype 
Tri- and multinucleated 
erythroblasts 
Invagination of the 


















with a paucity of alpha 
granules 
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2.2. MATERIAL AN METHODS 
 
2.2.1. Patients and validation 
CoDysAn web algorithm has been tested with a set of 48 patients, 24 of which were genetically 
diagnosed as CDA, counting: 18 CDA type II, 1 CDA type Ib, 4 CDA type Ia and 1 XLTDA. The 19 
remaining patients were genetically diagnosed of non-CDA congenital anemias (negative controls), 
including: 8 hereditary spherocytosis, 4 patients with pyruvate kinase defects, 1 patient with pyruvate 
kinase defect and a beta thalassemia trait, 1 patient with defects in Hemolytic anemia due to 
adenylate kinase deficiency (AK1 gene), 1 patient with X-linked sideroblastic anemia, 8 patients with 
dehydrated hereditary stomatocytosis type 1 (DHS1) and 1 patient with dehydrated hereditary 
stomatocytosis type 2 (DHS2). A second set of 23 CDA II patients was used to validate the sensitivity 
of the algorithm. Patients where previously reported (Schwarz et al. 2009; Iolascon et al. 2010; Russo 
et al. 2011; 2013; 2014; Unal et al. 2014; Pierro et al. 2015; Andolfo et al. 2015; Russo et al. 2016; 
2018; Andolfo et al. 2018) and diagnosed at Medical Genetics Unit of A.O.U. Federico, CEINGE – 
Biotecnologie Avanzate (Napoli). See Table 2.2.  
 







CDA Ia 4  
Ib 1  
II 18 23 
XLTDA 1  
Total CDA 24 23 
Non-CDA Hereditary spherocytosis 8  
Pyruvate kinase defects 4  
Pyruvate kinase defect and a beta thalassemia trait 1  
Hemolytic anemia due to adenylate kinase deficiency 1  
X-linked sideroblastic anemia 1  
Dehydrated hereditary stomatocytosis type 1 (DHS1) 3  
Dehydrated hereditary stomatocytosis type 2 (DHS2) 1  
Total Non-CDA 19  
  TOTAL OF SAMPLES 43 23 
CDA, Congenital Dyserythropoietic Anemia, N, number of samples 
 
2.2.2. Design of the web server 
CoDysAn is implemented in PHP, HTML5, CSS and Javascript. Coding was performed by 
bioinformaticians from Mayka Sanchez research group (Iron Metabolism group, UIC), and Whole Genix 
company. The web server is executed in a XAMPP. Network visualization and interactive exploration 
modules are based on several open-source projects: Bootstrap, jQuery and Filezilla. The source code 




of the diagnostic tool algorithm is implemented in php at http://www.codysan.eu/diagnostics-
tool.html. It is integrated within this web page between lines 661 and 1204 in four steps corresponding 
to the four steps of the form. The code can be checked by typing in a browser: “view-source: http: 
//www.codysan.eu/diagnostics-tool.html”. 
2.2.3. Diagnostic algorithm for CDA 
CoDysAn algorithm has been created based on different publications and databases (OMIM, 
ORPHANET, GARD) and it has been approved and corroborated by experts in hereditary hematological 
diseases and CDA. This algorithm is based on hematological parameters depending on age and gender 
(Table 2.3). Three different ranges of age have been considered: infancy (from 0 months to 6 months), 
childhood (from 6 months to 12 years), and adulthood (older than 12 years old). The differential 
diagnosis of CDA is translated in the CoDysAn algorithm in 4 steps (Figure 2.2). (1) The first required 
criteria for CDA is the evidence of anemia. CDA patients, independently of the subtype, present 
hemoglobin levels (Hb) lower than the reference values. (2) Abnormal levels of other hematological 
parameters, including mean corpuscular volume (MCV), reticulocytes count and platelets count, are 
presented in CDA subtypes differently. The reticulocyte count is normal or decreased in all CDA 
subtypes, MCV is increased in CDA type I, and a shortage of platelets count is presented in XLTDA. (3) 
Exclusion of other congenital anemias with similar hematological parameters must be considered. (4) 
And finally, evidence of other typical manifestations of the CDA subtype is shown. References values 
for hematological data are obtained from general hematological reference books (Hoffman et al. 2018; 
Wakeman et al. 2007; Rabinovitch 1990). 
 
Table 2. 3 Normal ranges for hematological values used by the diagnostic CoDysAn algorithm. 
MCV: Mean Corpuscular Volume; M: male; and F: female 
 
Parameter  0 to 6 months 
6 months to 12 
years 
>12 years Units 
Hemoglobin M 9.5-18 11-15.5 13-17.5 
g/dL 
 F 9.5-18 11-15.5 12-16 
MCV* M 77.5-111.5 74-89.5 80-100 
fL 
 F 77.5-111.5 74-89.5 80-100 
Reticulocytes M 61-134 24-114 29-95 
X109/L 
 F 67-142 40-162 27-91 
Platelets M 145-450 145-450 145-450 
X109/L 
 F 145-450 145-450 145-450 
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2.3. RESULTS  
 
2.3.1. CoDysAn scope 
We have developed CoDysAn web tool, a user-friendly webpage for better awareness of congenital 
dyserythropoietic anemia (CDA), including a step-by-step diagnostic algorithm based on hematological 
parameters (Figure 2.2). The website is freely available at URL http://www.codysan.eu in four 
languages (Catalan, Spanish, Italian, and English). 
Algorithm for differential diagnosis of Congenital Dyserythropoietic Anemia (CDAs) 
 
Figure 2. 2 Algorithm for differential diagnosis of Congenital Dyserythropoietic Anemia (CDAs). The algorithm is structured 
in five steps. (1) Anemia, the hemoglobin levels are considered for the presence of anemia. (2) Other hematological 
parameters are evaluated: reticulocytes, platelets, and Mean Corpuscular Volume (MCV). (3) Exclusion of other diseases with 
similar characteristics is performed. (4) Other clinical features are examined. (5) The clinical suspicious of CDA is shown, 
including the gene that is involved in the CDA subtype.  This figure is also shown in supplementary material Figure S1.  in two 





2.3.2. Webpage structure and design 
The CoDysAn website is configurated in 8 sections.  
1- The home section is the welcome page that describes the goal of the website, and contains 
links to the most important sections, including; description of CDA, an interactive algorithm 
of diagnosis, information about CoDysAn project, and guidance to collaborators of the project.  






Figure 2. 3 Home page from CoDysAn website. 
 
2- The CoDysAn section encloses five subdivisions. 
a. “About the disease” subsection gives some information about CDA (description of the 
disease, subtypes, and genetic and clinical information 
b. “What is CoDysAn?” subsection describes the research project that is behind the 
CoDysAn acronym, also titled as “Towards the improvement of diagnosis and 
treatment in Congenital Dyserythropoietic Anemias”. The page informs about the 
intention and the goal of the research project and gives some details of the foundation 
research grant.  
c. “Privacy policy” subsection informs about the storage, processing and manage the 
user´s data. 
d. “Cookies” subsection describes the used cookies in CoDysAn webpage.  
e. Disclaimer subsection specifies the warnings and expectations to users in order to 
fulfill the duty of care. CoDysAn is a telemedicine diagnostic tool intended to be used 
as a preliminary diagnostic test. A specialist medical doctor should verify a conclusive 
diagnosis. 
 
CHAPTER II: CoDysAn, a web tool for the diagnosis of CDA 
71 
 
3- The diagnostic section contains a step-by-step CDA diagnostic tool, the algorithm flowchart 
for the diagnosis of CDA (Figure 2.2), and specific instructions on how to use the telemedicine 
tool.    
 
4- The collaborator section includes links to the contributors for the CoDysAn project, patient 
associations (ADISCON, http://www.adiscon.es/; and APU, 
http://www.asociacionpablougarte.es/index.htm) and a link to a similar telemedicine tool, 
the HIGHFERRITIN web server (http://highferritin.imppc.org/) (Altes, Perez-Lucena, and 
Bruguera 2014).  
 
5- In the resource section, the most relevant bibliographical references related to CDA can be 
found, but also news on the CoDysAn project and reference values used for the diagnostic 
algorithm (Table 2.3).  
 
6- The opinion section sends the user to a questionnaire to express its opinion and degree of 
satisfaction with the website. This information will lead us to future improvements and 
updates for the website.  
 
7- In the contact section, users can directly contact with CoDysAn developers through a web 
form, to address any doubt, suggestion or complain regarding the webpage. 
 
8- The FAQs sections contain the frequently asked questions. 
 
2.3.3. Implementation of the web tool 
The algorithm used for setting up the CoDysAn diagnostic tool is depicted in Figure 2.2. A user-friendly 
and four-steps form will progressively ask to the user for relevant information from the patient. The 
first step evaluates the level of hemoglobin according to age and gender (Figure 2.4). Three different 
ranges of age have been considered: infancy (from 0 months to 6 months), childhood (from 6 months 
to 12 years), and adulthood (older than 12 years old). Patients with hemoglobin levels higher than 
normal range (for the indicated gender and age, table 2.3), will be diagnosed as 
hyperhemoglobinemia. If normal levels of hemoglobin are provided, the web tool will indicate that 
the patient is not suffering from anemia.   
 
 
Figure 2. 4 Step 1 of CoDysAn diagnostic algorithm: evaluation of anemia. 
 
If anemia is detected, the telemedicine tool drives the user to the second step, where three additional 





reticulocytes count and the platelets count. Varied units for the hematological parameter are 
facilitated (Figure 2.5).  
 
Figure 2. 5 Step 2 of CoDysAn diagnostic algorithm: evaluation of other hematological parameters 
The algorithm will evaluate the hematological parameters, which will be compared with the normal 
ranges (table 2.3) and make a proper subclassification of the CDA. Depending on the data provided, a 
new form will appear asking to exclude for specific possible causes of macrocytic, normocytic or 
microcytic anemia (figure 2.6). At least one alternative cause of anemia should be excluded to 
continuous to next step of the diagnostic tool. In the fourth and final step, the user is asked to select 
other clinical manifestations or biochemical factors that are present in the patient, such as physical 
malformations, peripheral blood smear features or bone marrow evaluation by optical or electron 
microscopy (figure 2.7).   
 
Figure 2. 6 Step 3 of CoDysAn diagnostic algorithm: exclusion of other diseases with similar manifestations. 




Figure 2. 7 Step 4 of CoDysAn diagnostic algorithm: evaluation of other clinical features. 
Finally, depending on the information provided, the user will obtain the clinical suspicion: the CDA 
subtype if it applies, or “not suffering CDA” outcome if there is no clinical suspicion of CDA, including 
a brief explanation (figure 2.8).  
 
Figure 2. 8 Results window of CoDySan. The results include the clinical suspicious, the recommended molecular diagnosis 
and two links: one for search a laboratory which offers the genetic test, and a second button to start a new diagnosis. 
If the clinical suspicion indicates one of the CDA subtypes, the associated genes for the particular CDA 
subtype are shown, and a genetic diagnosis test is recommended in order to verify the clinical 
suspicion. The user has the option to automatically search for a molecular laboratory that provides 
genetic tests for CDA (“Search Lab” button). The list of genetic laboratories is obtained from the NCBI’s 
Genetic Testing Registry (GTR) webpage (Rubinstein et al. 2013). A new diagnostic test is possible to 
perform by pressing the “New diagnostic” button.  
2.3.4. Validation 
Forty-three patients with congenital anemia have been used to test the CodysAn algorithm, including 
24 patients genetically diagnosed of different types of CDA (18 CDA type II, 1 CDA type Ib, 4 CDA type 
IIa and 1 XLTDA) and 19 additional patients genetically diagnosed of non-CDA congenital anemias. The 





and a sensitivity of 87.5% (21 out of 24 true positives). An additional set of 23 patients (all CDA II) was 
used to validate the algorithm, which returned a sensitivity of 87% (20 out of 23). 




Telemedicine webpages and tools are significantly changing the way medical doctors and patients 
approach health care and diagnosis (Dinesen et al. 2016). Here, we have developed CoDysAn, a 
telemedicine tool intended to increase awareness about the rare disease CDA as, currently, patients 
suffering from this disease are under-diagnosed (Russo et al. 2014). The content of the webpage 
serves as an informative and training resource for the general public, patients and medical doctors. In 
addition to the brief explanation of the disease and subtypes, this web page includes a user-friendly 
step-by-step diagnostic algorithm based on hematological parameters and other clinical features. The 
website is freely available at URL http://www.codysan.eu in four languages (Catalan, Spanish, Italian, 
and English). 
The use of this tool presents limits. Patients should be considered as a whole entity and multiple 
biochemical determinations are needed due to time fluctuation of biochemical parameters in the 
same subject. Although hematological reference ranges are useful in results interpretation and in 
clinical decision-making, it should be borne in mind that variations within the population may affect 
some outcomes. 
Other specific limitation of the web tool is that the CoDysAn algorithm is not fully able to distinguish 
between CDA type II, III and IV if test results on specific techniques or technologies (i.e. electron 
microscopy), that are not always available in routine hematological services, are not provided. This 
CDA subtypes present overlapping hematological parameters and cytologic features. The three 
subtypes hold high or normal platelets level, low or normal MCV, and bi- or multinucleated 
erythroblasts. The program recommends to genetically test SEC23B, KIF23, KLF1 genes to confirm the 
subtype, and perform an extensive medical examination. 
In the addition to previous limitations, the program is not able to classify the CDA subtype when no 
other disease is discarded in the third step (“Exclusion of other causes of anemia”), and the patient is 
categorized as not suffering from CDA. At least one disease must be excluded for the program to work 
properly, and this issue implies that patients should be examined with caution.  
Despite the limitations previously described, CoDysAn is the first web tool dedicated to the diagnosis 
of CDA, with a high specificity of and sensitivity (89.5% and 87-87.5% respectively). CoDysAn 
incorporates a diagnostic algorithm that proved to be useful for a preliminary diagnostic. It will help 
medical doctors to know which molecular diagnosis they should request, reducing time and effort 
necessary for the diagnosis of CDA and allowing a direct implementation of a proper treatment once 
reached a definitive molecular diagnosis. Few reference centers are now offering genetic diagnostic 
panels screening the six known genes causing CDA. CoDysAn algorithm is connected to the NCBI 
Genetic Testing Registry (GTR) in a way to inform medical doctors about the existence of these 
accredited diagnostic centers to perform a complete genetic test, if required. This telemedicine tool 
aims to inform the general public and aid in the diagnosis of CDA. It is not intended as an attempt to 
practice medicine or provide specific medical advice and it should not be used to replace or overrule 
a qualified health care provider’s judgment. Users should not rely upon this website for self-
medication. We believe that CoDysAn webpage will positively contribute to improve medical and 
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BEA (BioMark Expression Analysis): a 
web-based tool for gene expression 
Analysis from BioMark-Fluidigm 
Dynamic Arrays data. 
 
 




3.1.  INTRODUCTION 
BEA (BioMark Expression Analysis software) is a Shiny-based app to help wet-bench biologist with 
poor knowledge of programming and statistics, to perform gene expression analysis from qPCR 
(quantitative Polymerase Chain Reaction, or real-time PCR) BioMark-Fluidigm data. BEA was designed 
to provide an easy step-by-step analysis workflow, with an appropriated statistical pipeline in a user-
friendly interface. This enables users with low levels of programming and statistics knowledge to 
perform differential gene expression analysis for two or three groups of samples. The results exposed 
here are in preparation for a future publication. 
3.1.1. Background – transcriptomics methods 
The high-throughput technologies for transcriptome analysis is ubiquitously used in modern biology 
and medical research. Nowadays researchers are employing these methods to analyze multiple genes 
from multiple samples in parallel, significatively reducing the handling time and the cost. There are 
different platforms available in the market based in different technologies, that share the same 
objective: quantify the expression of genes in tissues. Hybridization (microarrays), sequencing (RNA-
seq) and high-throughput qPCRs (such as BioMark) technologies are the most commonly used 
(Fassbinder-Orth 2014; Olwagen, Adrian, and Madhi 2019; Rao et al. 2019). 
Microarray / hybridization principle 
Microarrays consist of a large number of oligonucleotide sequences, known as "probes", which are 
immobilized on a solid surface (e.g. glass slides or nylon membranes) (Bumgarner 2013; Wang, 
Gerstein, and Snyder 2009).  One microarray can have between 10.000-50.000 probes, with several 
probe sets per gene. The principle of microarrays technologies consists in the hybridization of 
extracted cDNA, previously fluorescently labeled, to these probes.  The expression of the transcript is 
determined by the fluorescence intensity at each probe spotted on the microarray. There are two 
types of microarrays: single- or dual- channel design. Single-channel microarrays detect only one 
mRNA sample, detecting absolute gene expression levels. Affymetrix GeneChip array (Santa Clara, CA) 
is the most popular single-channel microarrays. Double-channel microarray design uses different 
fluorophores for test and control samples, and the relative expression is calculated by measuring the 
ratio of fluorescence (Bumgarner 2013). 
Microarrays measure the expression of a large number of genes in parallel, and hence they are 
appropriate for a screening study. Nevertheless, this methodology entails several limitations (Eszlinger 
et al. 2007). Firstly, lowly/highly expressed genes may not be detected properly due to the insufficient 
sensitivity of the analysis. Second, cross-hybridization may result in non-specific transcript-probe 
binding, increasing the rate of false-positive results. And third, the detecting dynamic range for 
expression analysis is limited, and therefore, microarray results require validation using more sensitive 
and quantitative assays, like qRT-PCR.   
Nanostring Technologies (nCounter platform) is another high-throughput technology based in 
hybridization for the analysis of gene expression (Margaret H. Veldman-Jones et al. 2015; M. H. 
Veldman-Jones et al. 2015). Nanostring presets excellent robustness and reproducibility, with high 
sensitivity even with very low input mRNA abundance (Margaret H. Veldman-Jones et al. 2015). 
RNA-Seq 
RNA-Seq is an approach that uses next-generation sequencing methodology in combination with 





into stable double-stranded cDNA (ds-cDNA) through reverse-transcription. cDNA is then sequenced 
using a high-throughput method, originating short sequencing reads that can range from 30 bp to over 
10,000 bp, depending on the sequencing technology used. The transcriptome is computationally re-
built by either de novo or reference-based assembly. The level of expression for each gene is 
quantified by the abundance of reads (sequencing deep coverage).   
RNA-Seq can be used to profile the whole transcriptome or to analyze only target genes. There are 
several high-throughput sequencing platforms commonly used for RNA-Seq: Illumina (Illumina, San 
Diego, CA, USA), SOLiD (Thermo Fisher Scientific, Waltham, MA, USA), Ion Torrent (Thermo Fisher 
Scientific, Waltham, MA, USA), PacBio (Pacbio, Menlo Park, CA, USA) (Chu and Corey 2012). 
RNA-Seq has some significant advantages to respect microarrays. First, the technique is more precise 
and is not subjected to cross-hybridization, reducing the false positive rate. Second, RNA-Seq has 
higher accuracy and wider dynamic range, and therefore, offers a more accurate capture level. Third, 
previous knowledge of the genes is not required, when analyzing the whole transcriptome, and this 
technology allows the possibility to identify novel genes. On the other hand, the labor intensity is 
higher during sample preparation and when analyzing the huge dataset generated. The data analysis 
commonly requires a high-performance computer system and bioinformatics specialists. The cost per 
sample is also higher than other transcriptomic methods, although it is continually decreasing.  
RT-qPCR 
RT-qPCR has been considered as the gold standard for transcription analysis by reason of high 
sensitivity, reproducibility and large dynamic range. The traditional format of RT-qPCR (96 and 384 
microwell plate) is low-throughput, significatively increasing time and cost when analyzing several 
samples and genes. However, “novel” technologies have developed RT-qPCR arrays that conserve the 
benefits of the conventional RT-qPCR, such as high sensitivity and a large dynamic range, while 
allowing gene expression analysis in a high throughput format (Korenková et al. 2015). High-
throughput RT-qPCR can analyze a larger number of reactions per run, making the technique more 
cost-effective and less time-consuming. This method is not suitable to perform general expression 
profiling, but it is ideal to measure genes that are involved in a specific pathway of interest. 
Up to date, three high-throughput RT-qPCR platforms are available in the market: Dynamic Array  
BioMark HD system (Fluidigm, South San Francisco, CA, USA) (Spurgeon, Jones, and Ramakrishnan 
2008), TaqMan OpenArray Real-Time PCR Assay (Applied Biosystems, Carlsbad, CA, USA), and 
SmartChip (Wafergen Bio-systems Inc., Fremont, CA, USA). These three qPCR platforms use 
nanofluidic scale technology, in which thousands of reactions are performed in a single run, reducing 
significatively the consumption of reagents and the hands-on time. BioMark system was the first high-
throughput qPCR instrument available in the market, and is at present, the qPCR platform that higher 
number of reactions can be processed in a single run (9216) with the lowest volume per reaction (7-
9 nl). OpenArray is able to process 3072 reactions, each one with a volume of 33 nl, and SmartChip 
5,184 reactions, with a reaction volume of 100 nl (Korenková et al. 2015).  
3.1.2. BioMark HD system (Fluidigm Technology) 
BioMark HD system is a nanofluidic automated RT-qPCR based on microfluidic technology from 
Fluidigm. This system uses Dynamic Arrays, a microfluidic device with integrated fluidic circuits (IFCs) 
that contain thousands of interconnected channels controlled by valves (Olwagen, Adrian, and Madhi 
2019). This system allows the automatic combination of biological samples and reagents in a central 
matrix with individual reaction chambers. There are four different Dynamic Array formats that differ 
in the number of samples and assays that the chip can analyze (Table 3.1). The most popular Dynamic 




Arrays are the 48.48 Dynamic Array IFC (48 samples x 48 assays) and the 96.96 Dynamic Array IFC (96 
samples and 96 assays) that can run 2304 and 9616 reactions respectively in a single run. 
Table 3. 1 Dynamic Array IFC subtypes 
IFC 48.48 Dynamic 
Array IFC  
96.96 Dynamic 




Assays 48 96 24 6×12 
Samples 48 96 192 6×12 
Reactions 2304 9616 4608 864 
Pipetting steps 96 192 216 Variable 
Reaction volume (nl)  9 7 8 9 
IFC, integrated fluidic circuits 
The workflow protocol is defined by the following four simple steps (Figure 3.1). First, samples and 
assays are manually pipetted in the inlets of the Dynamic Array chip. This is the only human-
manipulated step. Second, the array is loaded in the IFC Controller, where samples and reagents are 
automatically loaded in the chambers of the IFC chip. Third, the Dynamic array is loaded in the BioMark 
HD System (qPCR) where real-time PCR amplification and signal detection are performed. At the end 
of each PCR cycle, the chip is photographed to detect the emitted signal that is proportional to the 
abundance of DNA amplified. Finally, the data is extracted from the BioMark HD system and it is 
preprocessed using the Real-Time PCR software (Fluidigm), where PCR cycles are generated for each 
reaction, and the cycle threshold (Ct) values are calculated. The cycle threshold (Ct) value of a reaction 




Figure 3. 1 Fluidigm BioMark system workflow. Figure adapted from www.Fluidigm.com. 
 
Users can obtain the results in few hours after completion of the described simple assay workflow. 
The big challenge is to analyze the high-throughput data. Up to date, several tools are available to 
analyze qPCR data, but not so many are focused on high-throughput datasets and BioMark-Fluidigm 
output. The most commonly used is the software developed by Fluidigm, the “Fluidigm Real-Time PCR 
Analysis software”. This software is used to extract the Ct values (after determining fluorescence 
threshold, quality threshold and the accepted quantification cycle), define reference genes and 





and Schmittgen (Livak and Schmittgen 2001). However, this program have some limitations. First, 
when several housekeeping genes have been included in the experiment, the software cannot provide 
additional information to select the most efficient reference genes to perform an appropriate ΔΔCt 
normalization. And second, the proper statistical analysis when 3 groups of samples need to be tested 
gets much more complicated by using this software. For this reason, most of the users utilize this 
software to preprocess the results, obtain the Ct values of the experiment, and perform custom 
normalization and statistical analysis with other programs. Some researches use some statistical 
programs that do not require programming knowledge, to perform the statistical analysis (e.g. Excel, 
GraphPad, SPSS, STATA) (Olwagen, Adrian, and Madhi 2019; Jang et al. 2011). However, these 
methods are not the most appropriate for high-throughput outputs, leading to a waste of time for the 
research. Custom analysis often requires and expert in bioinformatics that can handle that amount of 
data by using programming languages such as perl, pyhton or R. For this reason, there is a need to 
develop a user-friendly tool for performing normalization and statistical analysis of BioMark output 
data, without programming and advance statistics knowledge requirement.  
3.1.3. BEA: BioMark Expression Analysis web tool 
To meet this need, we are developing BEA, BioMark Expression Analysis, an R/Shine-based desktop 
application designed to analyze Real-Time qPCR data from BioMark HD System across multiple 
conditions and replicates. The analysis includes relative quantification using normalization against a 
reference gene (∆∆CT method), and appropriate statistical testing to identify differential expressed 
genes between tested groups, taking into account test of normality and number of groups. Also, BEA 
program will help the user to select suitable reference gene for reliable qPCR data analysis, an 
essential step that has a significant impact on the final outcome (Vandesompele et al. 2002; Song et 
al. 2012). 
BEA will help scientists perform gene expression analyses by interactively visualizing each step with 
customizable options and intuitive graphical user interface. The program provides comprehensive 
results visualization, downloadable plots and a summarizing report, and it does not require 
programming knowledge. BEA will be an open source software freely available online at 
http://bloodgenetics.com/otros/ web page. 




3.2. MATERIAL AND METHODS 
 
3.2.1. Testing data (Myelodysplastic syndromes project) 
BEA has been tested using BioMark 96.96 Dynamic Array dataset acquired from a secondary research 
project: DJCLS R 14/04 Myelodysplastic syndromes, cause of mitochondrial iron overload in 
sideroblastic anemia (Principal Investigators: Dr. Mayka Sanchez (Spain) and Dr. Nobert Gattermann 
(Germany)) and financed by the Deutsche Josep Carreras Leukämie-Stiftung). The aim of this project 
was to identify genes associated with iron regulatory proteins (IRPs), that are differentially expressed 
between patients with myelodysplastic syndrome with ring sideroblasts development (MDS-RS), 
patients with myelodysplastic syndrome without ring sideroblasts development (MDS-nonRS) and 
healthy controls.   
3.2.1.1. MDS patients 
RNA samples from bone marrow were provided by Dr. Nobert Gattermann inside the research project 
DJCLS R 14/04 Myelodysplastic syndromes. Twenty-eight samples where from the MDS Registry in 
Dusseldorf (Germany) (14 were from MDS-RS patients, 14 from MDS-nonRS patients) and 4 from 
healthy control people. RNA integrity and concentration were evaluated using 2200 TapeStation 
system. The 32 samples obtained an RNA Integrity Number (RIN) higher than 7.2 and a nanodrop 
concentration of 5ng/µl with adequate 260/280 ratios ranged from 1.25 to 2.14. 
3.2.1.2. Experiment design 
The 96.96 Dynamic Array IFC was used to analyze 96 genes, of which four were housekeeping genes 
previously identified as an efficient normalization genes (ACTB, B2M, HPRT1 and TBP)(Dheda et al. 
2004; Lazarini et al. 2013; Dolatshad et al. 2015), three positive control genes (ALAS2, GDF15 and 
ARG2)(del Rey et al. 2015; Pellagatti et al. 2006), and 89 genes identified to be associated with IRP-
targets (Sanchez et al. 2011). No negative control genes were added. 
3.2.1.3. Real-time qPCR using the BioMark HD System (Fluidigm). 
RNA samples were reverse transcribed into cDNA and analyzed in the qPCR Fluidigm-BioMark 
instruments in the Fluidigm Platform from Josep Carreras Research Institute according to 
manufacturer instructions.  
3.2.1.4. Data acquisition and pre-processing 
Data was pre-processed by automatic threshold for each assay using BioMark Real-Time PCR Analysis 
Software 4.1.3 version (Fluidigm). The quality threshold was set at the default setting of 0.65, the 
baseline correction method was linear derivative and the Ct threshold method was automatically 
detected. The Ct values for each reaction were extracted in a csv (Export Type: Table Results). 
 
3.2.2. Implementation 
3.2.2.1. Programming languages 
BEA has been developed through the Shiny software-development platform, using R and Java Script 
languages. The R packages used to develop the program are described in Table 3.2.  
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Table 3. 2 Packages installed in R for the development of BEA 
Libraries Version Repository 
data.table 1.12.0 CRAN 
dplyr 0.7.8 CRAN 
DT 0.5 CRAN 
ggplot2 3.1.0 CRAN 
gplots 3.0.1 CRAN 
grid 3.5.2 CRAN 
gridBase 0.4-7 CRAN 
gridExtra 2.3 CRAN 
kableExtra 0.9.0 CRAN 
knitr 1.23 CRAN 
NormqPCR 1.28.0 Bioconductor 
RColorBrewer 1.1-2 CRAN 
reshape 0.8.8 CRAN 
rgl 0.99.16 CRAN 
shiny 1.2.0 CRAN 
shinyBS 0.61 CRAN 
shinyjs 1.0 CRAN 
rsconnect 0.8.13 CRAN 
 
3.2.2.2. Availability of data and materials 
The BEA program including the required secondary package and programs, the manual, and the 
example datasets are together compiled in zip folder and available to download in the project 
webpage. 
• Project name: BEA 
• Project web page: http://bloodgenetics.com/otros/ 
• Operating systems: Windows 
• Programming language: R, JavaScript and css. 
• License: GPLv3 
• Intellectual property (IP): The program has been registered in the intellectual property of 
Catalunya (B-2222-19).  
• Any restriction to use by non-academics: None 
 
3.2.2.3. Normalization and statistical workflow 
The normalization and the statistical workflow are done with BEA program. Although the BEA 
statistical analysis may be accommodated to user preference, the by default workflow is described in 
Figure 3.2. Ct values from the Fluidigm BioMark run are imported into BEA program. The gene 
expression data is first refined removing those genes and samples with low performance. FC values 
are calculated through the -2ΔΔCt method described by Livak and Schmittgen (Livak and Schmittgen 
2001) by using the selected normalization or housekeeping gens. Delta Ct data, the data calibrated by 
housekeeping genes, is used for the statistical analysis. The statistical analysis is determined by the 
number of groups and the normality distribution of our data. Shapiro-Wilk test is utilized to test for 
normality the expression of each gene and perform adequate test: ANOVA or Kruscal Wallis for three 




groups; T Student test for normal distribution, or Wilcoxon test for non-normal distribution data for 
two groups.    
 
Figure 3. 2 Statistical workflow of BEA program 
3.2.3. Error and running validation of BEA with external datasets 
The performance of the BEA program has been validated using four datasets: one 96.96 dataset 
(dataset 1) from public sources (https://github.com/jpouch/qPCR-BioMark) and 3 datasets from three 
different Dynamic Array formats (dataset 2, 12.12;  dataset 3, 48.48, and dataset 4, 96.96) coming 
from the collaboration with the Fluidigm Platform from Josep Carreras Leukemia Research Institute 
(Table 3.3). The four validating datasets were previously preprocessed as detailed in the BEA manual 
before being analyzed. A sample information file was created for each dataset, obtaining sample 
names from the results file, and organizing the samples in two or three groups. The four datasets 
contained negative control genes which were not used in the analysis. Dataset 2 and 3 contains some 
blank genes, and only 60 out of 96 and 13 out of 48 genes were included in the analysis respectively. 
In dataset 4, four samples in triplicate were analyzed.   








Observations N groups 
analyzed 
Dataset 1 Public 96.96 96 96 Negative control genes (NTC) 2 & 3 
Dataset 2 IJC 96.96 96 60 Negative control genes (NTC), 
Contains blank genes 
2 & 3 
Dataset 3 IJC 49.49 48 13 Negative control genes (NTC) 
Contains blank genes 
2 & 3 








3.3. RESULTS  
 
3.3.1. BEA scope 
BEA is a ready-to-use desktop program based in R/Shiny language. The program is hassle-free in 
installation and can be downloadable from http://bloodgenetics.com/otros/, along with user´s 
manual, and sample datasets. The program is implemented in an interactive desktop application (R 
Shiny) using a portable R and a portable Chrome browser, and all R packages and secondary programs 
(pandoc) required are already included. Therefore, users do not require to install R, integrated 
development environments (RStudio), R packages nor other web browser. Users can operate the 
program immediately after download and decompress the BEA zip. The program is sustained by 64-
bit Windows.  BEA is an open-source program available under the GNU General Public License v3.0 
(GPLv3, https://www.gnu.org/licenses/gpl-3.0.html), and registered in the Spanish intellectual 
property (2019). Video tutorial is available at https://youtu.be/GL2a1BLOnM8. 
3.3.2. Implementation 
 
3.3.2.1. Raw data preprocessing and acquisition 
Before starting the BEA program for the gene expression analysis, raw data (Fluidigm ChipRun.bml 
file) must be preprocessed using the Fluidigm Real-Time PCR Analysis Software. The steps required for 
a correct preprocessing of the raw data are described in the user`s manual (Supplementary material 
4. Other documents page 221 - Instruction of use of BEA program). User must specify the reference 
genes that have been introduced in the experiment. The procedure for the selection of the reference 
genes are also explained in the manual. The final preprocessed data must be extracted from the Real-
Time PCR Analysis software by selectin the “Table results (*.csv)” from the “Save as” type menu. The 
exported ChipRun_TableResults.csv file can then be used for analysis with the BEA program.  
3.3.2.2. Input files 
Two csv input files are required before running Bea (Figure 3.3): the BioMark raw data file and the 
sample information file.  
A “BioMark raw data file” (Figure 3.3 a) is a coma separated value file containing the results (Ct values) 
from BioMark Fluidigm platform after preprocessing the raw data using the Real-Time PCR Analysis 
software (“Table results” file, see Fig. 3.3). Sample names must have no spaces, start with a letter, and 
can contain letter, numbers and certain special characters (dot or underscore). Replicates or triplicates 
must have exactly the same sample name. The data must be separated by semicolon (;), and number 
are quoted.  
A “Sample information file” (or SIF) (Figure 3.3 b) is a comma separated value file containing three 
columns: 
• SampleName: Sample name used in the experiment. Remember that if you include replicates, 
those samples must be named identically. The program is letter case sensitive.  
• SampleType: Sample Type as described in the BioMark raw data file. 
• GROUP: Group of analysis (i.e. “Case” vs. “Control”; “Healthy” vs.” Treated” vs.” No-treated”). 
Minimum two groups and maximum three groups can be assigned. Group names only can 
contain letters, numbers and some special characters (dot or underscore). First character must 
be a letter, and no spaces are permitted. 




   a                                                                    b 
           
Figure 3. 3 Inputs files required to start the gene expression analysis with BEA. Two CSV format files must be prepared 
before starting the analysis: (a) the BioMark raw data file, with the preprocessed data of the BioMark gene expression 
experiment; and (b) the Sample Information File (SIF) with the names and group of analysis of all samples tested.  
3.3.2.3. Tabs 
The program is structured in eight steps that are incorporated in eight tabs respectively (Figure 3.4): 
file manager, heatmap, gene filtering, sample filtering, normalization, results, boxplots, and final 
report. The tabs are activated when the previously step is completed. 
      1                  2                   3                 4                  5                  6                   7                  8 
 
  
Figure 3. 4 Conceptual architecture of BEA software structured in eight tabs. 
“File Manager” tab: The two required input files are uploaded to BEA using this interface. An example 
of the sample information file can be downloaded through a link that redirects the user to another 
webpage. If the input files are uploaded properly, some tables appear automatically: head of the raw 
data input file from BioMark-Fluidigm preprocessed output; a table with information about the 
experiment and the chip; a table with the reference genes included; a table showing the sample 
information file uploaded; a table with groups names and number of sample per group.  
Figure 3. 5 First tab from BEA program (File Manager tab). From the first tab page the user can upload the input files, 
check out the data of these files, and redirect to two repositories: one to download a SIF example and, and other to 
download toy example data to try the program. 




From this page, users can also obtain a link to download a toy example to train themselves and 
understand the analysis. The toy example is a zip folder containing the two required input files (table 
results data, the sample information file), a standard protocol, a final report ,a video tutorial and a 
README file with all information about the repository content. Although these documents are also 
attached in the downloadable zip folder, this links were done in anticipation of having the program 
available in a web-server side, which is the purpose for the following version of the program.  
“Heatmap” tab: BEA provides in the second step a general visualization of the experiment with a gene 
expression heatmap. The Ct value for all genes and samples (individual replicates) are plotted ranged 
from high expression or low Ct value (red) to low expression or high Ct value (bluish). A black square 
indicates no Ct value or a value outside of the spectrum range. The heatmap is reconfigurable and 
axes can be sorted by user preferences. Sample order can be sorted by alphabetic sample name or 
clustered by the groups itemized in the sample information file. Gene axis can be sorted by alphabetic 
gene name or by mean gene expression. Heatmap plot can be downloaded in a pdf format by pressing 
in the “Download” button.  
“Gene filtering” tab: Some genes with low efficiency can be filtered out of the analysis to reduce noise 
in the analysis. The number of fail assays per gene is exposed in a barplot. The fail flag is assigned 
when the amplification curve for a specific assay does not pass the quality threshold (due to low 
amplification, out of range Ct value). Genes with high abundance of fails should be removed to reduce 
noise that degrades the quality of signals and data. The filtering threshold can be selected by the user, 
by default is 75%. User can discard other genes if desire by clicking over the plot, or by accessing to 
the “List of genes” and unselect its box.  
The barplot with the number of fails per gen can be rearranged by sorting gene axis alphabetically (A 
to Z) or numerically (low to highest abundance of fails). Discarded genes are colored in red on the 
barplot and typed under the plot. 
 “Sample filtering” tab: The filtration of samples with high count of fails can be done in this tab. The 
filtering process is performed in the same way that in “Gene filtering” tab. A barplot is displayed, and 
a list of samples can be checked. 
“Normalization” tab: In this tab user select all the parameters required to perform delta delta Ct 
normalization (Livak). First, the groups of samples defined in the sample information file are shown. 
User will have to select which groups wants to include in the analysis, and assign the appropriate flag: 
“Reference” for control group; “Target_1” for one group to test; “Target_2” for second group to test 
when three groups have been added; “Dont_study” if user doesn´t want to include that group in the 
analysis. Only one group can be assigned as a “Reference”, and at least one group has to be assigned 
as a “Target_1”. The aggregation of two different groups in one is possible for tested groups (two 
groups as a “Target_1).  
Secondly, the reference (or housekeeping) genes must be selected. The interface provides a list of the 
normalization genes that have been annotated in the pre-processing step with the Real Time PCR 
software, or have been selected by the user in the first step. The choice of the reference gene has a 
significant impact in the qPCR analysis and gene expression outcome. Hence, the selection of 
appropriate reference genes is critical for a reliable result [Song J,2012]. In the “Normalization” tab, a 
table that includes the mean, the standard deviation (SD) and the Gene Stability Measure (M) 
(Vandesompele et al. 2002) of used references genes is shown, to help the user to select adequate 
genes for normalization (see an example on Table 3.8). The Gene Stability Measure determine the 
expression stability of control genes on the basis of non-normalized expression levels and is calculated 




by the average pairwise variation for the control gene with all other tested reference genes 
(Vandesompele et al. 2002). Genes whose mean Ct differs more than 5-fold to all the genes analyzed 
are recommended to be avoided for normalization (Ma et al. 2016; Kozera and Rapacz 2013). Also, 
genes with lower SD and M-value are considered more stable reference genes (Dai et al. 2017; Lee et 
al. 2010). More than one reference gene can be selected for normalization.  
The user has the possibility to see the gene expression matrix with all the results. The Ct values for all 
samples (in columns) and genes (in rows) are shown in this matrix. When the experiment contains 
replicates, the gene expression matrix displays the median Ct value. 
 “Statistical Results” tab: Genes are analyzed following the statistical pipeline described in Figure 3.2, 
and results are presented in a table (Table 3.9). The results table contain the statistical results of the 
comparison between tested groups for each gene, including Shapiro-Wilk test, statistical test used 
according to normality, Fold Change, and adjusted p.value among others. Significant p.values are 
printed in bold. Genes that are differentially expressed in at least one group are printed in pink and 
marked with stars (*** p<0.005; **p<0.01; *p<0.05 or p< p-threshold). Genes are considered 
differentially expressed based on fold change and p.value. The minimum fold and the p.value 
thresholds can be chosen by the user (by default are 2 and 0.05, respectively). 
If users prefer to perform a parametric or a non-parametric test for all genes, they can easily change 
the statistical pipeline by selecting another method of analysis. If user selects “Parametric test”, 
analysis of variance (ANOVA) and Post Hoc Tukey´s tests are performed when analyzing 3 groups, and 
T-test is performed when analyzing 2 groups. Kruskal-Wallis and Wilcoxon test are carried out if user 
select “Non-parametric test”. Users are recommended to choose the non-parametric test if the gene 
expression data do not follow a normal distribution (Shapiro-Wilk > 0.05), and or/ the total sample 
size is small. P.values are corrected by false discovery rate (fdr) by default, but users can select 
Bonferroni’s multiple comparison method, or avoid multiple testing correction (“none”).  
The parameters used in this tab are shown in the results table. Final table can be download in csv 
format, containing the data displayed in the “Statistical Results” tab, plus other information of interest 
as the mean ΔCt and the ΔΔCt per group.  
“Boxplots” tab: Samples selected in the results table from previous tab are represented here by 
boxplots. One plot per gene is displayed, showing normalized fold change expression of the gene by 
tested groups. Boxplots can be downloaded in pdf format file (Figure 3.9). 
“Final report” tab: 
In this tab users have the option of downloading a final report in a pdf format. The report resumes the 
whole analysis process performed with BEA from all tabs, but the heatmap. Due to dimensionality 
problems, the heatmap representing the expression of all samples and all genes from step 2 of BEA 
workflow, is not added in the final report. Instead, a heatmap of the significantly expressed genes is 
included. A download bar gives to the user information about how long the process will take to 
generate the report. See Supplementary Materials. See Appendix – 4. Other documents (page 237) for 
an example of a report executed with the BEA program and the testing data. 
  




3.3.3. Results from the testing data (Myelodysplastic syndromes project) 
Biomark HD Fluidigm platform was used to analyze the expression profile of 96 genes (including 4 
calibration genes (Table 3.5), 3 positive control genes, and 89 IRP-target genes) in 32 bone marrow 
RNA samples in triplicate. Samples were from MDS-RS patients (“RS”; n=14), MDS-noRS patients 
(“nonRS”; n=14) or control healthy persons (“controls”; n=4). The relative gene expression using the 
ΔΔCt normalization method and the statistical analysis to identify the differential expressed genes 
between the three groups were performed using the BEA program.  
The program provides three tables with information about the data uploaded (Table 3.4, 3.5 and 3.6). 
In the gene expression analysis, 96 total genes have been tested, for 32 samples in triplicates (96 
samples in all). A total of 9216 reactions have been done, of which 835 were failed and 845 reactions 
had low quality. No blanks or negative samples were included. From the 96 samples studied, 12 were 
selected as a “reference” (4 unique samples in triplicates) and the rest were “unknown”. 
 
Tables from the final report 
 











NAC, No Amplification Control;  
NTC, No Template Control; 
N, number of assays 
 
A heatmap involving all the 96 samples and the 96 genes studied in the BioMark experiment was 
performed in the second step of BEA program (Figure 3.6). The range of gene expression of the assay 
is represented in different colors from yellow (low Ct value and high expression) to blue (high Ct value 
and low expression). Black squares indicate failed assays. The plot was sorted by sample groups, and 
gene-axis were arranged according to the mean expression. We can see that in general the triplicates 
have similar expression, implying a low dispersion between replicates and good performance of the 
analysis. The heatmap also suggests that there are some genes with unsuccessful results (black 
squares) that have low performance. Moreover, there is one sample which three replicates seem to 
have also failed (“R12_ID15_RCMD”).  
 





Figure 3. 6 Heatmap of gene expression (Ct) of samples with RS-MDS, nonRS-MDS and healthy controls for 96 genes. 
The Ct value tested with BioMark Fluidigm system is represented in the heatmap in a color range: yellow for low Ct 
values (high expression) and blue-purple for high Ct values (low expression). Failed reactions are colored in black. The 
heatmap is sorted by group of samples: dark grey for healthy controls, medium gray for patients with MDS with ring 
sideroblasts (RS) and light gray for MDS patients without ring sideroblasts (nonRS). 
 
A barplot with the number of failed assays per gene (Figure 3.8) confirm that 5 genes (KCNF1, SHISA2, 
SLC23A4, HAO1 and LGALS8) must be filtered out due to low performance since more than 75% of the 
reactions (72/96 fails as threshold) do not pass the quality control process of Fluidigm system, and are 
classified as “fail”. The same process was performed for the samples, and one sample 
(“R12_ID15_RCMD” in triplicate) was discarded from the analysis due to slightly elevated number of 
fails, around 37% (35.5/96) of the reactions failed (Figure 3.9).  





Figure 3. 7 Barplot of the number of failed reactions per gene. The graph shows the number of failed assays 
(reactions that do not approve the quality control process of the Fluidigm system) per gene. In red are represented 
those genes with a greater number of fails than the selected threshold (75% or 72 reactions of the total of 96) 
which are filtered out from the analysis. 
 
 
Figure 3. 8 Barplot of the number of failed reactions per sample. The three samples colored in red ("S42 - 
R12_ID15_RCMD", "S40 - R12_ID15_RCMD "and "S41 - R12_ID15_RCMD") are replicates of the same sample, and 
are filtered out of the analysis due to the slightly high number of fails compared with the rest of samples.  
The ΔΔCt normalization was executed taking the control group (Group 1 of Table 3.7) as a reference, 
and using HPRT1 and TBP as a normalization genes due to the low standard deviation, low gene 








Table 3. 7 Selection of groups for analysis 
 
Table 3. 8 Description of reference genes 
 
To evaluate the differential expression between control, RS and nonRS groups (Table 3.7), an 
appropriate statistical test was used per gene according to normality. Twenty-three genes were 
differentially expressed between at least one comparison of the three groups of analysis. Significance 
was established with an absolute fold change larger than 1.5 and a cutoff p value of 0.05. Results were 
not corrected by multiple comparison testing (Table 3.9 and Figure 3.10). Six of the genes were 
identified using nonparametric test, meanwhile parametric test was applied for the rest of genes.  Five 
genes were differentially expressed between control group and nonRS-MDS patients, sixteen genes 
between control groups and RS MDS patients and twelve genes between RS and nonRS-MDS patients.  
The three positive control genes including in the experiment (ALAS2, GDF15 and ARG2), resulted to be 
significative in the differential expression analysis. These genes have been previously reported to be 
more expressed in RS-MDS compared with other cases. In our study, ALAS2 gene was higher expressed 
in patients with MDS with or without the development of ring sideroblasts, compared with control 
group (FC = 90-128 and p < 0.001). However, ARG2 and GDF15 were highly expressed in RS-MDS 
compared with nonRS-MDS patients and controls (FC ARG2(RS vs nonRS) = 6, and p ARG2(RS vs nonRS) = 0.014; FC 
GDF15(RS vs nonRS) = 7.5, and p GDF15 (RS vs nonRS) = 0.012). These genes have been previously reported to be 
differentially expressed in ring sideroblasts MDS patients (del Rey et al. 2015; Pellagatti et al. 2006; 
Malcovati and Cazzola 2016). Differential expression of these three genes can be easily detected in 
the heatmap of Figure 3.10, along with NR4A3 and PABPC4L, due to the high fold change.  
NR4A3 and PABPC4L were the genes with higher fold change and significant p.value among the rest 
of the genes and excluding the positive control genes. In our data, the gene NR4A3 was lower in both 
MDS groups (including RS and non-RS) compared with healthy group (FC NR4A3 (nonRS vs control) = -19, and p 
NR4A3 (nonRS vs control) = 0.004; FC NR4A3 (RS vs control) = -10, and p NR4A3 (RS vs control) = 0.004). No differences were 
found between the RS and non-RS MDS patients. This results support the Ramirez-Herrick et al. study, 
which found the NR4A3 gene to be down-regulated in hematopoietic stem cells from MDS mice model 
(Ramirez-Herrick et al. 2011).   
PABPC4L genes was found to be downregulated in RS-MDS compared with nonRS-MDS group (FC 
PABPC4L (RS vs nonRS) = -6.8, and p PABPC4L (RS vs nonRS) = 0.002). No previous study identified PABPC4L as a possible 









Table 3. 9 Differentially expressed genes between tested groups 
 
FC, fold change; Ref, Control group; Target 1, nonRS group; Target 2, RS group (see Table 3.7) 
*** p<0.005; **p<0.01; *p<0.05 
 




Differential expression of significative genes 
 
Figure 3. 9 Boxplot of gene expression of significative genes in the three tested groups. The expression  (x-axis) is the normalized fold change (FC). The three groups are respresented in 
three different colors: red for healthy controls, green for patiens of MDS without ring sideroblast (nonRS), and blue for MDS patients with ring sideroblast (RS). Significance is indicated as: 
*** p<0.005; **p<0.01; *p<0.05. 
 






Figure 3. 10 Heatmap of the 23 significative genes. The heatmap is sorted by groups of samples: dark grey for healthy 
controls, medium gray for patients with MDS with ring sideroblasts (RS) and light gray for MDS patients without ring 
sideroblasts (nonRS). The significative genes with higher FC are indicated with yellow squares.  
 
3.3.4. Error correction and running validation of BEA with external datasets 
Four datasets from BioMark-Fluidigm analysis with three different array formats (96.96, 48.48, and 
12.12 Flex formats) have been used to validate the performance of the program, and control or correct 
the software program errors that were unnoticed with the initial test dataset (MDS). The sample 
names were edited if they contain spaces or special characters others than dots, underscore or 
hyphen. The csv results table files were also edited with excel to ensure that the data was separated 
by a semicolon (;), and the files were saved as csv format. The SIFs were created for dataset 1, 2, 3 and 
4 assigned to the samples two or three groups.  
The four datasets were correctly analyzed with the BEA program. The different array formats do not 
influence the performance of the program, although, as it is expected, they have an effect on the 
statistical results: the smaller the sample size the lower the statistical significance. Datasets with 
incomplete assays (blank genes) were processed without error. Results from blank genes were 
removed from the analysis. None of the datasets contain information about the reference genes, so 
the genes for normalization were selected from the list supplied for the program with all analyzed 
genes. Widely used standard reference genes were used (e.g. GAPDH, ACTB or HPRT1) (Kozera and 
Rapacz 2013; Radonić et al. 2004; Dheda et al. 2004; Lee et al. 2010). The program responds 




adequately even if only one gene is selected by the user, and when more than one reference genes 
are selected. However, when only one gene is selected, the gene-stability-measure cannot be 
calculated, since it needs the comparison with other reference genes, and an “NA” outcome is given.  
The program can analyze data from two and three groups only and must be defined in the SIF file. 
When two groups are investigated, in the normalization tab step the third group is assigned as “NA” 
and this group is blocked as “Dont_study”. Negative control samples (sample type “NTC” or “NAC”) 
are described in the SIF as NA in the GROUP column and are excluded for the analysis in the BEA 
program. Rest of steps and analysis were carried out without issues, and final report with statistical 









BEA is a ready-to-use desktop program based in R/Shiny language that is easy to install and deploy, 
whose purpose is to provide an interactive statistic tools for the analysis of BioMark-Fluidigm data in 
an intuitive step-by-step process. BEA is ideal for biologists with not much experience in 
bioinformatics, since it allows the user to benefit from the power of R/Bioconductor packages without 
having programming knowledge. BEA has been designed to analyze different IFC array formats, 
multiple conditions and replicates. The analysis includes relative quantification using ∆∆CT 
normalization and appropriate statistical testing to identify differentially expressed genes between 
tested groups, considering test of normality and number of groups. Also, BEA program will help the 
user to select suitable reference gene for reliable normalization and a qPCR data analysis, by providing 
three essential parameters: mean Ct value, deviation of the data, and gene-stability measure value 
(Thellin et al. 1999; Vandesompele et al. 2002).  
BEA has been tested using data from three groups of individuals: patients of MDS with development 
of ring sideroblasts (MDS-RS), patients of MDS which did not develop ring sideroblasts, and healthy 
group control. Using the BEA program, twenty-three genes were identified as differentially expressed 
between at least one group. The three positive control genes included in the experiment (ALAS2, 
GDF15 and ARG2), were statistically significant in the differential expression analysis, confirming the 
good performance of the experiment and the analysis pipeline.  
Twelve out of the twenty-three identified genes were significative differentially expressed between 
RS and nonRS-MDS patients. ARG2, GDF15, and SLC11A2_IRE genes were overexpressed in RS MDS, 
meanwhile the rest of significant genes (CAMK1D, CEP95, DHX32, DLG2, LPAR1, MPV17L2, PABPC4L, 
PARC14 and PDCL3) were down regulated. Conte et all identified that the CAMK1D  gene was down-
regulated in RS-MDS bone marrow compared with healthy bone marrow samples (Conte et al. 2015) 
and del Rey et al. found that SLC11A2 gene is overexpressed in RS patients (del Rey et al. 2015), 
confirming our findings. We indeed identify that is the IRE isoform of SLC11A2 the one that is  
overexpressed and not the SLC11A2 non-IRE isoform that was also included in the list of 96 genes. 
Except for CAMK1D, SLC11A2 and the positive control genes ARG2 and GDF15, no studies were found 
to support the differential expression of rest of the twelve genes identified to be differentially 
expressed in RS-MDS.  
Four external datasets were used to validate the correct performance of the program, and correct 
possible errors generated by the training of the program with the test dataset. The preprocessed data 
converted in the “Ct-values results table” file can differ from the different experiment due to several 
factors (i.e. number of assays, type of experiment: EvaGreen or Taqman workflow, description of 
reference genes…), and these differences may cause problem in the program performance. For this 
reason, the correct performance of BEA program was validated by analyzing four external datasets 
with differences in the IFC design, the sample size and number of genes analyzed, and the chemistry 
workflow (EvaGreen or Taqman). 
BEA is the only bioinformatic tool available for the analysis of BioMark-Fluidigm data for non-
bioinformatics that can perform relative quantification and statistical analysis for two and three 
groups in an easy, intuitive and interactive step-by-step process. Other programs for transcriptomic 
analysis have been developed, but were focused in low-throughput analysis (regular qPCR) or other 
high-throughput analysis such as RNA-seq or microarray (Mallona et al. 2017; K. Choi and Ratner 2019; 
Kallio et al. 2011). Other web tools were created for the analysis of other BioMark-Fluidigm data, such 
as SCExV, that was designed for the analysis of single cell BioMark data (Lang et al. 2015). 




Current limitations and future improvements 
Although BEA is an useful software, it is in its early stage (alpha version) and  we are aware that the 
program has some limitations that need to be improved in future versions. Firstly, BEA is designed to 
perform analysis only when two or three groups of samples are present. The program is not able to 
process data with more than three groups, and although most of the relative quantification studies 
reported in the past are from two groups (case vs control studies) (Igci et al. 2016; Tabur et al. 2015) 
or three groups of patients (Yang et al. 2017; Li et al. 2019), the high-throughput technology is bringing 
more complex analysis including several groups (Kebschull et al. 2017). 
Other important limitation is that the program is not able to perform background correction by using 
negative control samples (“NTC” or “NAC” sample types). The program automatically removes these 
negative control samples, and performs the relative quantification by using the ∆∆CT normalization 
method (Livak and Schmittgen 2001). Background calibration could be made using BioMark qPCR 
software in the preprocessing step, before exporting the Ct-value results table. However, in order to 
provide all the utilities that the user may require, the background calibration will be implemented in 
a future version of the program. 
BEA can only be executed from Windows operating system, so users with Linux and MacOS computers 
are not able to use the program. In order to make the program completely available, two possibilities 
have been considered for future version of the program: create compiled package for Linux and macOS 
also and recommend to download the required program based in user operating system (K. Choi and 
Ratner 2019), or create a web page server-side so BEA would be available for any operating system 
computer with internet connection and web browser (Q. Liu and Gregory 2019). The creation of 
compiled zip folder with the program (as is currently done in the present version for Windows) for all 
operating systems is used in other published bioinformatics programs. Choi et al. developed a Shiny 
based desktop application for the analysis of RNA-seq data. Same as BEA, the program can be 
downloaded in a compiled folder and executed in a portable R and portable chrome browser. 
However, iGEAK is available both for windows, Linux and macOS, so three options of download are 
available from the IGEAK project web page (K. Choi and Ratner 2019). This option makes the 
programming process simpler than the creation of a web server-side. Some advantages include that 
user do not require internet connection, or separately web browser, but could be less attractive and 
accessible than a server-side web service. On the other hand, the creation of a web-server page as 
other shiny application (Koeppen, Stanton, and Hampton 2017; Ramirez et al. 2019; Mallona et al. 
2017), make the program on hand from commodity computer or mobile devices, as far as they have 
internet connection and updated web browser installed.  
BEA is designed to analyze gene expression data from high-throughput BioMark Fluidigm system, and 
technology is at present widely used to identify molecular biomarkers that help to better classify of 
different phenotypes. However, results from the analysis of gene expression data alone may be 
misleading since other possible factor (i.e. environmental, socio-economics, population ancestry…) 
might be obviated. In order to make the analysis more complete, an integrative analysis that include 
the gene expression data and other non-genomic data (clinical, pathological, environmental data…) 
should be performed (López de Maturana et al. 2019). Future improvements of the program include 
the possibility to include non-genomic data in the analysis, and the implementation of an integrative 
modelling approach (see chapter 4 for more details about integration of genomics and non-genomics 
data). 
To sum up, BEA is the unique open source program freely available dedicated to help the wet-lab users 
with limited knowledge in bioinformatics to analyze the high-throughput data originated by BioMark 




Fluidigm system in an intuitive and interactive eight-tab process (video tutorial available at 
https://youtu.be/GL2a1BLOnM8). In this research, we described an alpha version of the program, fully 
functional and available in http://bloodgenetics.com/otros/. However, further work must be carried 
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4.1.1. Gene expression signatures in biomedicine  
The advance and expansion of high-throughput technology has brought the opportunity to increase 
our knowledge of the molecular biology of different cellular conditions (Macgregor and Squire 2002) 
and to identify specific genetic signatures (Colombo et al. 2011; Tonella et al. 2017). A gene expression 
signature is a characteristic patter of gene expression for a group of genes that occurs in a normal or 
altered biologic process, pathogenic medical condition or pharmacological responses to a specified 
treatment (Itadani, Mizuarai, and Kotani 2008). These types of biomarkers are mostly studied in 
oncology to understand the signaling pathways involved in the development of cancer and drug 
sensitivity (Itadani, Mizuarai, and Kotani 2008; Chibon 2013).  
Genetic signatures have three main clinical application: diagnosis, prognosis or prediction of 
therapeutic response. Diagnostic gene signatures refer to biomarkers that have the potential to better 
identify and/or classify a disease, and also to understand the biology of the disease. These biomarkers 
could help practitioners to verify the clinical diagnosis and provide more accurate healthcare and 
therapeutic options (Nguyen, Welty, and Cooperberg 2015). Prognostic gene signatures are 
biomarkers for prediction of the likely outcome or development of a disease. Identification of 
subgroups of tumor with different biology can provide a prognostic biomarker for the disease or the 
associated phenotype (Tonella et al. 2017). And finally, the predictive gene signature intends to 
predict the response and the effect to treatment. The objective of this type of genetic signature, that 
is highly popular in pharmacogenomics, is to identify the group of subjects who respond efficiently to 
a specific treatment. These signatures are involved in the evolution and growth of the personalized 
medicine by identifying novel therapeutic targets and the most qualified patients for specific 
treatments.  
 
4.1.2. Genetic signatures in complex traits and the challenge of 
integration of genomic and non-genomic data. 
Most phenotypes are complex traits, resulting from the influence of internal alterations (genomic 
factors) and external conditions such as environmental circumstances (non-genomic factors). To 
understand these complex traits and be able to define a genetic signature of these phenotypes, it is 
essential to study the genomic information and the non-genomic information jointly. However, the 
integration of genomic data with clinical/epidemiological data requires elaborated modeling and 
engenders some challenges that must be considered. One of the challenges in integrating genomic 
and non-genomic data are associated with the constitution of each type of data. The 
clinical/epidemiological data are complex to define and subjective. Some clinical variables have not 
yet a standardized protocol, and are subject to different clinical procedures and the knowledge of 
practitioners. This subjectivity may produce inconsistent and heterogeneous data that may influence 
the quality and the grade of comparability of the data, and as a result, the inaccuracy in the outcome 
prediction. Also, in contrast with genomic data, clinical/epidemiological variables are very 
heterogeneous, from qualitative (i.e., gender, presence of pathogenic events such as hydronephrosis, 
lymphovascular invasion) to quantitative variables of different scales (i.e., age, number of nodes, 





Other challenges of the integration of genomic and non-genomic data are due to the relationship 
between them: ascertainment bias or the presence of interaction between the genomic data with 
phenotypic variables.   
Three modeling methods have been characterized for integrative modeling: independent, conditional 
and joint modeling (López de Maturana et al. 2019). In the independent modeling, the genetic and 
non-genetic models are built independently. The clinical/epidemiological variables are selected 
separately to fit the clinical model, and the genetic variables are selected in parallel to build the 
genetic model. The clinical model and the genetic model are combined finally, and the predictive 
power is estimated. The conditional modeling strategy is based in a two steps process. First, the clinical 
model is constructed only using the clinical/epidemiological variables. And second, the genomic 
variables are selected according to a model that adjusts for the clinical variables. As exposed in López 
de Maturana et.al., “the key point of this conditional modeling approach is to decide which omics 
variables should be added to the clinical model” (López de Maturana et al. 2019). Finally, the joint 
modeling approach build the final model by using the genomic and clinical data in conjunction.  
In order to build the genetic signature, regression analysis through generalized linear models is the 
most commonly used statistical modelling technique. Regression analysis is a parametric statistical 
technique that expresses the relationship between a dependent variable (response) and a set of 
independent variables (also called explanatory variables or “predictors”) through some regression 
coefficients (Gordis L. 2013). The aim of regression analysis is to build the model that best fits the 
observed data set according to some loss function (MSE, deviance, etc.). When building genetic 
signatures, the genetic data and the clinical/epidemiological data are the explanatory variables and 
their association with the response variable (e.g., survival, response to treatment, tumor growth) is 
evaluated. Three different generalized linear models may be used depending on the nature of our 
outcome: linear regression, logistic regression and Cox regression (Figure 4.1). Linear regression is 
used when the dependent variable is a quantitative continuous outcome with approximately normal 
distribution.  We refer to simple regression when a single independent variable (“the regressor”) is 
analyzed with the dependent variable, and multiple linear regression when more than one explanatory 
variable is evaluated. Logistic regression provides a setting for modeling dichotomous outcomes based 
on multiple categorical or continuous predictors (Hosmer DW, Lemeshow S, Sturdivant RX. 2013). Cox 
regression model or proportional hazards regression is used for investigating the relationship between 
time-to-event (survival-time) outcomes on one or more predictors. The three regression models have 
a unified formulation as generalized linear models where a transformation of the mean of the 
response variable is expressed as a linear function of the explanatory variables: 
 
𝑔(𝜇(𝑌)) = 𝛽0 + 𝛽1𝑋1 +⋯+ 𝛽𝑘𝑋𝑘 
 
For the linear regression model 𝑔() is the identity function, for the logistic regression model 𝑔() is the 
logistic function, that  is, 𝑔(𝑥) = log⁡(
𝑥
1−𝑥
), and for the Cox model, 𝑔() is the hazard ratio with respect 
to the baseline hazard. 
 





Figure 4. 1 Regression techniques according to the dependent variable. This figure is original and was designed by 
Beatriz Cadenas 
 
4.1.3. Statistical strategies for variable selection 
Different statistical strategies are available for selection of variables. The simplest strategy is the 
univariate analysis, which evaluates individually the association of each covariate (or gene in the 
genetic signature) with the response variable. Univariate selection performs poorly because it ignores 
possible correlations between the predictors. This can generate misleading results when several 
covariates are tested, and the multivariate analysis is more appropriate. The multivariate strategy is 
used to analyze the relationship of more than one independent variable with the dependent variable 
at a time. This technique considers the effect of all covariates on the response variable. Logistic 
regression is the standard method for modeling binary outcomes since it allows to calculate and easily 
interpret the odd ratios (Rothman KJ, Greenland S, Lash TL. 2012; Hosmer DW, Lemeshow S, 
Sturdivant RX. 2013; Gordis L. 2013). However, the classical logistic regression does not perform 
properly when the number of variables is larger than the number of observations, and problems of 
multicollinearity and overfitting may arise. This may lead to loss of predictive power of the model and 
biased risk estimates, or inability of estimation at all (Doerken et al. 2019). An alternative approach to 
avoid these challenges is to implement penalized regression models such as LASSO, ridge or elastic-
net that performs dimensionality reduction within the inference process (Ishizawa et al. 2018). In 
penalized or regularized regression models, a penalty term is added to the linear regression to reduce 
the complexity of the model and mitigate multi-collinearity. 
Ridge regression adds an L2 penalized least squares criterion to the regular lineal regression (Hoerl 






If lambda is equal to zero, the regression has no penalization and it reduces to the standard linear 





towards zero. This method reduces the complexity of the model by decreasing the variance and the 
error, but it does not reduce the number of variables.  
LASSO (Least Absolute Shrinkage and Selection Operator) is a regularization method that uses an L1 






Same as in ridge, when lambda is zero, a linear regression is obtained. When increasing lambda, some 
coefficients are driven to zero. The larger is lambda, more variables are shrunk to zero. With this 
regularization method, some variables are eliminated, reducing the complexity of the model and the 
multi-collinearity. Lasso is a popular variable selection method widely used in genomics (Ogutu, 
Schulz-Streeck, and Piepho 2012). 
Elastic Net (ENET) is an extension of LASSO that uses a mixture of the L1 (LASSO) and L2 (Ridge) 













Additionally, to the estimation of lambda, ENET uses also the parameter alpha. The ENET simplifies to 
simple ridge regression when 𝛼 =1 and to the lasso when 𝛼 =0 (Ogutu, Schulz-Streeck, and Piepho 
2012). This method is useful when there is correlation between the covariates; ENET tends to 
eliminate together groups of correlated variables that are not informative (Zou and Hastie 2005). 
 
4.1.4. Bladder cancer study 
Bladder cancer is the seventh most frequent tumor worldwide in men and the tenth for both sexes. In 
2018, 549,393 new cases of bladder cancer and 176,963 deaths were registered around the world, 
and more than 75% of the cases and deaths were men. The incidence is 9.6 annual rate per 100,000 
persons at risk (ASRs per 100,000 person-years) in men and 2.4 in women, and the mortality rate is 
3.2 deaths in men and 0.9 in women (Wong et al. 2018; Bray et al. 2018). 
Tobacco smoking is the most important risk factor for bladder cancer. Smokers are at least 3 times as 
likely to get bladder cancer as non-smokers. More than 50% of bladder cancer cases are associated to 
smoking in both sexes in United States.  Other causes as certain exposures to chemicals during work, 
or water contaminants as arsenics, or some analgesics, can increase the risk to develop bladder cancer 
(Saint-Jacques et al. 2014). Moreover, some genetic studies have confirmed that the incidence of 
bladder cancer can be influenced by genetic susceptibility factor (Murta-Nascimento et al. 2007; 
Rothman et al. 2010; Kiemeney et al. 2008; Garcia-Closas et al. 2013). 
A 25% of all patients with bladder cancer develop cancer in the thick detrusor muscle of the bladder, 
a condition that is known as muscle-invasive bladder cancer (MIBC). This type of cancer has higher risk 
to spread and metastasis, increasing the likelihood to death. Between 20-25% of affected MIBC who 
have received radical cystectomy develop microscopic spread to the lymph nodes. Hence, the 
treatment targets are the cancer cells in both bladder and lymph nodes (Lerner, Schoenberg, and 
Sternberg 2015). 




If the bladder cancer has invaded the muscle of the bladder wall, then there is a very high risk of death 
for the patient unless radical treatment is applied. Radical treatment includes either radical 
cystectomy or radiotherapy, and although both of them offers the best chance of cure, 50% of patients 
die due to tumor progression despite the treatment received. The probability of relapse can be 
reduced or delayed by administrating chemotherapy before the radical surgery or radiotherapy 
(Neoadjuvant chemotherapy). Treatment with neoadjuvant chemotherapy based in cisplatin (NAC) 
followed by radical cystectomy is the reference standard for MIBC, increasing the survival ratio a 5% 
to 10% compared to cystectomy alone (Grossman et al. 2003; Griffiths et al. 2011; Hensley et al. 2019). 
Several biomarkers involved in different metabolic pathways have been identified to be associated 
with prediction response of neoadjuvant cisplatin-based chemotherapy. These biomarkers are 
involved in regulation of apoptosis and cell differentiation, DNA repair pathways, receptor tyrosine 
kinases, chromatin remodeling targets, taxonomic classification genes and immune response 
pathways (Supplementary material Table S4) (Brown et al. 2017; Buttigliero et al. 2017; Font et al. 
2011; Pitroda et al. 2014; Yoshida et al. 2019). The identification of reliable biomarkers that allow the 
identification of patients who will really benefit from neoadjuvant chemotherapy is a significant 
challenge. This identification could lead to precision medicine, setting an individualized therapy in 
order to optimize the response and thus avoiding the negative impact of neoadjuvant treatment. 
 
4.1.5. MIBC Project 
The main objective of this research is to establish a statistical pipeline to build genetic signatures 
integrating genomic and non-genomic data. This pipeline has been constructed by using genomic and 
clinical/epidemiological data from MIBC patients treated with NACs followed by cystectomy (part of 
other project titled “Invasive bladder cancer: toward a precision medicine”). The intention of this 
study was to establish a clinical-molecular signature to predict the efficacy of the chemotherapeutic 
treatment. Details of this project are described below.  
Name of the project: “Invasive bladder cancer: toward a precision medicine” 
Coordinating institute: CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) 
Scientific coordinator: Francisco X. Real Arribas 
Participant organisms: 
1. SOGUG (GRUPO ESPAÑOL DE ONCOLOGÍA GENITOURINARIA). (Grupo II). Daniel Castellano 
2. INSTITUT CATALÀ D´ONCOLOGIA (ICO)-HOSPITAL GERMANS TRIAS I PUJOL-IGTP (Grupo III). Albert 
Font 
3. CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (Grupo IV). Nuria Malats 
Financing: ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER (AECC) 










4.2. MATERIAL AND METHODS 
 
4.2.1. Data from the MIBC Project 
Genomic and clinical/molecular data was obtained from 123 MIBC patients treated with neoadjuvant 
chemotherapy (NAC). Three NAC schemes were used: CMV (cisplatin, methotrexate vinblastine); 
cisplatin with gemcitabine (CDDP + GMZ); and carboplatin with gemcitabine (CARBO + GMZ). All 
subjects gave their informed consent for inclusion before they participated in the study. The study 
was approved by the corresponding Research Ethics Committees (REC).  
Clinical and pathologic anatomy history of all patients were registered, including age, sex, presence 
of, presence of lymphovascular invasion, the morphology of the tumor, TNM stage, presence of 
hydronephrosis or neoadjuvant chemotherapy used. The taxonomic classification of the tumor was 
estimated by evaluating the expression of four genes: FOXA1, GATA3, KRT5 and KRT14 (W. Choi et al. 
2014). 
Gene expression data was extracted from the analysis of expression of 41 genes in the transurethral 
resection of bladder tumor of these 123 patients. Gene expression analysis was performed by using 
nCounter® assay (NanoString Technologies, Seattle, WA). The complete list of genes included in the 
assay can be found in Supplementary material Table S4. Background correction and sample 
normalization was performed in R using custom pipeline according to manufacturer instructions (Gene 
Expression Data Analysis Guidelines from Nanostring). The data were logarithmically transformed to 
ensure normal distribution.  
 
4.2.2. Statistical strategy 
 
1. Preprocessing 
a. Filtering process 
In the genomic dataset, those samples with expression values lower than the negative control in more 
than 80% of the genes were filtered out. In the same way, those genes with more than 80% of their 
values lower than the negative control were discarded. Values below negative control indicate low 
performance or deficiency assays. 
Regarding the non-genomic dataset, those samples with incomplete clinical/molecular registry were 
excluded.  
b. Descriptive analysis of the clinical/molecular variables 
A descriptive analysis of non-genomic variables was performed for the selected samples to study the 
distribution of the samples for each covariate.  
2. Construction of genetic signatures integrating the genomic and non-genomic datasets 
The purpose was to build a gene expression signature of the non-response risk to neoadjuvant 
treatment in patients with MIBC. A conditional modeling approach was followed for construction of 
the genetic signature model. The clinical model was defined only including the non-genomic variables. 
Secondly, the genomic covariates were included to the preset clinical model to build the genetic 
 
 
signature. Two multivariate logistic strategies were considered for the selection of the non-genomic 
and genomic variables and a cross-validation process to measure the predictive ability of the models.  
a. Construction of the clinical model  
A multivariate strategy (stepwise regression method) was used to identify the non-genomic variables 
that are associated to the response variable (cisplatin response). Among the non-genomic data one 
variable was the molecular classification of the tumor (cluster), which was established based on the 
genomic information. Since this variable is genomic dependent, we considered to evaluate two 
different models: a model with clinical and pathological variables but not the taxonomic classification 
(model 1) and a second model (model 2) including all the variables included in the first model and also 
the taxonomic classification variable. 
b. Construction of the clinical-pathological-genetic model 
Multivariate logistic penalized regression (LASSO and Elastic-Net) was applied to identify genetic 
biomarkers associated with cisplatin response, considering the associated variables studied in model 
1 and model 2. The linear predictors from model 1 and model 2 were used as scores representing the 
associated variables of each model and these score were attached to the gene expression data to build 
model 3 (genetic variables with score of model 1) and 4 (genetic variables with score of model 2) 
respectively (Figure 4.2). The penalization of the model (lambda) and the optimal number of variables 
for the model was calculated with a cross-validated LASSO.  
 
Figure 4. 2. Design of the models to evaluate the clinical and genomic signature from patients with MIBC. 
To reduce overfitting, the sample set was split in a training set (70% of samples) and a test set (30% 
remaining). The genetic signature was modeled with the training set, and the predictive ability was 
calculated with the test set by estimating the AUC (Area Under the Curve) of the ROC (Receiver 
Operating Characteristics) curve for the four models previously described. In order to obtain more 
robust results, the sampling step, the modelling process and the AUC measurement were cross-
validated in a hundred cycles (k=100). The mean AUC of the cross-validation was finally determined 
for the four models.  
3. Estimation of the increasing predictive ability with the selected genes 
Additionally, the increase of the predictive ability was evaluated with the addition of the genes 
selected by LASSO one by one. The purpose of this step is to evaluate the discriminatory information 
given for each gene of the genetic signature.  
 




4. Univariant analysis  
A univariant analysis (simple logistic regression) was performed to assess the independent association 
of each gene with the pathological response.  
5. Survival analysis  
Survival analysis of the model with better prediction power was performed to evaluate the prognosis 
of patients with favorable and unfavorable genetic signature. These two groups of patients were 
formulated by qualifying the linear predictors of the final model. Samples with a linear predictor value 
higher than the median were assigned as patients with favorable response to the cisplatin treatment 
(“Firm 1”); and on the contrary, samples with lower linear predictor value than the media were 
assigned as an unfavorable response (“Firm 2”). Survival curves were studied using the Kaplan-Meier 
estimator, and the survival discrepancy between the two groups of signatures was calculated using 
Log-rank test. Four types of survival were studied: progression-free survival (PFS), time during and 
after the treatment in which the disease being treated does not worsen; overall survival (OS) , time to 
death from any cause; disease-specific survival (DSS), time to death from the specific disease studied; 
and event-free survival (EFS), time to death or progression of the disease. 
To evaluate how the information of each gene that is part of the genetic signature is reflected in the 
prognosis and survival of the patients, the survival analysis was performed in different models: from 
only the clinical model, to the complete clinical-genetic model, adding the genes selected by LASSO 
one by one.  
 
Table 4. 1 Increasing gene models for survival analysis 
 Model Non-genomic variables Genonmic variables 
1 Clinical model only Clinical model NA 
2 Clinical + 1 gene Clinical model 1st gene (selected by LASSO) 
3 Clinical + 2 genes Clinical model 1st gene + 2nd gene 
4 Clinical + 3 genes Clinical model 1st gene + 2nd gene + 3rd gene 










4.3. RESULTS  
 
4.3.1. Pipeline to construct genetic signatures integrating genomic and non-
genomic data 
A pipeline has been developed to construct genetic signatures integrating genomic and non-genomic 
data following a conditional integrative strategy (Figure 4.3). The pipeline is structured in 5 steps: 
preprocessing, clinical model construction, genetic signature construction, estimation of the 
increasing AUC, and survival analysis.  
In the preprocessing step, samples with incomplete non-genomic variables are discarded. Also, the 
normalized genomic data set is filtered according to the gene expression values. Samples or genes 
with lower value than the negative control are excluded.  
In the clinical model construction step, the multivariate stepwise regression test is used to build the 
clinical model that provides the best goodness-of-fit. The non-genomic variables with a higher 
association to the dependent variable are selected to construct the clinical model. The linear predictor 
(clinical score) of the clinical model are extracted as a single and numerical representation of the 
clinical model. The clinical score attached to the genomic dataset for the next step of the conditional 
strategy.  
In the genetic signature construction step, the genetic variables with a higher association to the 
dependent variable are selected while adjusted by the clinical score. A cross-validation process is 
performed to avoid overestimation of the predictive ability of the model. The data is split in training 
(70%) and test (30%) sets. The clinical-genetic model is built with the training set using LASSO 
methodology, and the prediction capacity (AUC) of the model is estimated using the test-set. The 
sampling process and the variable selection is performed 100 times to obtain more robust and reliable 
results. The genetic signature is finally chosen depending on the selection rate of the genes by LASSO. 
The mean AUC of all AUC calculated in the loop is obtained. Univariant logistic regression analysis is 
performed in order to describe the independent association of the gene with the dependent variable. 
The following step is the estimation of the increasing classification (AUC) as the different selected 
genes are added to the clinical score. The selected genes are ranked according to their LASSO selection 
rate. Then, sequential models are considered by adding a new gene to the clinical score: (1) only the 
clinical variable; (2) the clinical score and the most selected gene by LASSO, (3) the clinical score and 
the two most selected genes and so on. The AUC is calculated for these models to observe the increase 
in the predictive power with each variable added.  
Finally, survival analysis is done for the previously described models (adding the variables one by one), 
to evaluate the prognosis effect of the genetic signature. The linear predictors are extracted from the 
models as a representation of the risk of non-response of the samples. Linear predictors with values 
higher than the median are associated with one specific genetic signature profile (Firm 1), and linear 
predictors which values are lower than the median are assigned to an opposite genetic signature (Firm 
2). The Kaplan Meier curves, and the Log-Rank test are studied for each model to evaluate the survival 








Figure 4. 3 Pipeline for the construction of genetic signatures by integrating genetic and non-genetic data. 
 




4.3.2. Validation of the pipeline with bladder cancer data 
Genomic and non-genomic (clinical/pathological/taxonomical) data from patients with MIBC have 
been used to validate the statistical pipeline for the construction of genetic signatures integrating 
genomic and non-genomic data. The objective of this study was to establish a clinical-molecular 
signature to predict the efficacy of the neoadjuvant chemotherapeutic treatment. The dependent 
variable here is the response to the chemotherapy (complete vs partial/non-response).  
4.3.2.1. Filtering of samples and genes. 
Only 112 samples out of the 123 samples analyzed in the Nanostring were selected for statistical 
analysis. Four samples were discarded due to bad Nanostring performance and 7 because of 
incomplete clinical history. Three genes (PD1, FANCC and IFNG) were filtered out of the analysis since 
more than 80% of the values were null (Table 4.2). So finally, 112 samples and 39 genes were used for 
the statistical analysis.  
Table 4. 2 Genes discarded for the analysis 
 
% null values  Number of correct (no null) values 
   N (Complete) N (partial/No response) 
PD1 99.10  1 0 
FANCC 83.92  6 12 
IFNG 83.03  9 10 
 
4.3.2.2. Descriptive analysis of the clinical and pathological variables of samples. 
A descriptive analysis of the clinical, pathological and taxonomic variable was performed for the 112 
selected samples (Table 4.3). 
Table 4. 3 Description of the clinical, pathological and taxonomic variables 
 
Variable n % 
Gender Male 104 92,86 
Female 8 7,14 








No 98 87,50 
Yes 14 12,50 
Urothelial morphology Urothelial 96 85,71 
Squamous 12 10,71 
Other 4 3,57 
Clinic TNM (A) <T2N0M0 10 8,93 
(B) T3a-4aN0M0 83 74,11 
(C) >N1Mx 19 16,96 
Hydronephrosis No 67 59,821 
Yes 45 40,179 
CT Scheme CDDP+GMZ        68 60,714 





CMV 28 25 
Others 4 3,5714 
Previous superficial 
bladder tumor 
No 93 83,036 
Yes 19 16,964 
Taxonomy / cluster BASQ-like 44 39,286 
Luminal-like 38 33,929 
Mixed 30 26,786 
Pathological response Complete 36 32,143 
Partial or No response 76 67,857 
  
4.3.2.3. Clinical, pathological and taxonomical modeling and construction of the genetic 
signature. 
Stepwise regression analysis was used to analyze which clinical, pathological and taxonomical 
variables are associated to response to cisplatin treatment. The selected variables were those that 
minimize the Akaike information criteria (AIC). The results of the multivariate logistic models 1 (all 
clinical and pathological covariates) and model 2 (covariates from model 1 and the taxonomic 
classification variable) are shown in Table 4.4 and 4.5 respectively. Limphovascular invasion, urothelial 
morphology and TNM scheme were selected by stepwise regression of model 1, meanwhile 
morphology, presence of hydronephrosis, and cluster taxonomy were selected for model 2.   
Table 4. 4 Stepwise regression coefficients of Model 1 (clinical-pathological model) 
 β coefficient  Std. Error z value Pr(>|z|) 
(Intercept) 0.626 0.255 2.450 0.014 
Limphovacular invasion (Yes vs No) 1.250 0.717 1.744 0.081 
Morphology (Squamous vs Urothelial) 0.979 0.812 1.205 0.228 
TNM scheme (‘>N1Mx’ vs ‘T3a-4aN0M0’) -0.288 0.575 -0.502 0.616 
TNM scheme (‘>N1Mx’ vs ‘<T2N0M0‘) -1.506 0.642 -2.346 0.019 
 
Table 4. 5 Stepwise regression coefficients of Model 2 (clinical-pathological and taxonomic model) 
 β coefficient Std. Error z value Pr(>|z|) 
(Intercept) -0.559 0.421 -1.329 0.184 
Morphology (Squamous vs Urothelial) 1.6555 0.874 1.893 0.058 
Hydronephrosis (Yes vs No) 0.698 0.470 1.485 0.137 
Cluster (Luminal-like vs BASQ-like) 0.939 0.510 1.842 0.065 
Cluster (Mixed vs BASQ-like) 2.218 0.665 3.334 0.0009 
 
The linear predictors of both stepwise regression models, referred as model 1 score and model 2 score, 
were attached to the genetic data to construct the model 3 and 4, respectively. The dataset was split 
in the training set (70% of the data) and test set (30% remaining). LASSO regression modeling (least 
absolute shrinkage and selection operator) was performed using the training set, to select those 
genetic variables with higher association to pathological response adjusted by the clinical model. The 
test set was used to estimate the prediction capacity of the LASSO model.  The process was repeated 
100 times (5-fold cross validation with 20 iterations), and the genetic signature was built extracting 
those genes with higher percentage of selection of LASSO. Genes selected for model 3 and 4 are shown 
in Table 4.6. The model 4 results had higher prediction capacity (AUC = 0.663). The genes selected by 




Lasso for model 4 are shown in table 4.7 sorted according to the percentage of selection of each gene 
in the 100 iterations performed by cross-validation. For genes with a negative coefficient, higher 
expression is associated with a higher probability of response, while for genes with a positive 
coefficient the association is in the opposite direction. The variable containing the clinical, pathological 
and taxonomy information (model 2 score) was selected in 100% of the cases. The differential 
expression of the selected genes for complete response vs partial or non-response are presented in 
figure 4.4. Only CXCL9 was significant for univariant analysis (see Supplementary material Table S5 for 
the univariant results of all genes).  
Table 4. 6 Predictive ability (AUC) of the four models 
MODELS Stepwise variable 
selection 
AUC Lasso variable selection 
(genes) 












Model 3 Clinical-pathological 





0.642 RAD51, CXCL9, PARP, HERC2, 
53BP1, ERCC2, RNF168, Ku80, 
ATR 
Model 4 Clinical-pathological and 
taxonomic variables (model 




0.663 RAD51, CXCL9, PARP, 53BP1, 
HERC2, ERCC2, CHEK1, Ku80, 
RNF168 
NOTE: AUC = Area Under the Curve. 
Table 4. 7 Variable selection for Lasso in Model 4. 
  LASSO  Mean 
  Selection (%) β Coefficient  Complete Partial/noResp 
1 Clinical-path-taxon variable 
(model 2 score) 
100 -  - - 
2 RAD51 92 -0.257  0.976 0.569 
3 CXCL9 88 -0.108  4.748 3.606 
4 PARP 70 -0.198  5.716 5.483 
5 53BP1 51 0.102  5.206 5.618 
6 HERC2 51 0.149  5.514 5.816 
7 ERCC2 44 0.099  2.944 3.375 
8 CHEK1 37 -0.078  3.724 3.404 
9 Ku80 37 -0.339  7.379 7.335 







Gene expression of genes selected in Model 4 
 
Figure 4. 4 Boxplot of the logarithm of the gene expression of the genes selected by Lasso. Patients with complete 
response are in light grey and patients with partial response or no response in the dark. In brackets, the number of 
samples per group for each gene (n) is shown. Below each graph, the p-value obtained in the univariate analysis is 
specified. 
4.3.2.4. The increasing predictive ability 
The increasing predictive ability was estimated when adding the taxonomical and genetic variables to 
the clinical-pathological model (model 1 with AUC of 0.52). First, the taxonomy information was 
added, and the AUC increased to 0.58. Subsequently, the 9 genes selected by LASSO were added in 
order of selection, one by one. Thus, the increase in predictive ability was observed with each gene 
that was added (Figure 4.5).  
The predictive ability reaches the maximum value when adding the cluster variable and the first two 
genes selected by LASSO (RAD51 and CXCL9) to the clinic-pathological model (“+CXCL9” in Figure 4.5). 
The incorporation of the rest of the genes does not increase the predictive ability.  
 
 





Clinical  0.52 











Figure 4. 5 Increase of the predictive ability (AUC) of pathological response by adding variables to the model. The first 
(clinical) model belongs to the clinical and pathological model. The second model (+ cluster) adds the taxonomy variable. 
Subsequently, the information of the genes is added one by one in the order of selection of Lasso. 
4.3.2.5. Survival analysis 
Kaplan-Meier curves were studied based on the variables selected by model 4 to compare the survival 
risk in patients with favorable and unfavorable genetic signature. In order to evaluate the survival  
information added for each gene, ten models were studied (described in Table 4.8) for four types of 
survivals: Progression-free survival (PFS – Figure 4.6), overall survival (OS , Figure 4.7), disease-specific 
survival (DSS Figure 4.8) and event-free survival (EFS, Figure 4.9). Samples with favorable and 
unfavorable genetic signature for chemotherapy response were assigned according to the linear 
predictor of the model: favorable signature for linear predictors higher than the median for (“Firm 1”), 
and unfavorable signature for linear predictors lower than the median (“Firm 2”). 
Table 4. 8 Models studied in the survival analysis 
Model Clinical/pathological variables Genes 
Clinical model 2 
(no genes) 
Morphology, Hydronephrosis and cluster - 
Clinical model 2 
+ 1 gene 
Morphology, Hydronephrosis and cluster RAD51 
Clinical model 2 
+ 2 genes 
Morphology, Hydronephrosis and cluster RAD51 +CXCL9 
Clinical model 2 
+ 3 genes 
Morphology, Hydronephrosis and cluster RAD51 +CXCL9 +PARP 
Clinical model 2 
+ 4 genes 
Morphology, Hydronephrosis and cluster RAD51 +CXCL9 +PARP +X53BP1 
Clinical model 2 
+ 5 genes 
Morphology, Hydronephrosis and cluster RAD51 +CXCL9 +PARP +X53BP1 +HERC2 
Clinical model 2 
+ 6 genes 
Morphology, Hydronephrosis and cluster RAD51 +CXCL9 +PARP +X53BP1 +HERC2 +ERCC2 
Clinical model 2 
+ 7 genes 
Morphology, Hydronephrosis and cluster RAD51 +CXCL9 +PARP +X53BP1 +HERC2 +ERCC2 
+CHEK1 
Clinical model 2 
+ 8 genes 
Morphology, Hydronephrosis and cluster RAD51 +CXCL9 +PARP +X53BP1 +HERC2 +ERCC2 
+CHEK1 +Ku80 
Clinical model 2 
+ 9 genes 
Morphology, Hydronephrosis and cluster RAD51 +CXCL9 +PARP +X53BP1 +HERC2 +ERCC2 






The survival analysis showed an increase in discrimination between the two groups of patients as the 
genes were added, in the four types of survival (PFS, OS, DSS and EFS). The model with the first 3 genes 
added (RAD51 + CXCL9 + PARP) obtained the highest discrimination with the least number of genes 
incorporated. The Log-rank test p.value is significant (p<0.05) for OS, DSS and EFS, and it is relatively 
close to the significance for PFS (p.value = 0.059).  
In the analysis of the PFS, none of the models reached the statistical significance. The closest model 
to significance corresponded to the model with the nine genes (p = 0.056). In the OS analysis, the 
highest statistical significance was obtained with seven genes (p = 0.0058), although the model with 3 
genes was powerful enough to discriminate the two signatures (p = 0.01). For the DSS, the greatest 
statistical significance was achieved with the 9 genes (p = 0.026), but as in OS, the model with 3 genes 
obtained a significant Log-rank test p.value (p = 0.033). 











Figure 4. 7 Kaplan-Meier curves for Overall survival (OS) comparison of patients with favorable (in yellow) and unfavorable (in blue) genetic signature for the models. 












Figure 4. 9 Kaplan-Meier curves for Event Free survival (EFS) comparison of patients with favorable (in yellow) and unfavorable (in blue) genetic signature for the models. 





4.4.1. Pipeline and genetic signatures 
Here, we have developed a statistical pipeline to construct gene expression signatures integrating 
genomic and non-genomic data based on a conditional integrative strategy (Figure 4.3). The pipeline 
is structured in 5 steps: preprocessing, clinical model construction, genetic signature construction, 
estimation of the increasing AUC, and survival analysis. The preprocessing step helps to improve the 
quality of the data and to reduce noise before the analysis. Following the conditional modeling 
strategy, the non-genomic variables are selected from the primary estimated model (clinical model) 
using stepwise regression.  The stepwise regression performs model selection, successively applying 
regression analysis with the addition and removal of the variables in each step. The set of variables 
with higher goodness of fit constitute the final non-genomic model.  
Once the non-genomic variables are selected, the genomic data is aggregated to construct the final 
model (the genomic-and-non-genomic model). The genomic variables are selected adjusted by the 
non-genomic data. To join these two different types of data, the non-genomic variables (mostly 
qualitative date) are transformed into a numerical score (quantitative) by using the linear predictors 
of the non-genomic model. This score is attached to the genomic variables as one more variable and 
represents the set of non-genomic variables. The genetic signature is estimated by using LASSO in a 
cross-validation process, to avoid overfitting. The penalized regression Elastic-net was also tested, but 
the model provided lower capacity of prediction than LASSO.  
To analyze more in detail the genetic information given by each gene of the signature, an increasing 
predictive ability analysis was performed. The objective of this step was to build different models 
increasing the number of genes and estimate the AUC for each model. The clinical or non-genomic 
model was analyzed. Then, the genes selected by LASSO were incorporated one by one, and the 
predictive ability was estimated for each model to test the variability of the AUC with each added 
gene.  
Finally, survival analysis was performed to verify if the differential expression in the genetic signature 
was reflected in the survival. This analysis was also performed for different models including the 
selected genes one by one. Besides the increasing capacity, we obtained the effect on the survival for 
each gene. Therefore, the final genetic signature can be optimized according to the results from the 
increased capacity and the survival analyses.  
The main objective in genetic or gene expression signatures for predictive purpose, is to obtain the 
lowest number of genes with higher predictive ability. The pipeline exposed here, helps shorten the 
number of genes without jeopardizing the predictive ability. One of the utilities of genetic signatures 
is the development of molecular tests that can profile the expression of selected genes to perform 
molecular diagnosis, prediction of the response to a specific treatment, or the prognosis of a 
determined disease (Chen 2013). The lower the number of the genetic signature, the simpler is the 
molecular test.  
Moreover, gene expression signatures are useful for the identification of biomarkers that guide in 
pharmacogenomics to drug discovery (Bai et al. 2013). The genetic signature can be converted into 
possible targets for the development of new treatments. The gene expression signatures may be also 
useful in later stages of the drug development process, as in the identification of pharmacodynamic 





biomarkers is commonly used in clinical trials to determine the optimal dose and the sensitivity of the 
drug. The gene expression analysis can reveal the action of the drug on target pathways (Mizuarai et 
al. 2009) and in toxicological pathways (Liebler and Guengerich 2005). The pipeline exposed here can 
help to prioritize the possible targets for drug discovery and depict the drug action at molecular level. 
Altogether, these results support the utility of gene expression as a tool in personalized medicine 
(Kamel and Al-Amodi 2017).  
4.4.2. MIBC project 
The statistical pipeline was tested with data from MIBC, whose aim was to identify a clinical-molecular 
signature that predict the efficacy of neoadjuvant chemotherapeutic treatment. The signature 
selected was compounded of three non-genomic variables (morphology, presence of hydronephrosis 
and taxonomic classification or cluster) and nine genes (RAD51, CXCL9, PARP, 53BP1, HERC2, ERCC2, 
CHEK1, Ku80 and RNF168), resulting in an AUC of 0.663. The integrative model including genomic and 
non-genomic covariates resulted in better prognostic performance than the non-genomic model alone 
(AUC= 0.52 or 0.58 with the taxonomic variable). 
Through the increasing predictive ability analysis, we can observe that with the two first selected 
genes (RAD51 and CXCL9), the AUC get the higher value (AUC=0.671), also obtained including the next 
two genes (PARP and 53BP1). Our results suggest that the overexpression of RAD51, CXCL9 and PARP, 
and the lower expression of 53BP1 were associated with better response to the treatment. Several 
studies have been done about these biomarkers that support these results (Zhang et al. 2006). For 
example, the overexpression of RAD51 has been previously associated with increased resistance to 
platinum in several tumors including bladder cancer (Mullane et al. 2016).   
Survival analysis of PFS, OS, DSS and EFS was performed between samples with favorable and 
unfavorable genetic signature to treatment response, over the increasing gene models. Results 
showed a higher distinction in the survival of the two groups of samples, as more genes were added 
in the genetic signature. MIBC patients with favorable gene expression profile for the nine genes 
selected by LASSO have higher survival than patients with unfavorable gene expression signature (PFS 
p = 0.059, OS p = 0.013, DSS p = 0.026, EFS p = 0.019). However, the signature including the 
clinical/pathological/taxonomical variables and three first genes selected by LASSO (RAD51, CXCL9 and 
PARP) reached the statistical significance for OS, DSS and EFS (p < 0.05), and was close to the 
significance for PFS (p = 0.059).  
Thanks to the developed statistical pipeline, we can conclude that our data suggest that the best 
signature to predict the response to cisplatin treatment is composed of three non-genomic variables 
(morphology, presence of hydronephrosis and taxonomic classification or cluster) and 9 genes 
(RAD51, CXCL9, PARP, 53BP1, HERC2, ERCC2, CHEK1, Ku80 and RNF168). However, the signature 
including the non-genomic variables and three or four genes (RAD51, CXCL9, PARP, 53BP1 and HERC2)  
might be powerful enough to predict the treatment response. Therefore, the signature should be 
validated in another cohort of patients with MIBC. Further investigation are required to achieve the 
final genomic and non-genomic signature. 
4.4.3. Conditional integrative strategy 
López de Maturana and colleges describe the challenges of the integration of omics and non-omics 
data sets and consider the conditional integrative approach as one of the most suitable in this context 
(López de Maturana et al. 2019; Bazzoli and Lambert-Lacroix 2018; Bøvelstad, Nygård, and Borgan 
2009). In contrast with our study, Bazzoli research resulted in better prediction performance for only 
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gene expression dataset than the model that include genomics and non-genomics data (Bazzoli and 
Lambert-Lacroix 2018). However, the second omics dataset studied in that work (somatic copy 
number alterations) obtained higher prediction performance when was tested together with the non-
genomic data. Bovelstad et al (Bøvelstad, Nygård, and Borgan 2009) studied three gene expression 
datasets of different tumors, and two of them obtained the higher prediction performance with the 
integrative model. In general, several studies confirm that models that integrate genomic and non-
genomic data have better prognostic performance than one of them alone (Jayawardana et al. 2015; 
Thompson, Christensen, and Marsit 2018; van Vliet et al. 2012; Zhu et al. 2017), independently of the 
integrative model approach. However, some studies have reported no improvement in predictive 
ability when genomic data and non-genomic data is integrated (Chaudhary et al. 2018; de Maturana 
et al. 2014).  
A complex trait is as a trait that does not follow Mendelian inheritance laws and is likely the 
consequence of the effect of multiple genes. However, the molecular part is not the only factor to be 
considered when studying these traits, since other non-biological factors that are probably influencing 
the phenotype (i.e. environmental). The integration of omics and non-omics data can guide to find 
new risk factors in these traits, design better predictive models, or discriminate patients with 
favorable response to treatment. The pipeline developed here can help to all these purposes and 





























General discussion of all projects 
 
This industrial doctorate has accomplished the four objectives of the company Whole Genix: (1) 
acquire better know-how of Next Generation Sequencing (NGS) protocols; (2) cover different types of 
cancer and expand to other genetic diseases; (3) develop new bioinformatic and telemedicine tools 
for analysis of different omics data; and (4) progress towards personalized medicine. This has been 
possible thanks to the collaboration with academia (Josep Carreras Research Institute and the 
University of Vic - Central University of Catalonia) that provided the theoretical and practical guidance 
in hematologic and bioinformatic research, respectively. 
 
1. Acquire better expertise in Next Generation Sequencing (NGS). 
The design and development of the HHD panel described in chapter 1 has increased the knowledge 
about the NGS technology, not only from the bioinformatics point of view, but also from others such 
as the design of targeting NGS panels, or optimization of wet lab protocols. The study of four design 
improvements of the HHD panel, has helped to understand how faster the genomic knowledge is 
increasing in short period of time for all genetic fields, including rare diseases and cancer (Fernandez-
Marmiesse, Gouveia, and Couce 2018; Sabour, Sabour, and Ghorbian 2017). In the last years, the 
number of identified novel genetic alteration associated with diseases has grown exponentially due 
to the emergence of NGS-based studies. In four years (from 2015 to 2019), the number of genes 
identified to be associated to HHD has increased from 58 genes (panel version 13) to 107 (panel 
version 16), only considering the same groups of diseases and not the new diseases. From panel 
version 15 to version 16, the number of genes increased from 153 to 203. This number will be 
continually increasing since more genetic cases are continuously diagnosticated and studied. Similar 
to these rare diseases, the number of genes associated with oncogenesis, progression and metastasis 
of cancer have increased since the emerging of NGS technology. This fact forces to the genetic 
diagnostic laboratories to continuously search and be updated for new causative genes of these 
disorders. 
Furthermore, WG has gain experience in designing targeting NGS panels. Targeted sequencing may be 
more appropriate when there is previous knowledge of the associated-disease genes, since it 
increases the sensibility to detect variants due to the deep coverage augmentation, while reducing 
significatively the time and cost (Shefer Averbuch et al. 2018; Suwinski et al. 2019). The development 
of custom pipeline to extract the coordinates of all isoforms of our selected genes, increases the 
chance of success to detect mutations that are only in particular isoforms. Also, the use of targeting 
sequencing reduces considerably the number of incidental findings (Buermans and den Dunnen 2014). 
However, it is a reality that the WES is gaining more space in the genetic labs due to the drop in price 
and the increase in significant findings. The price of targeted sequencing gene panel per samples is on 
average €1455 (US$1609, range: US$488‐US$3443), and although the average price for WES per 
samples is still considerable higher (€5534), the minimum has fallen to €432 (£382) (Schwarze et al. 
2018). The cost-effectiveness is higher in targeted sequencing panel and WES compared to WGS. 
Additionally to the exposed in this research, this industrial Ph.D has contributing in enabling WES and 
WGS services in WG company for clinical and research purposes.  
Whole Genix was, and still is, a company specialized in the bioinformatic analysis of NGS data both in 
WES, WGS and targeted sequencing. The immersion of WG in the industrial PhD with the collaboration 





awareness about NGS technology. In order to speed up the analysis process of HHD with the NGS gene 
panel, our own database which variants associated with HHD has been created. Those variants have 
been identified from previously reported publications, databases for human variations (i.e. ClinVar 
and HGMD), our own results, and from collaborations with other hematological laboratories. The 
development of this database helps to identify reported pathogenic variants, filter variants that seem 
to have more significant pathogenic effect, and prioritize the functional analysis for those VUS variants 
that resemble to other pathogenic variant in position or function. 
Besides, it is a reality that the third-generation sequencing (TGS) is approaching for clinical diagnosis 
(Au et al. 2019). As it was commented in chapter 1, the TGS technology will solve some of the 
difficulties that the NGS is facing; as  1) the detection of structural variants,  2) the proper sequencing 
of homologous genes and 3) the sequencing of problematic regions (i.e.  high GC content)  (van Dijk 
et al. 2018), that are implicated in both in Mendelian and somatic-oncological diseases (Weischenfeldt 
et al. 2013).  
2. Cover different types of cancer and expand to other genetic diseases.  
WG is specialized in neoplastic diseases. However, the company has obtained greater specialization in 
bladder cancer (chapter 4) and myelodysplastic syndromes (chapter 3) due to the collaboration in two 
external research projects: the DJCLS R 14/04 Myelodysplastic syndromes project, which Principal 
Investigators are Dr. Mayka Sanchez (Spain) and Dr. Nobert Gattermann (Germany); and the bladder 
cancer project (SOG-CVI-2014-05) which principal investigator is Francisco X. Real Arribas. In the 
Sanchez & Gatterman´s project, a gene expression signature of 23 genes was identified to be 
differentially expressed comparing MDS patients with and without ring sideroblasts development, and 
the healthy controls. These genes contribute to a better understanding of the molecular pathways 
and the pathogenesis of MDS and the classification in disease subtypes.  In the collaboration with 
Real´s project, a genetic signature to predict the response to cisplatin treatment in patients with MIBC 
was studied. The genetic signature resulted to be in 9 genes and 3 non-genomic 
(clinical/pathological/taxonomic) variables, that might predict the response to cisplatin with a 
predictive ability of 66.3% (AUC=0.663). Although further analysis should be performed to corroborate 
the results, the gene expression signatures studied helped to better understand the molecular 
pathways behind the MDS and MIBC disorders. 
WG has spread to other non-oncological diseases: the hereditary hematological diseases (HDD). The 
collaboration with BloodGenetics company and the development of the HHD targeted panel, have 
introduced a new spectrum of diseases, no related to neoplastic disorders. This places WG as a 
versatile and flexible company that provides services to analyze genomic and transcriptomic data from 
oncological and non-oncological diseases.   
 
3. Develop new bioinformatic and telemedicine tools for analysis of different omics data.  
WG has been introduced and expanded in other high-throughput technology from different omics 
data, the transcriptomics. The development of BEA program (chapter 3) and the statistical pipeline to 
identify gene expression signatures (chapter 4), have made that WG gets new techniques of analysis 
of high-throughput transcriptomics data from BioMark-Fluidigm and Nanostring technologies. As was 
mentioned in chapter 4, the analysis of transcriptomic data can be used for the construction of gene 
expression signatures. These signatures are mostly studied in oncology to study the diagnosis, the 





Addittionally, the machine learning techniques developed here have been also employed in other 
research projects of WG, such as the study of epilepsy.  
On the other hand, CoDysAn is a new telemedicine tool for the management and diagnosis of patients 
with this congenital dyserythropoietic anemia. The web tool provides awareness of the disease, and 
this is relevant since some patients suffering from CDA are under-diagnosed. The telemedicine tool 
includes a diagnosis algorithm to facilitate the classification and diagnosis of CDA types. (Tornador et 
al. 2019). Computational science is the base of this biotech company, and the development of new 
computational tools and bioinformatics pipelines are crucial for the sustainability of WG. 
4. Progress towards personalized medicine.  
One of the definitions of personalized medicine is the set of factors (mainly genomics), that can 
influence in the effectiveness or the adverse effect observed during drug treatment. The presence of 
the DNA variants and the differential expression of determined genes can be related to drug response 
(pharmacogenomics). All the four projects undertaken here contribute in one way or another in the 
advancement to the future personalized medicine. Congenital anemias represent a heterogeneous 
group of anemias in which the identification of genetic variants is essential for suitable treatment and 
patient care (Iolascon, Andolfo, and Russo 2015). The emergence of NGS technologies helps to 
improve timely diagnosis of anemias, understand the RCB function in disease, and applicate the 
personalized avoiding possible harmful treatments. The development of the HHD gene panel, supports 
one of the key priorities of the European Anemia Research Roadmap: “use of new technology for a 
personalized diagnosis and therapy” (Engert et al. 2016). The correct genetic diagnosis and the 
continuous discovery of genes associated with HHD increase the possibilities of development of gene 
therapy. Preclinical gene therapy studies for some HHD, such as hemolytic anemia due to Pyruvate 
Kinase Deficiency (Garcia-Gomez et al. 2016), have been successfully described.  
The CoDysAn web tool is also closely linked with personalized medicine (Tornador et al. 2019). The 
diagnostic algorithm not only presents the clinical suspicion of CDA subtype, but also provide a link to 
connect to the NCBI Genetic Testing Registry (GTR) to perform a complete genetic test, if required. 
The importance of a correct and early genetic diagnosis for the subsequent implementation of proper 
treatment, avoiding detrimental or inappropriate treatments is crucial in CDA diseases.  
As was described in chapter 4, the objective of transcriptomics analysis is to identify a gene expression 
profile that is associated to a pathological condition in terms of pathogenesis, course of the disease 
or response to a treatment. The creation of BEA program and the statistical pipeline to construct gene 
expression signatures with integrative models encourage the identification of those gene expression 
profiles, that can better diagnose a particular disease, improve classification of disorder subtypes that 
can course with worse prognosis, or predict the response  to a specific treatment.  
WG wants to endorse genetics and genomics in research and integrate this knowledge into clinical 





















































CONCLUSION CHAPTER 1: Hereditary Hematologic Diseases Next Generation Sequencing Panel 
• The implementation of the NGS methodology in clinical practice for the diagnosis of 
hereditary hematological diseases allows the inclusion of the study of multiple genes and a 
rapid and effective diagnosis of these cases. 
 
● The use of the new targeted-NGS panels have allowed to reach a final diagnosis in 42.9% of 
analyzed cases. 
 
● The use of the panel has allowed to identify clinically positive but genetic negative cases that 
were subsequently studied by WES (analysis on progress) that may allow for the future 
identification of new genes involved in HHD.  
 
● As knowledgment is increasing in the field, the HHD gene panel must be frequently updated 
due to the continuous discovery of new genes associated with HHD.  
 
● L-ferritin disease is a clear case of Mendelian disease-related genes that are associated with 
multiple diseases, including Hereditary Hyperferritinemia Cataract Syndrome (HHCS), benign 
hyperferritinemia, neuroferritinopathy (NBIA3), and L-ferritin deficiency with autosomal 
recessive and autosomal dominant inheritance. We have reported three variants: two novel 
mutations in L-ferritin deficiency with autosomal dominant inheritance and HHCS diseases 
(Publication: Cadenas et al. page 193), and the second case reported for L-ferritin deficiency 
due to p.Met1Val (Cremonesi et al. 2004). 
 
CONCLUSION CHAPTER 2: CoDysAn: A telemedicine tool to improve awareness and diagnosis for 
patients with Congenital Dyserythropoietic Anemia (Publication: Tornador et al. 2019) 
• CoDysAn is a freely accessible web site that provides awareness of congenital 
dyserythropoietic anemia (CDA) where general public, patients and medical doctors can 
better understand and learn more about this disease, and use the diagnosis algorithm tool to 
ease the classification and diagnostic of CDA types. 
 
• The diagnostic algorithm of CoDysAn has been validated, resulting in a high specificity (89.5%) 
and sensitivity (78.5%). 
 
• CoDysAn algorithm is connected to the NCBI Genetic Testing Registry (GTR) in a way to inform 
medical doctors about the existence of these accredited diagnostic centers to perform a 
complete genetic test, if required. 
 
• CoDysAn includes a questionnaire to evaluate user opinion and degree of satisfaction with the 







CONCLUSION CHAPTER 3: BEA (BioMark Expression Analysis), a web-based tool for gene expression 
Analysis from BioMark-Fluidigm Dynamic Arrays. 
• BEA is a ready-to-use desktop program based in R/Shiny language that is easy to install and 
deploy, whose purpose is to provide an interactive statistic tools for the analysis of Biomark-
Fluidigm data in an intuitive step-by-step process.  
 
• BEA is oriented to users with limited knowledge in bioinformatics and advanced statistics, and 
allows the user to benefit from the power of R/Bioconductor packages without having 
programming experience.  
 
• BEA has been designed to analyze different IFC array formats, multiple conditions and 
replicates. Analysis include relative quantification using ∆∆CT normalization and appropriate 
statistical testing to identify differential expressed genes between tested groups, considering 
test of normality and number of groups.  
 
• BEA program helps the user to select suitable reference gene for reliable normalization and a 
qPCR data analysis, by providing three essential parameters: mean Ct value, deviation of the 
data, and gene-stability measure value. 
 
• The analysis pipeline, the results and plots generated in each step of the analysis are 
incorporated in a final report, that can be exported in a PDF file format. Other plots and tables 
including the complete heatmap, the normalized data table and results table, can be exported 
in a PDF and CSV format. 
• The use of BEA in a setting of biological sample of patients with MDS (with and without RS) 
and control samples has detected 23 genes differentially expressed (in a set of 96 genes 
selected as potential interactors with the iron regulatory proteins or IRPs). Further studies are 
needed to decipher the biological mean of these changes in expression profiles and their 
potential use as biomarkers in MDS.    
 
CONCLUSION CHAPTER 4: Pipeline for construction of gene expression signatures for prediction and 
prognosis 
• The statistical pipeline developed here, helps to build gene expression signatures for 
prediction and prognosis purposes by integrating genomic and non-genomic data. 
 
• The pipeline is based on an integrative conditional modeling approach, in which the non-
genomic model is built first using stepwise regression, and a second model is estimated by 
including the genomic variables to the first model and performing variable selection by LASSO 
in a cross validation procedure.  
 
• The pipeline estimates the best genomic and non-genomic signature for the tested dataset, 
but also provides the flexibility to value the reduction of the number of genetic variables in 
the signature without compromising the predictive ability of the model.  
 
• The pipeline has been tested using data from MIBC patients. The predictive signature that 




classification variables (non-genomic covariates) and 9 genes (RAD51, CXCL9, PARP, 53BP1, 
HERC2, ERCC2, CHEK1, Ku80 and RNF168) obtained the highest predictive ability to predict 
cisplatin response (AUC = 0.663). However, results suggest that the non-genomic variables 
and the first three or four genes selected by LASSO (RAD51, CXCL9, PARP and 53BP1) may 
have enough predictive ability to predict response to the treatment (AUC =0.671 ) and higher 
survival (Log-rank test p.value < 0.05). Nevertheless, further analysis must be performed. 
 
• The statistical pipeline can help to better understand complex traits and find new risk factors, 
design better predictive models, or discriminate patients with favorable response to 
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Supplementary Material Table S1.  Summary of hereditary hematological disorders covered by HHD panel version 15. (Chapter I) 
Panel Disease group Disease Acronym Gen Inheritance OMIM 
10010 Hereditary hemochromatosis 
and Hyperferritinemia / 
hypoferritinemia 
Hereditary hemochromatosis Type 1  HFE1 HFE AR 235200 
Hereditary hemochromatosis Type 2 HFE2A HFE2 AR 602390 
Hereditary hemochromatosis Type 2 HFE2B HAMP AR 613313 
Hereditary hemochromatosis Type 3 HFE3 TFR2 AR 604250 
Hereditary hemochromatosis Type 4 HFE4 SLC40A1 AD 606069 
Hereditary hemochromatosis Type 5 HFE5 FTH1 AD 615517 
Hereditary hemochromatosis   BMP6 
  
HFE modifier gene   GNPAT 
  
L-ferritin deficiency (due to ATP4A)   ATP4A 
  
Hyperferritinemia with Cataract Syndrome HHCS FTL AD 600886 
Benign Hyperferritinemia   FTL AD 600886 
L-Ferritin deficiency   FTL AD,AR 615604 
Neuroferritinopathy NCBI3 FTL AD 606159 
10020 Congenital sideroblastic 
anemias and acquired 
sideroblastic anemia 
X-linked sideroblastic anemia due to ALAS2 mutation XLSA ALAS2 X-linked 300751 
SLC25A38 deficiency SA SLC25A38 AR 205950 
Thiamine-responsive megaloblastic anemia due to SLC19A2 mutation TRMA SLC19A2 AR 249270 
X-linked SA with ataxia due to defects in ABCB7 XLSA/A ABCB7 X-linked 301310 
Glutaredoxin 5 deficiency SA GLRX5 AR 616860 
HSPA9 deficiency SA HSPA9 AR/D? 600548 
Mitochondrial myopathy with lactic acidosis and sideroblastic 1 MLASA PUS1 AR 600462 
Mitochondrial myopathy with lactic acidosis and sideroblastic 2 MLASA YARS2 AR 613561 
MLASA-like  MLASA mt-ATP6 Maternal or 
sporadic 
500011 
Sideroblastic anemia, B cell immunodeficiency, fevers and 
developmental  
SIFD TRNT1 AR 616084 
LARS2 deficiency SA LARS2 AR 
 





CSA due to mutation in STEAP3 SA STEAP3 AD 
 
Acquired sideroblastic anemia, myelodysplastic syndrome with ring 
sideroblasts 
  SF3B1 Somatic 
 
10030 Iron and Copper related Anemia Atransferrinemia   TF AR 209300 
Aceruloplasminemia    CP AR 604290 
Microcytic and hypochromic anemia with iron overload AHMIO1 SLC11A2 AR 206100 
Microcytic and hypochromic anemia with iron overload AHMIO1 STEAP3 
  
Iron-refractory Iron-Deficiency Anemia IRIDA TMPRSS6 AR 206200 
New form of IRIDA IRIDA ACVR1 AR 
 
Wilson disease   ATP7B 
  
10040 Congenital dyserythropoietic 
anemia 
Congenital dyserythropoietic anemia Type I CDA I CDAN1 AR 224120 
Congenital dyserythropoietic anemia Type I CDA I C15ORF41 AR 224120 
Congenital dyserythropoietic anemia Type II CDA II SEC23B AR 224100 
Congenital dyserythropoietic anemia Type III CDA III KIF23 AD 105600 
Congenital dyserythropoietic anemia Type IV CDA IV KLF1 AD 613673 




Type 1 familial erythrocytosis  ECYT1 JAK2; SH2B3; 
EPOR 
AD 133100 
Type 2 familial erythrocytosis  ECYT2 VHL AR 263400 
Type 3 familial erythrocytosis  ECYT3 EGLN1 AD 609820 
Type 4 familial erythrocytosis  ECYT4 EPAS1 AD 611783 
Type 8 familial erythrocytosis  ECYT8 BPGM AR 222800 
10061 Hereditary hemolytic anemias 
due to RBC enzymopathies or 
glycogen storage disease 
Pyruvate kinase deficiency   PKLR AR 266200 
Hemolytic anemia, G6PD deficient    G6PD XLD 300908 
Hemolytic anemia due to hexokinase deficiency   HK1 AR 235700 
Hemolytic anemia, nonspherocytic, due to glucose phosphate 
isomerase deficiency 
  GPI AR 613470 
Diphosphoglycerate mutase deficiency of erythrocyte, DPGM 
Deficiency (Erythrocytosis, familial, 8) 





Hemolytic anemia due to glutathione reductase deficiency   GSR A codominant 
 
Hemolytic anemia due to glutathione synthetase deficiency   GSS AR 231900 
Hemolytic anemia due to glutathione peroxidase deficiency   GPX1 AR 614164 
Hemolytic anemia due to gamma-glutamylcysteine synthetase 
deficiency 
  GCLC AR 230450 
Anemia, hemolytic, due to UMPH1 deficiency   NT5C3A AR 266120 
Hemolytic anemia due to adenylate kinase deficiency   AK1 AR 612631 
Phosphoglycerate kinase 1 deficiency   PGK1 XLR 300653 
Hemolytic anemia due to triosephosphate isomerase deficiency   TPI1 AR 615512 
Glycogen storage disease VII   PFKM AR 232800 
Glycogen storage disease XII   ALDOA AR 611881 
Hemolytic anemia due to elevated adenosine deaminase   ADA 
 
102700 
Methemoglobinemia, type I and type II   CYB5R3 AR 613213 




stomatocytosis) and Gilbert 
syndrome 
Hereditary spherocytosis Type 1   ANK1 AD 182900 
Hereditary spherocytosis Type 2   SPTB AD 616649 
Hereditary spherocytosis Type 3   SPAT1 AR 270970 
Hereditary spherocytosis Type 4   SLC4A1 AD 612653 
Hereditary spherocytosis Type 5   EPB42 AR 612690 
Hereditary elliptocytosis Type 1   EPB41 AR,AD 611804 
Hereditary elliptocytosis Type 2   SPAT1 AD 130600 
Hereditary elliptocytosis Type 3   SPTB AD 617948 
Hereditary elliptocytosis Type 4 / Ovalocytosis, SA type   SLC4A1 AD 166900 
Gilbert syndrome   UGT1A1 AR 143500 
Hereditary elliptocytosis by GYPC   GYPC AR, AD 616089 
Dehydrated hereditary stomatocytosis with or without 
pseudohyperkalemia and/or perinatal edema 
  PIEZO1 AD 194380 
Dehydrated hereditary stomatocytosis 2   KCNN4 AD 616689 




Pseudohyperkalemia, familial, 2, due to red cell leak PSHK2 ABCB6 AD 609153 
Overhydrated hereditary stomatocytosis OHST RHAG AD 185000 
Sitosterolemia   ABCG5 AR 210250 
Sitosterolemia   ABCG8 AR 210250 
McLeod syndrome with or without chronic granulomatous disease   XK X-linked 300842 
Pyropoikilocytosis   SPTA1 AR 266140 
Cryohydrocytosis   SLC4A1 AD 185020 
10080 Erythropoietic Protoporphyria 
and Congenital Erythropoietic 
Porphyria 
Protoporphyria, erythropoietic, 1 EPP1 FECH AR 177000 
Protoporphyria, erythropoietic, X-linked XLEPP ALAS2 X-Linked 300752 
Protoporphyria, erythropoietic, 2 EEP2 CLPX AD 618015 
Porphyria, congenital erythropoietic CEO UROS AR 263700 
10090 Fanconi Anemia Fanconi anemia, complementation group A FANCA FANCA AR 227650 
Fanconi anemia, complementation group B FANCB FANCB XL 300514 
Fanconi anemia, complementation group C FANCC FANCC AR 227645 
Fanconi anemia, complementation group D1 FANCD1 BRCA2 AR 605724 
Fanconi anemia, complementation group D2 FANCD2 FANCD2 AR 227646 
Fanconi anemia, complementation group E FANCE FANCE AR 600901 
Fanconi anemia, complementation group F FANCF FANCF AR 603467 
Fanconi anemia, complementation group G FANCG XRCC9 AR 614082 
Fanconi anemia, complementation group I FANCI FANCI AR 609053 
Fanconi anemia, complementation group J FANCJ BRIP1 AR 609054 
Fanconi anemia, complementation group L FANCL FANCL AR 608111 
Fanconi anemia, complementation group M FANCM FANCM AR 
 
Fanconi anemia, complementation group N FANCN PALB2 AR 610832 
Fanconi anemia, complementation group O FANCO RAD51C AR 613390 
Fanconi anemia, complementation group P FANCP SLX4 AR 613951 
Fanconi anemia, complementation group Q FANCQ ERCC4 AR 615272 





Fanconi anemia, complementation group S FANCS BRCA1 AR 617883 
Fanconi anemia, complementation group T FANCT UBE2T AR 616435 
Fanconi anemia, complementation group U FANCU XRCC2 AR 617247 
Fanconi anemia, complementation group V FANCV MAD2L2 AR 617243 
Fanconi anemia, complementation group W FANCW RFWD3 AR 617784 
10100 Diamond- Blackfan-Anemia Diamond-Blackfan anemia 1 DBA1 RPS19 AD 105650 
Diamond-Blackfan anemia 3 DBA3 RPS24 AD 610629 
Diamond-Blackfan anemia 4 DBA4 RPS17 AD 612527 
Diamond-Blackfan anemia 5 DBA5 RPL35A AD 612528 
Diamond-Blackfan anemia 6 DBA6 RPL5 AD 612561 
Diamond-Blackfan anemia 7 DBA7 RPL11 AD 612562 
Diamond-Blackfan anemia 8 DBA8 RPS7 AD 612563 
Diamond-Blackfan anemia 9 DBA9 RPS10 AD 613308 
Diamond-Blackfan anemia 10 DBA10 RPS26 AD 613309 
Diamond-Blackfan anemia 11 DBA11 RPL26 AD 614900 
Diamond-Blackfan anemia 12 DBA12 RPL15 AD 615550 
Diamond-Blackfan anemia 13 DBA13 RPS29 AD 615909 
Diamond-Blackfan anemia 14 DBA14 TSR2 XLR 300946 
Diamond-Blackfan anemia 15 DBA15 RPS28 AD 606164 
Diamond-Blackfan anemia 16 DBA16 RPL27 AD 617408 
Diamond-Blackfan anemia 17 DBA17 RPS27 AD 617409 
Diamond-Blackfan anemia   GATA1 XLR 
 
Diamond-Blackfan anemia   RPL19 
  
Diamond-Blackfan anemia   RPL31 AD 
 
Diamond-Blackfan anemia   RPS15 
  
Diamond-Blackfan anemia   RPS27A 
  
Diamond-Blackfan anemia   RPL36 
  
Diamond-Blackfan anemia   RPL9 
  




10110 Dyskeratosis congenita Dyskeratosis congenita, X-linked  DKCX DKC1 XLR 305000 
Dyskeratosis congenita, autosomal dominant 1 DKCA1 TERC AD 127550 
Dyskeratosis congenita, autosomal dominant 2 DKCA2 TERT AD, AR 613989 
Dyskeratosis congenita, autosomal recessive 4   TERT AD, AR 613989 
Dyskeratosis congenita, autosomal recessive 6   PARN AR 616353 
Dyskeratosis congenita, autosomal recessive 2   NOLA2 AR 613987 
Dyskeratosis congenita, autosomal dominant 3   TINF2 AD 613990 
Dyskeratosis congenita, autosomal dominant 6   ACD AD, AR 616553 
Dyskeratosis congenita, autosomal recessive 7   ACD AD, AR 616553 
Dyskeratosis congenita, autosomal recessive 1   NOLA3 AR 224230 
Dyskeratosis congenita, autosomal recessive 3   WRAP53 AR 613988 
Dyskeratosis congenita, autosomal dominant 4 DKCA4 RTEL1 AD, AR 615190 
Dyskeratosis congenita, autosomal recessive 5 DKCB5 RTEL1 AD, AR 615190 
Dyskeratosis congenita   USB1 AR 
 
Dyskeratosis congenita   CTC1 AR 
 
Pantothenate Kinase-associated neurodegeneration (PKAN) 
 
PANK2 AR 234200 
PLA2G6-associated neurodegeneration (PLAN) 
 
PLA2G6 AR 256600 
10120 NBIA, Neurodegeneration with 
brain iron accumulation 
Neuroferritinopathy (NF) NBIA1 FTL AD 606159 
Mitochondrial membrane protein-associated neurodegeneration 
(MPAN) 
NBIA2 C19orf12 AR 614298 
B-propeller-associated neurodegeneration (BPAN) NBIA3 WDR45 X-Linked 300894 
COASY protein-associated neurodegeneration (CoPAN) NBIA4 COASY AR 615643 
Aceruplasminemia NBIA5 CP AR 
 
Fatty acid hydroxylase-associated neurodegeneration NBIA6 FA2H AR 
 
Kufor-Rakeb disease (KRS)   ATP13A2 AR 
 















Supplementary Material Table S2. Summary of FTL identified mutations. (Chapter I) 
Table summarizing all mutations in FTL described up to now in the literature that may cause one of the five diseases. The table shows for each mutation, the conventional 
nomenclature according to HGVS (corresponding to [NCBI:NM_000146.3] reference sequence), the traditional nomenclature, the position in the IRE structure, and the 
corresponding published report. NA (not available). 
 
N Disease HGVS nomenclature Mutation type Mutation position First Publication Old Nomenclature 
1 HHCS c.-216C>A IRE regulatory Promoter FTL (Faniello et al. 
2009) 
NA 
2 HHCS c.-193C>G + c.-160A>G IRE regulatory lower stem + 
hexanucleotide loop 
(Castiglioni et al. 
2010) 
+7C>G & +40A>G 
3 HHCS c.-190C>T IRE regulatory lower stem (Cremonesi et al. 
2003) 
+10C>U 
4 HHCS c.-186C>G IRE regulatory lower stem (Cremonesi et al. 
2001) 
+14C>G 
5 HHCS c.-184C>T IRE regulatory lower stem (Cremonesi et al. 
2003) 
+16C>U 
6 HHCS c.-182C>T + c.-178T>G IRE regulatory lower stem (Cazzola et al. 
1997)  
Paiva-2 + 18C>U & 22U>G 
7 HHCS c.-176T>C IRE regulatory lower stem (Rufer et al. 2011) +24U>C 
8 HHCS c.-171C>G IRE regulatory lower stem (Bosio et al. 2004) Torino +29C>G 
9 HHCS c.-168G>A IRE regulatory lower stem (Cazzola et al. 
1997) 
Pavia-1 +32G>A 
10 HHCS c.-168G>C IRE regulatory lower stem ((first) Kato and 
Casella, F 1999) 
Baltimore-1 +32G>C 
11 HHCS c.-168G>T IRE regulatory lower stem (Martin et al. 
1998) 
Paris-2 or Milano-1 +32G>U 
12 HHCS c.-167C>A IRE regulatory C bulge (Durupt et al. 
2001) 
Paris +33C>A 
13 HHCS c.-167C>T IRE regulatory C bulge (Balas et al. 1999) Madrid or Philadelphia +33C>U 
14 HHCS c.-166T>C IRE regulatory upper stem (Hetet et al. 2003)  Paris +34U>C 
15 HHCS c.-164C>A IRE regulatory upper stem (Mumford et al. 
1998)  
London-2 +36C>A 
16 HHCS c.-164C>G IRE regulatory upper stem (Cremonesi et al. 
2003)  
Milano +36C>G 







18 HHCS c.-163A>C IRE regulatory upper stem (Ferrari et al. 
2006) 
Pavia +37A>C 
19 HHCS c.-163A>G IRE regulatory upper stem (Cremonesi et al. 
2003) 
Milano +37A>G 
20 HHCS c.-163A>T IRE regulatory upper stem (Garcia Erce et al. 
2006) 
Zaragoza +37A>U 
21 HHCS c.-161C>A IRE regulatory hexanucleotide loop (McLeod et al. 
2002) 
Geelong +39C>A 
22 HHCS c.-161C>G IRE regulatory hexanucleotide loop (Garderet et al. 
2004) 
Paris +39C>G 
23 HHCS c.-161C>T IRE regulatory hexanucleotide loop (Mumford et al. 
1998)  
London-1 +39C>U 
24 HHCS c.-160A>G IRE regulatory hexanucleotide loop (Beaumont et al. 
1995) 
Paris-1 or Montpellier-1 +40A>G 
25 HHCS c.-160A>G + c.-159G>C IRE regulatory hexanucleotide loop (Cremonesi et al. 
2001)  
Paris-1 or Montpellier-1 +40A>G & 
Verona-1 +41G>C 
26 HHCS c.-159G>C IRE regulatory hexanucleotide loop (Meneses et al. 
2011) 
Verona-1 +41G>C 
27 HHCS c.-157G>A IRE regulatory hexanucleotide loop (Phillips, Warby, 
and Kushner 
2005)  
Salt Lake City +43G>A 
28 HHCS c.-154T>G IRE regulatory upper stem (Messa et al. 
2009) 
+46U>G 
29 HHCS c.-153G>A IRE regulatory upper stem (Hetet et al. 2003)  Paris +47G>A 
30 HHCS c.-151A>C IRE regulatory lower stem (Castiglioni et al. 
2010)  
+49A>C 
31 HHCS c.-151A>G IRE regulatory lower stem (Sompele et al. 
2017)  
Ghent +49A > G 
32 HHCS c.-150C>A IRE regulatory lower stem (Gonzalez-Huerta 
et al. 2008)  
+50C>A 
33 HHCS c.-149G>C IRE regulatory lower stem (Camaschella, 
Zecchina, et al. 
2000) 
Torino +51G>C 
34 HHCS c.-148G>C IRE regulatory lower stem (Sara Luscieti et 
al. 2013) 
Heidelberg +52G>C 
35 HHCS c.-144A>T IRE regulatory lower stem (Ferrari et al. 
2006)  
Paris +56A>U 






37 HHCS c.-220_-196del25 IRE regulatory new transcription 
starting site (resulting 
IRE lacks nt 1-24)  
(Burdon et al. 
2007)  
NA 
38 HHCS c.-190-162del29 IRE regulatory eliminating IRE (Girelli et al. 1997)  Verona-2 +10_38del29 
39 HHCS c.-182_-174delCGGGTCTGTinsAGGGGCCGG $ IRE regulatory eliminating part of 
lower stem 
(Lenzhofer et al. 
2015)  
+18_+26 delCGGGTCTGTinsAGGGGCCGG 
40 HHCS c.-178_-173del6 IRE regulatory eliminating part of 
lower stem 
(Cazzola et al. 
2002)  
+22_27del6 
41 HHCS c.-168_-165delGCTT IRE regulatory eliminating C bulge (Garber and 
Pudek 2014)  
+32_35delGCTT 
42 HHCS c.-164_158del7 IRE regulatory eliminating part of 
hexanucleotide loop 
(Cadenas et al. 
2019) 
Esplugues +36_42del7 
43 HHCS c.-161delC IRE regulatory eliminating IRE (Muñoz-Muñoz et 
al. 2013)  
+39delC 
44 HHCS c.-162_-161delCA IRE regulatory eliminating part of 
hexanucleotide loop 
(Giansily et al. 
2001)  
+38_39del AC 
45 HHCS c.-158_-143del16 IRE regulatory eliminating part of 
hexanucleotide loop 
(Giansily et al. 
2001)  
+42_57del16 
46 HHCS c.-153_-152delGGinsCT IRE regulatory eliminating part of 
upper stem 
(Mattila et al. 
2018)  
+47_48delGGinsCT 
47 HHCS c.-44delT IRE regulatory eliminating IRE (Cremonesi et al. 
2003)  
  
1 Neuroferritinopathy c.[474G>A]; p.(Ala96Thr) Missense exon3 (Maciel et al. 
2005)  
  
2 Neuroferritinopathy c.641_642 4bp_dup Frameshift exon 4 (Kubota et al. 
2009)  
  
3 Neuroferritinopathy c.646InsC Frameshift exon 4 (Mancuso et al. 
2005)  
  
4 Neuroferritinopathy c.458dupA Frameshift exon 4 (Devos et al. 
2009)  
  
5 Neuroferritinopathy c.460InsA Frameshift exon 4 (Curtis et al. 2001)    
6 Neuroferritinopathy c.468_483 dup16nt Frameshift exon 4 (Nishida et al. 
2014)  
  
7 Neuroferritinopathy c.469_484 dup16nt Frameshift exon 4 (Ohta et al. 2008)    
8 Neuroferritinopathy c.498InsTC Frameshift exon 4 (R. Vidal et al. 
2004)  
  







10 Neuroferritinopathy c.467_470dupGTGG Frameshift exon 4 (Ni et al. 2016)    
1 Benign 
Hyperferritinemia 
c.[77A<T]; p.(Gln26Leu) Missense exon 1 (Thurlow et al. 
2012) 
  
2 Benign Hyperferritinemia c.[80C>T]; p.(Ala27Val) Missense exon 1 (Thurlow et al. 
2012)  
  
3 Benign Hyperferritinemia c.[89C>T]; p.Thr30Ile Missense exon 1 (C. Kannengiesser 
et al. 2009)  
  
1 L-ferritin deficiency 
Dominant 
c[1A>G]; p.(M1V) Missense start codon (Cremonesi et al. 
2004)  
  
2 L-ferritin deficiency 
Dominant 
c.375+2T>A Splicing intronic (Cadenas et al. 
2019) 
  
1 L-ferritin deficiency 
Recessive 
c.[310G>T];p. (E104X] Nonsense exon3 (Cozzi et al. 2013)    
NOTES: 














Supplementary Material Table S4. Biomarkers candidates to predict response to cisplatin treatment 
(Chapter IV). 
Pathway/mechanism Gene 











Fanconi Anemia FANCC 
FANCA 
FANCD2 














Genes of therapeutic 
targets and chromatin 
remodeling 
Tyrosine kinase receptor Axl 
c-MET 
RON 













INF pathway INFG 






Supplementary Material Table S5. Univariant analysis (simple logistic regression) of all genes (Chapter IV). 
Gene β Cofactor Std. Error z value Pr(>|z|) 
53BP1 0.274 0.172 1.596 0.111 
ATM 0.045 0.122 0.370 0.711 
ATR 0.325 0.316 1.028 0.304 
Axl -0.098 0.142 -0.686 0.493 
BRCA1 -0.083 0.127 -0.651 0.515 
BRCA2 -0.079 0.123 -0.641 0.522 
CHEK1 -0.121 0.128 -0.943 0.346 
CHEK2 -0.016 0.121 -0.135 0.892 
CXCL9 -0.209 0.093 -2.254 0.024 
ERCC1 0.212 0.248 0.856 0.392 
ERCC2 0.177 0.129 1.375 0.169 
ERCC5 0.057 0.133 0.425 0.671 
ERCC6 -0.035 0.142 -0.247 0.805 
FANCA -0.033 0.131 -0.252 0.801 
FANCD2 0.032 0.119 0.272 0.786 
FOXA1 0.105 0.080 1.310 0.190 
GATA3 -0.007 0.093 -0.080 0.936 
HERC2 0.359 0.236 1.520 0.129 
KRT14 -0.037 0.056 -0.667 0.505 
KRT5/6 0.016 0.060 0.259 0.795 
Ku80 -0.170 0.399 -0.426 0.670 
LAG3 -0.090 0.107 -0.848 0.396 
NBN 0.000 0.109 -0.004 0.997 
PALB2 -0.027 0.124 -0.220 0.826 
PARP -0.440 0.319 -1.381 0.167 
PDL1 -0.096 0.146 -0.660 0.509 
POL theta -0.027 0.112 -0.242 0.809 
PTIP 0.004 0.117 0.034 0.973 
RAD50 0.074 0.109 0.675 0.500 
RAD51 -0.343 0.185 -1.858 0.063 
REV7 (MAD2L2) 0.105 0.112 0.937 0.349 
RNF168 0.146 0.129 1.126 0.260 
RNF8 -0.073 0.161 -0.454 0.650 
RON 0.052 0.100 0.514 0.607 
Rif1 0.050 0.151 0.334 0.739 
TERT -0.186 0.150 -1.240 0.215 
c-Met 0.000 0.137 0.002 0.998 






Supplementary Material Figure S1. Algorithm for differential diagnosis of Congenital Dyserythropoietic Anemia (CDA). (Chapter II) 
This figure is also showed in chapter II (Figure 2.2). Here, the imagen has been zoomed in and divided in two pages for better visualization. The algorithm is structured in 
five steps. (1) Anemia, the hemoglobin levels are considered for the presence of anemia. (2) Other hematological parameters are evaluated. (3) Exclusion of other diseases 
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4. Other documents 
Certificate of participation in 2018 EMQN external quality assessment for NGS and Sanger 
sequencing. Both results were satisfactory (see page 216).  
 
Example of Clinical report of BloodGenetics (see page 217) 
 
Instruction of use of BEA program (see page 221) 
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